

Curriculum Vitae för Parkinsonfondens Vetenskapskommitté

Curriculum Vitae

Prof. Per Lars Anders ODIN

Auf dem Hohen Ufer 65b
D-28759 Bremen
Mobile +49(0)1752048124
e-mail: per.odin@med.lu.se
Nationality: Swedish
Born: 10th July, 1957 in Uppsala
Family: Married to Katja Odin, 3 children.

Education:

9 years of compulsory school, Örjansskolan, Halmstad	1965-1973
3 years of college, Natural Science Program, Halmstad	1973-1976
Medical studies, University of Uppsala	1976-1982
“Medicine Kandidat” Degree, University of Uppsala	19.06.78
“Läkarexamen” Degree, University of Uppsala	18.01.82

PhD research, Dept. of Medical and Physiological Chemistry, Uppsala Univ. 1982-1987
(Tutor: Professor Björn Öbrink).

Doctor of Medical Sciences, University of Uppsala	23.05.87
Thesis: “Chemical, immunochemical and immunohistochemical characterization of the cell adhesion molecule CellCAM 105”	

Employment/Exams (employment details separately below):

Clinical duties and research 1987-1996

Department of Neurology, Lund University

(Research area: Neurotransplantation, Neuroprotection)

(Heads of Department: Prof. Olle Lindvall and Prof. Anders Björklund)

Certified physician (“legitimerad läkare”), University Hospital, Lund	01.11.89
Neurology Specialist, University Hospital, Lund	16.11.93
Associate Professor (“Docent”) of Neurology, Lund University	08.09.94
Specialist, Consultant (“Bitr. Överläkare”), Dept. of Neurology, Lund	1994-1996
Lecturer (“Universitetslektor” (50%)), Lund University	1995-1996

Consultant (“Oberarzt”), Dept. of Neurology, The Hannover Medical School 1996-1999
(Head of Department: Prof. Reinhard Dengler)

Associate Professor (“Dr. med. habil.”), The Hannover Medical School	15.01.97
Extraordinary Professor, (“Außerplanmäßiger Professor”), The Hannover Medical School	14.10.98

National Coordinator of Kompetenznetz-Parkinson and 1999-2001

**Consultant at the Dept. of Neurology, Philipps-University, Marburg
(Head of Department: Prof. Wolfgang Oertel)**

Head of the Dept. of Neurology, Central Hospital, Bremerhaven 2001-

Professor 2009-

Department of Neurology, Lund University

Scientific publications: 143 (including 75 original publications and 67 bookchapters/reviews)

H-index: 29 **Average Citations per item:** 18.11

Scientific lectures and posters: >200

Clinical positions

University Hospital, Lund 31.10.89	Internship (“AT-läkare”)	01.02.88 -
University Hospital, Lund 30.11.93	Resident physician (“FV-läkare”)	01.11.89 -
University Hospital, Lund Dept. of Neurology 30.09.96	Specialist (“avdelningsläkare”)/ Consultant (“bitr. överläkare”)	01.12.93 -
The Hannover Medical School 31.10.99	Consultant (“Oberassistent“)	01.10.96 –
Dept. of Neurology Philipps-University Marburg 31.03.01	Consultant, Coordinator of	01.11.99 –
Dept. of Neurology Central Hospital, Bremerhaven Dept. of Neurology	Kompetenznetz-Parkinson Head of Dept	01.04.01 -

Research positions

University of Uppsala	PhD-Student “Doktorand”	01.07.78 - 31.07.78
Dept. of Med. and Physiol. Chemistry	PhD-Student “Doktorand” (Tutor)	01.02.82 - 28.02.83
	PhD-Student “Doktorand” (MFR*)	01.03.83 - 28.02.87
	PhD-Student “Doktorand”	01.03.87 - 31.07.87
Lund University	Post-doc. “Forskarassistent”(MFR*)	01.09.91 - 30.11.91
Dept. of Neurology	Post-doc. “Forskarassistent”	01.07.92 - 01.09.92
	Post-doc. “Forskarassistent”(MFR*)	01.09.92 - 30.11.92
	Post-doc. “Forskarassistent”	01.12.92 - 31.12.92
	Post-doc. “Forskarassistent”	01.05.93 - 30.06.93
	Post-doc. “Forskarassistent”(MFR*)	01.08.93 - 31.10.93
	Post-doc. “Forskarassistent”	01.11.93 - 09.01.94
	Post-doc. “Forskarassistent”	28.02.94 - 31.03.94
	Post-doc. “Forskarassistent”	15.04.94 - 30.04.94
	Post-doc. “Forskarassistent”	16.05.94 - 16.06.94
	Post-doc. “Forskarassistent”	01.07.94 - 15.09.94
	Post-doc. “Forskarassistent”	17.10.94 - 27.11.94
	Post-doc. “Forskarassistent”	19.12.94 - 08.01.95
Lund University	Senior research fellow	06.02.95 - 02.04.95
Dept. of Neurology	(“Universitetslektor”)	01.05.95 - 07.05.95

		05.06.95 - 18.06.95
		14.08.95 - 01.10.95
		23.10.95 - 03.12.95
		12.02.96 - 10.03.96
		14.04.96 - 31.08.96
Lund University	Professor	01.09.09 - 31.07.13
Dept. of Neurology	("Adj. Professor")	
Lund University	Professor of Clinical Neuroscience	01.08.13 –
Dept. of Neurology		

Tutor for doctoral students, thesis finished*:

N. Schimke, 2003

A. Brederlau, 2003

A. van den Hoogen, 2005

H. Honig, 2011

T. Fox, 2013

**A German medical dissertation is normally based on about one year of full-time research and is usually equivalent to one scientific publication.*

Leading posts in academic organizations

Chairman, Scientific Committee, Swedish National Guidelines for PD (Socialstyrelsen), 2014-

Chairman, "Swedish Movement Disorder Society, SWEMODIS", 2002-2014

Chairman, "Scandinavian Movement Disorder Society, ScandMODIS", 2008-

Chairman, SWEPAR (Swedish Parkinson Research Network), 2010-

Member of the executive committee of Movement Disorder Society, European Section, 2011-

Member of the CSPC (Congress Scientific Program Committee) of MDS, 2009-

Member of the board (treasurer) of Competence Network Parkinsons disease, CNP, 2010-

Clinical trials

I have been actively involved as principal investigator in the clinical studies listed below, was national co-ordinating investigator for the high-dose cabergoline study and leading German investigator (LKP) for the nasal apomorphine study (20102D05):

Apomorphin Inj. Sponsor: Novo Nordisk	Lund University		1993-95
Riluzol Sponsor: Aventis	The Hannover Medical School	Phase III	1997-99
High dose Cabergolin Sponsor: Pharmacia	University of Marburg	Phase III	1998-2001
E2007-204 Sponsor: Eisai/i3	Central hospital, Bremerhaven	Phase IIb	2004-5
E2007-205 Sponsor: Eisai/i3	Central hospital, Bremerhaven	Phase IIb	2004-5

PDT 301, DAT-Scan in PD +Dementia Sponsor: GE Health	Central hospital, Bremerhaven	Phase III	2004-6
SP790/791, Rotigotine in RLS Sponsor: Schwarz Pharma	Central hospital, Bremerhaven	Phase III	2005-7
E2007-E044-301 Sponsor: Eisai/Quintiles	Central hospital, Bremerhaven	Phase III	2006-7
20102D05 Apomorphine Nasal Sponsor: MDS/Britannia	Central hospital, Bremerhaven	Phase III	2006-7
E2007-G000-303 Sponsor: Eisai/Quintiles	Central hospital, Bremerhaven	Phase III	2007
248.596 Pramipexole in Parkinson+Depression Sponsor: Boehringer-Ingelheim	Central hospital, Bremerhaven	Phase III	2007
248.524 Pramipexole ER Sponsor: Boehringer-Ingelheim	Central hospital, Bremerhaven	Phase III	2007
S308.3.004 Rubens Study Sponsor: Solvay Pharma	Central hospital, Bremerhaven	Phase III	2008
SP882 Neupro perioperativ Sponsor: Schwarz Pharma	Central hospital, Bremerhaven	Phase III	2008
S187.3.001 Duodopa Sponsor: Solvay Pharma	Central hospital, Bremerhaven	Phase III	2008-
S187.3.004 Duodopa Sponsor: Solvay Pharma	Central hospital, Bremerhaven	Phase III	2008-
VR040/2/008 Apomorphine Inhalation Sponsor: Vectura	Central hospital, Bremerhaven	Phase III	2008
S187.1.001 Duodopa Sponsor: Solvay Pharma	Central hospital, Bremerhaven	Phase I	2010
PYM50028 Cogane Sponsor: Phytopharm	Central hospital, Bremerhaven	Phase II	2011
PO4938 Predeladent Sponsor: Schering	Central hospital, Bremerhaven	Phase III	2011
PO5664 Predeladent	Central hospital, Bremerhaven	Phase III	2011

Sponsor: Schering

NIC-PD Central Hospital, Bremerhaven Phase III 2012
Sponsor: German Parkinson Study Group

Toledo Apomorphine Central Hospital, Bremerhaven Phase III 2014
Sponsor: Stada

sNN0031-004 PDGF Central Hospital, Bremerhaven Phase II
2014
Sponsor: EU, Newron

KW-6002 Istradefylline Central Hospital Bremerhaven Phase III
2014
Sponsor: Kyowa

10 best original publications:

Pietz K., **Odin P.**, Funa K. and Lindvall O. (1996) Protective Effect of Platelet-Derived Growth Factor protects against 6-hydroxydopamine-induced lesion of rat dopaminergic neurons in culture. *Neurosci Lett*, **204**, 101-104.

Wenning G.K., **Odin P.**, Morrish P., Rehnström S., Widner H., Brundin P., Rothwell J.C., Brown R., Gustavii B., Hagell P., Jahanshahi M., Sawle G., Björklund A., Brooks J.D., Marsden C.D., Quinn N.P. and Lindvall O. (1997) Short- and Long-term Survival and Function of Unilateral Intrastratial Dopaminergic Grafts in Parkinson's Disease. *Ann Neurol*, **42**, 95-107.

Pietz K., Hagell P. and **Odin P.** (1998) Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up. *J Neurol Neurosurg Psychiatry*, **65**, 709-716.

Odin P., Oehlwein C., Storch A., Polzer U., Werner G., Renner R., Shing M., Ludolph A., Schüler P. (2006) Efficacy and safety of high-dose cabergoline in Parkinson's disease. *Acta Neurol Scand*, **113**, 18-24.

Eggert K., Schrader C., Hahn M., Stamelou M., Rüssmann A., Dengler R., Oertel W., **Odin P.** (2008) Continuous jejunal levodopa infusion in patients with advanced Parkinson's disease: Practical aspects and outcome of motor and non-motor complications. *Clin Neuropharmacol*, **31**, 151-66.

Brüggemann N., **Odin P.**, Grünewald A., Tadic V., Hagenah J., Seidel G., Lohmann K., Klein C., Djarmati A. (2008) Alpha-synuclein duplication is present in sporadic Parkinson disease. *Neurology*, **71**, 1294.

Honig H., Antonini A., Martinez-Martin P., Forgacs I., Faye G.C., Fox T., Fox K., Mancini F., Caneci M., **Odin P.**, Chaudhuri K.R. (2008) Intrajejunal levodopa infusion in advanced Parkinson's disease: a pilot multicentre study of effects on non-motor symptoms and quality of life. *Mov Disord*, **24**, 1468-74.

Antonini A., **Odin P.**, Opiano L., Tomantscheger V., Pacchetti C., Pickut B., Gasser U.E., Calandrella D., Mancini F., Zibetti M., Minafra B., Bertaina I., De Deyn P., Cras C., Wolf E., Spielberger S., Poewe W. (2013) Effect and safety of duodenal infusion in advanced Parkinson's disease: a retrospective multicenter outcome assessment in patient routine care. *J. Neurol. Transm.* **120**, 1553-8.

Nyholm D., **Odin P.**, Johansson A., Chatamra K, Locke C., Freeman S., Dutta S., Othman A.A. (2013) Stable Levodopa Plasma Levels with Jejunal Infusion of Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease Patients. *AAPS J.* **15**:316-23.

Olanow C.W., Kieburtz K., **Odin P.**, Espay A.J., Standaert D.G., Fernandez H.H., Vanaganas A., Othman A.A., Widnell K.L., Robieson W.Z., Pritchett Y., Chatamra K., Benesh J., Lenz R.A., Antonini A.; LCIG Horizon Study Group. (2014) Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced

Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. *Lancet Neurol.* **13**, 141-9.

Bremerhaven 13. Aug 2014



Per Odin

CV Lars Forsgren

Lars Forsgren	Professor, överläkare
---------------	-----------------------

A. Akademisk och gymnasial utbildning			
Utbildning	Examina	År	Ämnesområde
Forskarutbildning	Dr Med Vet	1990	Neurologi
Specialistutb i neurologi	Special.komp	1984	Neurologi
Epidemiologi statistik 10 p		1988	
Legitimerad läkare		1979	
Läkarutbildning	Läkarexamen	1978	
Psykologi 40 p		1970-71	
Gymnasieutb samhällsvet & naturvetenskaplig linje	Studenten	1970 och 1972 (natur)	
High School USA	High school examen	1967-68	

B. Professionella befattningar	
År	Befattning
2014-	Medlem i forskningsstrategiska nämnden, med.fak, Umeå universitet
2012-	Medlem i vetenskapliga rådet för Stiftelsen Parkinson Research Foundat
2012-	Medlem i strategiska gruppen för biobanksforskning, Umeå universitet
2011-2013	Medlem i en neurobedömargrupp vid Vetenskapsrådet (medicin)
2009-	Medlem i Parkinsonfondens vetenskapliga nämnd
2006-2012	Medlem i Hjärnfondens vetenskapliga nämnd, 2012- ordf för 1/3 grupper
2006-2011	Ordförande i neuroprioriteringsgruppen för ALF i Stockholm (KS/Hudd)

2005-2007	Ordförande i 1 av 2-3 kommittéer för fördelning av ALF-medel i Umeå
2004-2007	Ordförande vetenskapskommittén Neurologisk Handikappades Riksförb
2004-	Sveriges representant i World Federation of Neurology
2004-2006	Book review editor Acta Neurologica Scandinavica
2002-2008	Ledamot i Umeå universitets medicinska fakultets forskningsråd
2003-	Member European Brain Council group on epidemiology
2002-	Expertmedlem Medicinska biobanken i Umeå (i kommittén för kardiovaskulära och andra sjukdomar)
2002-	Member Editorial Board Acta Neurologica Scandinavica
1998-2004	Member Editorial Board Epilepsia
1996-	Ledamot i kommittén för utdelande av Mångbergs pris
1996-	Professor och överläkare i neurologi vid Umeå universitet/sjukhus
1996-2002	Klinikchef vid neurologiska kliniken, Norrlands universitetssjukhus
1996-	Prefekt eller ställföreträdande prefekt vid Institutionen för Farmakologi och Klinisk Neurovetenskap, Umeå universitet.
1998-2002	Ordförande i Nordisk Neurologisk Förening (från 2002 styrelsemedlem)
1995-1998	Ordförande i Svenska Neurologföreningen (styrelsemedlem ytterlig 6 år)
1995-2007	Medlem i vetenskapskommittén Neurologisk Handikappades Riksförb
1994-1997	Committee member of the International League Against Epilepsy's Commission on Epidemiology and Prognosis
1991-1998	Styrelsemedlem i Svenska Epilepsisällskapet
1991	Docent i neurologi vid Umeå universitet
1991-	Corresponding Fellow of the American Academy of Neurology (FAAN)
1989-1996	Sekreterare i Umeå Neurovetenskapliga Sällskap
1986-1991	Biträdande överläkare i neurologi vid Regionsjukhuset i Umeå
1986 (July)	Visiting Research Fellow Dystonia Clinical Research Center, New York (professor Stanley Fahn)
1984-1986	Avdelningsläkare i neurologi vid Regionsjukhuset i Umeå
1982 Febr/March	Visiting Research Fellow Texas Institute of Rehabilitation and Research (professor M Dimitrijevic)
1980-1984	FV-läkare i neurologi vid Regionsjukhuset i Umeå
1978-1980	AT-läkare vid Örnsköldsviks sjukhus

C. Meriter och utmärkelser	
År	Meriter och utmärkelser
2009	Parkinsonförbundets hedersmedalj Utöver vad som nämns ovan har jag bedömt ansökningar för Brittiska och Danska forskningsråden samt FAS. Har också varit sakkunnig på akademiska tjänster, främst professurer, vid samtliga Svenska universitet, samt vid Columbia university, New York.

CURRICULUM VITAE

Name Peter Hagell

Date of Birth December 28, 1966

Address Norra Storgatan 14
SE-252 20 Helsingborg, Sweden

E-mail Peter.Hagell@hkr.se (work)
petehagell@hotmail.com (private)

PROFESSIONAL AND ACADEMIC DEGREES

1989 Registered Nurse (RN), Halland College of Nursing, Halmstad, Sweden.

2002 Doctor of Philosophy (PhD; Doctor of Medical Science, in the area of Neurology), Faculty of Medicine, Lund University, Lund, Sweden.

2007 Associate Professor (Docent) of Caring Science, Faculty of Medicine, Lund University, Lund, Sweden.

2011 Professor of Neurological Caring Science, Kristianstad University, Kristianstad, Sweden.

EDUCATIONS

1989 University Certificate (UC) in Nursing (RN), General Nursing, Halland College of Nursing, Halmstad, Sweden.

1991-1997 Specialist Training, Neuroscience Nursing, 60 university points, Department of Clinical Neuroscience, Medical Faculty, Lund University, Lund, Sweden.

1990 Healthcare in developing countries, 5 university points, Department of Community Medicine, Medical Faculty, Lund University, Malmö, Sweden.

1994 Tropical medicine, 5 university points, Department of Infectious Diseases, Medical Faculty, Lund University, Malmö, Sweden.

1995 Medical English; TBV, Lund.

1995 Short Course on Movement Disorders, Institute of Neurology, National Hospital for Neurology and Neurosurgery, University of London, London, UK.

1995 Pharmacology, 5 university points, Medical Faculty, Department of Pharmacology, Lund University, Lund, Sweden.

1999 9th Annual Course on Movement Disorders for the Clinical Practitioner, Columbia University, New York, NY, USA.

2001 Rasch Measurement Theory/WINSTEPS software training workshop (J.M. Linacre, PhD and Prof. B.D. Wright, PhD), MESA Psychometric Laboratory, University of Chicago, Chicago, IL, USA.

2002 PhD (Doctor of Philosophy, in the field of Neurology), Department of Clinical Neuroscience, Faculty of Medicine, Lund University, Lund, Sweden.

Graduate Courses:

- Research Ethics 2
- Information Sources and Retrieval Methods in Medical Research
- Oral Communication
- Statistical Methods in Experimental Research
- Measurement- and Test Theory (5 university points)
- Research Strategy and Design Problems in Caring Sciences and Clinical Research (10 university points)
- Information Technology
- Additional Course in Statistics

2002 Modern Test Theory in Education and Psychology, Murdoch University, Perth, Australia.

2003-2007 *Postgraduate Teaching Courses:*

- Case methodology, Medical Faculty, Lund University, Lund, Sweden.
- Problem-based learning, Medical Faculty, Lund University, Lund, Sweden.
- Supervising undergraduate (BSc, MSc) student papers, Medical Faculty, Lund University, Lund, Sweden.
- Clinical teaching, Medical Faculty, Lund University, Lund, Sweden.
- Course management, Medical Faculty, Lund University, Lund, Sweden.
- Supervising postgraduate (doctoral) students, Learning and Teaching Development Centre, Lund University, Lund, Sweden.
- Introduction to university teaching, Medical Faculty, Lund University, Lund, Sweden.
- Supervising PhD-students, Medical Faculty, Lund University, Lund, Sweden.
- Additional university teaching course, Medical Faculty, Lund University, Lund, Sweden.

2004 European Science Foundation (ESF) program “Quantitative Methods in the Social Sciences” (QMSS): 10-day workshop/seminar “Measurement, Data Collection and Data Quality”, Università della Svizzera Italiana, Lugano, Switzerland.

2004-2005 Academic leadership. Vårdalinstitutet/The Swedish Institute for Health Science, Lund and Gothenburg Universities, Sweden.

2006 Intermediate Rasch Analysis. Psychometric Laboratory for Health Sciences, The Academic Unit of Musculoskeletal & Rehabilitation Medicine, School of Medicine, University of Leeds, Leeds, UK.

2007 MetaMetrics Workshop Series on Psychometrics: Rasch Measurement: Theory and Application, by David Andrich PhD. MetaMetrics Inc., Durham, NC, USA.

2007 Experimental and quasi-experimental designs in natural environments, by Prof. Thomas D. Cook PhD. The Swedish Institute for Health Sciences, Lund University, Lund, Sweden.

2008 Introductory Course on Rasch Measurement. Graduate School of Education, University of Western Australia, Perth, WA, Australia.

2008 Advanced Course on Rasch Measurement. Graduate School of Education, University of Western Australia, Perth, WA, Australia.

3

2008 Advanced Rasch Analysis. Psychometric Laboratory for Health Sciences, The Academic Unit of Musculoskeletal & Rehabilitation Medicine, School of Medicine, University of Leeds, Leeds, UK.

2009 Structural Equation Modeling. Psychometric Laboratory for Health Sciences, The Academic Unit of Musculoskeletal & Rehabilitation Medicine, School of Medicine, University of Leeds, Leeds, UK.

2009 Concept Mapping using Concept Systems. Concept Systems Inc., Ithaca, NY, USA.

2011 Advanced training in Concept Mapping using Concept Systems. Concept Systems Inc., Ithaca, NY, USA.

2012 Advanced Rasch Analysis. Psychometric Laboratory for Health Sciences, The Academic Unit of Musculoskeletal & Rehabilitation Medicine, School of Medicine, University of Leeds, Leeds, UK.

EMPLOYMENTS

1989-1991 RN, General Neurology, Department of Neurology, University Hospital, Lund, Sweden.

1991-1992 RN, General Neurology, Department of Neurology, University Hospital, Malmö, Sweden.

1992-1995 RN, Specialized Diagnosis and Treatment of Movement Disorders, Department of Neurology, University Hospital, Lund, Sweden.

1996-1998 RN, Research nurse, Department of Clinical Neuroscience, Lund University, Lund, Sweden.

1999-2012 RN, Department of Neurology, University Hospital, Lund, Sweden. (on leave 2003-2012)

2003-2004 Senior Lecturer, Department of Nursing, Faculty of Medicine, Lund University/Departments of Neurology and Neurosurgery, University Hospital, Lund, Sweden.

2005-2009 Research Assistant, Department of Health Sciences, Faculty of Medicine, Lund University, Lund, Sweden. (Position funded by the Swedish Research Council)

2010-2012 Senior Lecturer, Department of Health Sciences, Faculty of Medicine, Lund University, Lund, Sweden.

2011- Professor of Neurological Caring Science, School of Health and Society, Kristianstad University, Kristianstad, Sweden.

CLINICAL VISITS

□ National Hospital for Neurology and Neurosurgery, Institute of Neurology, London, UK (Prof. C. David Marsden and Prof. Niall P. Quinn).

□ Center for Parkinson's Disease and Other Movement Disorders, Neurological Institute, Columbia-Presbyterian Medical Center, New York, USA (Prof. Stanley Fahn and Carol B. Moskowitz, RN, NP-C).

SOCIETY MEMBERSHIPS

□ American Association of Neuroscience Nurses (1993-2010).

□ European Association for Survey Research (2005-).

4

□ Honor Society of Nursing, Sigma Theta Tau International (Tau Omega Chapter) (2006-)

□ Institute for Objective Measurement (2001-).

□ International Society for Quality of Life Research (2002-2014).

□ Läkarsällskapet i Lund [Lund Medical Society] (2002-2008).

□ Movement Disorder Caring Society, Sweden (1995-).

□ Movement Disorder Society (1996-2008; 2015-).

□ Psychometric Society (2000-2002).

□ Rasch Measurement SIG, American Educational Research Association (2001-).

□ Svensk Förening för Sömnforskning och Sömnmedicin [Swedish Society for Sleep Research and Sleep Medicine] (2005-)

□ Swedish Movement Disorder Society (1995-).

□ Swedish Nurses' Association (1987-).

□ World Federation for NeuroRehabilitation (2002-).

□ World Federation of Neuroscience Nurses (1998-).

□ European Huntington's Disease Network (2009-).

TEACHING

1997-1998 Specialist training in neuroscience nursing, Medical Faculty, Lund University, Sweden.

1997 Specialist training course in movement disorders for residents in neurology, Medical Faculty, Lund University, Sweden.

2001-2002 Specialist training for Parkinson's disease nurse specialists, the Red Cross

College of Nursing, Stockholm.

2001-2002 Department of Nursing (visiting teacher), Medical Faculty, Lund University, Lund, Sweden:

- Supervisor for bachelor-level papers
- Movement disorders

2003- Department of Nursing/Health Sciences, Faculty of Medicine, Lund University, Lund, Sweden:

- Quantitative research methodology and statistics (Lecturer)
- Psychometrics (Lecturer)
- Survey methodology (Lecturer)
- Quantitative/statistical advisor for bachelor- & masters-level students
- Movement disorders (Lecturer)
- Supervisor for bachelor-level papers
- Examiner of: bachelor-level papers; quantitative research methodology; clinical skills.
- Course director: “Biomedicine 1” and “Biomedicine 2”, undergraduate nursing program (2003-2004).

2004 Course director: “Life Love & Death” [“Livet Kärleken & Döden”], 5-point undergraduate course, Medicine & the Humanities Program, Faculty of Medicine and Faculties of Humanities and Theology, Lund University, Lund, Sweden.

5

2004 Spring School course: “Regenerative Medicine: Use of Stem Cells in Neurodegenerative Diseases – Basics and Applications”, Department of Neurology, University of Rostock, Rostock, Germany.

2004 Specialist course on Parkinson’s and related diseases, Sahlgrenska University Hospital, Gothenburg, Sweden.

2004 CNRN (Certified Neuroscience Registered Nurse) Review Course, the Barrow Neurological Institute, Phoenix, Arizona, USA.

2004-2005 Faculty member of postgraduate seminar series on quantitative methods in health sciences, Department of Health Sciences, Faculty of Medicine, Lund University, Lund, Sweden.

2005-2009 Biostatistics I (annual Masters-level course), Department of Health Sciences, Faculty of Medicine, Lund University, Lund, Sweden. (lecturer, computer lab instructor and examiner)

2006 Test theory (postgraduate/PhD course), The Swedish Institute for Health Sciences, Lund University, Lund, Sweden. (Lecture on modern test theory)

2007-2008 Rasch analysis for researchers and postgraduate students in the clinical and caring sciences, Department of Health Sciences, Faculty of Medicine, Lund University, Lund, Sweden. (Workshop director, lecturer and instructor)

2008-2011 Measurement and test theory (postgraduate/PhD course), The Swedish Institute for Health Sciences, Lund University, Lund, Sweden. (Course director, lecturer and examiner)

2009 Biostatistics II (Masters-level course), Department of Health Sciences, Faculty of Medicine, Lund University, Lund, Sweden. (Course development, instructor, lecturer)

2009 Quality of Life (Masters-level course), Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden. (Lecture on Defining Quality of Life)

2009 Measurement and test theory (postgraduate/PhD course), The School of

Health Sciences and Social Work, Växjö University, Växjö, Sweden.

(Lecture on modern test theory)

2009 Specialist training for nurses, Department of Health and Society, Malmö University, Malmö, Sweden. (Lecture on measurement and survey methodology)

2010-2011 Biostatistics I (annual Masters-level course), Department of Health Sciences, Faculty of Medicine, Lund University, Lund, Sweden. (Course director, lecturer, computer lab instructor and examiner)

2010-2011 Subject Representative of Statistics, Division of Nursing, Department of Health Sciences, Faculty of Medicine, Lund University, Lund, Sweden.

2010-2011 Responsible for the nursing branch of the Masters Program in Medical Science, Department of Health Sciences, Faculty of Medicine, Lund University, Lund, Sweden.

2011- Methodological responsible for statistics and quantitative methods in nursing and health sciences, School of Health and Society, Kristianstad University, Kristianstad, Sweden.

2011- Undergraduate nursing program, School of Health and Society, Kristianstad University, Kristianstad, Sweden:

6

- Quantitative research methodology and statistics (Lecturer, examiner)

- Survey methodology (Lecturer)

- Quantitative/statistical advisor for bachelor- & masters-level students

- Examiner of: Bachelor-level papers; Quantitative research methodology; Biomedicine.

2011- Examiner, Master-level papers in integrative health science; School of Health and Society, Kristianstad University, Kristianstad, Sweden.

2012 Parkinson's disease: Multidisciplinary perspectives (Masters-level course), Department of Health Sciences, Faculty of Medicine, Lund University, Lund, Sweden. (Course development, lecturer and examiner)

2012 Psychometrics in the health sciences: Theory and application (postdoc course), The Swedish Institute for Health Sciences, Lund University, Lund, Sweden. (Course development, course director, lecturer and examiner)

2012 Transcultural Mental Health - screening, intervention and evaluation (postgraduate/PhD course), Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden. (Lecture on Questionnaire and Rating Scale Translation).

2012- Applied statistics in the health sciences (online Masters-level course, given in both Swedish and English), School of Health and Society, Kristianstad University, Kristianstad, Sweden. (Course development, course director, lecturer, computer lab instructor and examiner)

2013-2014 Psychometrics in the health sciences: Theory and application (postgraduate/PhD course), The Swedish Institute for Health Sciences, Lund University, Lund, Sweden. (Course development, course director, lecturer and examiner)

2014- Subject representative for Health Science, School of Health and Society, Kristianstad University, Kristianstad, Sweden.

2015- Health economic evaluation (online Masters-level course, given in English), School of Health and Society, Kristianstad University, Kristianstad, Sweden. (Course examiner)

2015- Research design (online Masters-level course, given in English), School of

Health and Society, Kristianstad University, Kristianstad, Sweden. (Course development, course examiner, lecturer)

2016 Theoretical perspectives on methodological choices in research on ageing and health (postgraduate/PhD course), Swedish Graduate School for Competitive Science on Ageing and Health (SWEAH), Lund University, Lund, Sweden. (Course development, course director and seminar leader)

COMPUTER SKILLS

Working skills with the following relevant computer software programs:

- Ariadne
- Concept Systems
- EndNote
- FACTOR
- GraphPad InStat
- Microsoft Word

7

- Microsoft Excel
- Microsoft PowerPoint
- RUMM 2020/2030
- RUMMss
- SPSS
- Stata
- Statistica
- Systat
- Winsteps

MASTERS STUDENTS

Supervisor for the following MSc-projects (graduated)

- Bedömning av aktivitetsutförande i samband med läkemedelstester av patienter med parkinsonism [Assessment of activity performance in conjunction with drug challenges in patients with Parkinson's disease]. Student: Birgitta Sandlund OT MSc. Graduated 2003.
- Hälsoeffekter av patientundervisning och läkemedelsanvändning vid Parkinsons sjukdom [Health effects and requirement following patient education in Parkinson's disease]. Student: Susanne Lindskov RN MSc. Graduated 2005.
- Sömnkvalitet och dagsömnighet vid Parkinsons sjukdom och dess samband med sjukdomens svårighetsgrad och affektiva symtom [Sleep Quality and Excessive Daytime Sleepiness in Parkinson's Disease and correlates with disease severity and mood]. Student: Arja Höglund RN MSc. Graduated 2006.
- Effekter av standardiserad skriftlig patientinformation inför magnetisk resonanstomografi: En randomiserad placebo-kontrollerad studie [Effects of standardized written patient information before magnetic resonance imaging: a randomized placebo-controlled study]. Student: Anetta Bolejko RN MSc. Graduated 2007.
- Närstående till personer med Parkinsons sjukdom: Upplevelse av hjälp, stöd och vård [Family caregivers of people with Parkinson's disease: Perceived help, support and care]. Students: Yvonne Olsson RN MSc, Lena Carlén RN MSc. Graduated 2009.
- Handhavande och skötsel av centrala venösa infarter: Utvärdering av ett utbildningsprogram [Managing central venous catheters: Evaluation of a training program]. Student: Margareta Troeng RN MSc. Graduated 2009.
- Swedish Walk-12G: Validity and reliability in multiple sclerosis and Parkinson's disease. Student: Stina Bladh PT MSc. Graduated 2010.

□ Intensivvårdspatienter ur genusperspektiv: En retrospektiv registerstudie [Intensive care patients from a gender perspective: A retrospective registry study]. Students: Ulrika Petersson RN MSc, Dariusz Sobiecki RN MSc. Graduated 2010.

Supervisor for the following ongoing MSc-projects

nil

8

POST-GRADUATE STUDENTS

Main supervisor for the following post-graduate (PhD/PhL) projects (graduated)

□ Psychosocial consequences of false-positive mammography among women attending breast cancer screening – Assessment, prediction and coping. PhD-student: Anetta Bolejko RN PhD. Department of Health Sciences, Lund University. Graduated 2014.

□ Fear of falling, falls and near falls in Parkinson's disease. PhD-student: Beata Lindholm PT PhD. Department of Clinical Sciences Lund, Lund University. Graduated 2017.

Main supervisor for the following ongoing post-graduate (PhD/PhL) projects

□ Person-centered care in rheumatologic nurse-led outpatient clinics. PhD-student: Sidona-Valentina Bala RN MSc. Department of Health Sciences, Lund University.

Co-supervisor for the following post-graduate (PhD/PhL) projects (graduated)

□ Psycho-pedagogical work among individuals with autism spectrum disorders in community-based accommodation. Development and psychometric testing of the Environmental Rating Scale Questionnaire (ERS-Q) for assessment of residential programmes. PhD-student: Marie Hübel RN MSc; Main supervisor: Bengt Sivberg PhD. Department of Health Sciences, Lund University. Graduated 2008.

□ Safety and efficacy of oral care for intubated neuroscience intensive care unit patients. PhD-student: Virginia Prendergast RN MSc; Main supervisor: Ingalill Rahm-Hallberg RN PhD. Department of Health Sciences, Lund University. Graduated 2012.

□ Insomnia symptoms in elderly persons: Assessment, associated factors and nonpharmacological

nursing interventions. PhD-student: Amanda Hellström RN MSc;

Main supervisor: Ania Willman RN PhD. Department of Health Sciences, Lund University / School of Health Science, Blekinge Institute of Technology. Graduated 2013.

□ Nutritional status and weight change in Parkinson's disease. Licentiate-student: Susanne Lindskov RN MSc; Main supervisor: Klas Sjöberg MD PhD. Department of Clinical Sciences Malmö, Lund University. Graduated 2015 (licentiate).

□ Biomarkers in Parkinson's disease and related disorders. Diagnostic value of biochemical markers and their relation to disease progression. PhD-student: Sara Hall MD; Main supervisor: Oskar Hansson MD PhD. Department of Clinical Sciences Lund, Lund University. Graduated 2017.

Co-supervisor for the following ongoing post-graduate (PhD/PhL) projects

□ Excessive daytime sleepiness in Parkinson's disease: Relation to other disease aspects and consequences in daily life. PhD-student: Arja Höglund RN MSc; Main supervisor: Sten Fredriksson MD PhD. Department of Clinical Neuroscience, Karolinska Institute, Stockholm.

□ Towards a better care for late stage Parkinson's disease. PhD-student: Kristina Rosqvist PT MSc; Main supervisor: Per Odin MD PhD. Department of Clinical Sciences Lund, Lund University.

□ Personcentrerad vård för ökad livskvalitet - Parkinsonskola för personer med Parkinsons sjukdom och deras närstående [Person-centred care for enhanced quality of life – Parkinson school for people with Parkinson's disease and their carers]. PhD9

student: Carina Hellqvist RN MSc; Main supervisor: Carina Berterö RN PhD.
Department of Medical and Health Sciences, Linköping University.

□ Life satisfaction in Parkinson's disease. PhD-student: Lise Løvereide RN MSc; Main supervisor: Kolbjørn Brønnick PhD. Stavanger University, Norway.

HALF-TIME REVIEWER FOR THE FOLLOWING PhD-STUDENTS

□ Sigrid Tibaek, Section of Physiotherapy, Department of Health Sciences, Lund University, Sweden (2005)

□ Thomas Carlsson, Section of Neuroscience, Department of experimental medical science, Lund University, Sweden (2005)

□ Kay Sundberg, Department of Neurobiology, Care Science and Society, Karolinska Institutet, Stockholm, Sweden (2009)

□ Jerker Westin, Department of Medical Sciences, Biomedical Informatics and Engineering, Uppsala University, Uppsala, Sweden (2010)

□ Pia Strand, Department of Clinical Sciences, Lund University, Lund, Sweden (2013)

EXAMINATION COMMITTEE APPOINTMENTS FOR THE FOLLOWING PHDDISERTATIONS

□ Hanneke Andriess: Follow-up of children with congenital clubfoot - Development of a new evaluation instrument. Division of Physiotherapy, Department of Health Sciences, Lund University (2007)

□ Sigrid Tibaek: Lower Urinary Tract Symptoms in Stroke Patients - A clinical study of prevalence, impact and effect of training. Division of Physiotherapy, Department of Health Sciences, Lund University (2007)

□ Guðrún Árnadóttir. Measuring the impact of body functions on occupational performance: Validation of the ADL-focused Occupation-based Neurobehavioral Evaluation (A-ONE). Department of Community Medicine and Rehabilitation, Occupational Therapy, Umeå University (2010)

□ Eva Ejlersen Wæhrens. Measuring Quality of Occupational Performance Based on Self-report and Observation: Development and Validation of Instruments to Evaluate ADL Task Performance. Department of Community Medicine and Rehabilitation, Occupational Therapy, Umeå University (2010)

□ Bertil Lundberg. Erfarenheter av stigmatisering och diskriminering bland personer med psykisk sjukdom. Division of Nursing, Department of Health Sciences, Lund University (2010)

□ Connie Lethin. Informal caregivers of older persons with dementia in eight European countries. Experiences, support, well-being and burden. Department of Health Sciences, Lund University (2016)

INVITED TO PRESENT AT THE FOLLOWING SCIENTIFIC MEETINGS

□ The 2nd European Conference on Parkinson's Disease. Stockholm, Sweden, 1996.

□ The 3rd European Conference on Parkinson's Disease. Barcelona, Spain, 1998.

□ NIPD Workshop: "The Future of Neural Grafting in Parkinson's Disease: Focus on improving graft survival, and the uses of stem cells and xenogeneic tissue as donor tissue". Santorini, Greece, 1999.

10

□ The 6th International Congress of Parkinson's Disease and Movement Disorders. Barcelona, Spain, 2000.

□ The 4th European Conference on Parkinson's Disease. Vienna, Austria, 2000.

□ Scandinavian-German Movement Disorder Meeting, Gothenburg, Sweden/Kiel, Germany, 2001.

□ 2nd German Congress on Parkinson's Disease: Satellite symposium "Apomorphine – Renaissance in the Treatment of Parkinson's Disease". Bochum, Germany, 2001.

- Annual Meeting of the Swedish Neurological Society. Lund, Sweden, 2001.
- Annual Meeting of the Swedish Medical Association, Stockholm, Sweden, 2001.
- Annual Meeting of the Movement Disorder Caring Society of Sweden, Stockholm, Sweden, 2002.
- 2nd Scandinavian Congress of Neurological Nursing, Reykjavik, Iceland, 2002.
- 14th NECTAR (Network for European CNS Transplantation and Restoration) Annual General Meeting, Amsterdam, The Netherlands, 2003.
- The 5th European Parkinson's Disease Association Multidisciplinary Conference. Lisbon, Portugal, 2004.
- Annual Meeting of the Movement Disorder Caring Society of Sweden, Sölvesborg, Sweden, 2005.
- The 9th Quadrennial Congress of the World Federation of Neuroscience Nurses. Barcelona, Spain, 2005.
- World Parkinson Congress. Washington, D.C., USA, 2006.
- The 5th Scandinavian-German Movement Disorder Meeting, Gothenburg, Sweden/Kiel, Germany, 2007. [Declined]
- The 5th German Congress on Parkinson's Disease. Ulm, Germany, 2007.
- Joint Annual Meeting of the Movement Disorder Caring Society of Sweden and the Swedish Movement Disorder Society, Stockholm, Sweden, 2007.
- XVIIth WFN World Congress on Parkinson's Disease and Related Disorders. Amsterdam, the Netherlands, 2007.
- Biannual conference of the Nordic Network of Parkinson's Disease nurses (NNPD) conference. Oslo, Norway, 2008.
- The 10th Quadrennial Congress of the World Federation of Neuroscience Nurses. Toronto, Canada, 2009.
- The Barrow Nursing Symposium. Barrow Neurological Institute, Phoenix, AZ, USA, 2009.
- The 2nd World Parkinson Congress. Glasgow, UK, 2010.
- The 14th International Congress of Parkinson's Disease and Movement Disorders. Buenos Aires, Argentina, 2010. [Declined]
- The 4th Western China International Neuroscience Forum. Tengchong, China, 2010. [Declined]
- The 15th International Congress of Parkinson's Disease and Movement Disorders. Toronto, Canada, 2011.
- The 18th Annual Conference of the International Society for Quality of Life Research. Denver, CO, USA, 2011. [Declined]
- The 16th International Congress of Parkinson's Disease and Movement Disorders. Dublin, Ireland, 2012. [Declined]

11

- Parkinsons sjukdom – när tablettbehandlingen sviktar. Johannesbergs slott, Gottfröa, Sweden, 2014.
 - Outcomes Group Meeting: Why Methodology Matters? London School of Hygiene & Tropical Medicine, London, UK, 2017.
 - Innovative measurements for improved diagnosis and management of neurodegenerative diseases (satellite meeting to the European project EMPIR 15HLT14 NeuroMet Consortium meeting). RI.SE, Gothenburg, Sweden, 2017.
- INVITED TO PRESENT AT THE FOLLOWING SEMINARS/INSTITUTIONS etc.**
- The Royal College of Nursing's Parkinson's Disease Nurse Specialist Weekend Conference. Grantham, UK, 1997.
 - Workshop: "Ethical Guidance of the Use of Embryonic and Fetal Tissue

Transplantation". Barcelona, Spain, 2000.

- Annual Meeting of the Swedish Parkinson's Disease Association. Stockholm, Sweden, 2000.
- Panel discussion [with Prof. Arvid Carlsson, Prof. Göran Steg, Dr. Bo Johnels, Susanna Lindvall & Anders Borgman] at the 15th anniversary of the Swedish Parkinson's Disease Association in Western Sweden. Gothenburg, Sweden, 2000.
- Seminar: "Quality of Life and Parkinson's Disease". Swedish Neuropsychological Society, Lund, Sweden, 2001.
- Seminar: "Outcomes Measurement in Parkinson's Disease: The Case of Quality of Life". School of Physiotherapy, La Trobe University, Melbourne, Australia, 2001.
- Seminar: "Outcomes Measurement in Parkinson's Disease". Center for Outcomes Research and Evaluation, Evanston Northwestern Healthcare, Evanston, IL, USA, 2002.
- Seminar: "Outcomes Measurement in Parkinson's Disease". Barrow Neurological Institute, Phoenix, AZ, USA, 2003.
- Seminarium om nya arbetsformer för klinisk utbildning, Örebro Universitet och Örebro Läns Landsting, Örebro, 2004 [Seminar on New Forms of Clinical Training, Örebro University and Örebro County Council, Örebro, Sweden, 2004].
- Klinisk utbildningskonferens. SSFs Utbildningsinstitut AB, Lund, 2004 [National Conference on Clinical Training, arranged by the Educational Institute of the Swedish Nurses' Association, Lund, Sweden, 2004].
- Seminar: "Outcomes Assessment in Parkinson's Disease". Solvay Pharmaceuticals GmbH, Hannover, Germany, 2006.
- Nordiskt Parkinsonfördjupningsmöte för sjuksköterskor, Sigtuna, 2007 [Advanced Nordic Meeting on Parkinson's Disease for Nurses, Sigtuna, Sweden, 2007].
- The importance of measurement in neurodegenerative diseases. National Institute for Health Research, Dementias & Neurodegenerative Diseases Research Network. London, UK, 2008.
- Nordiskt Parkinsonfördjupningsmöte för sjuksköterskor [Advanced Nordic Meeting on Parkinson's Disease for Nurses]. Sigtuna, Sweden, 2009.
- Parkinsonförbundets kongress 2009. Aronsborg, Bålsta, 2009 [Congress of the Swedish Parkinson's Disease Society, Aronsborg, Bålsta, Sweden, 2009].

12

- Diagnosis and Management of Non-Motor Symptoms in Parkinsonism. Milan, Italy, 2009. [Declined]
- BAGADILICO Live webinar: Patient Participation in Parkinson's. Lund University, Lund, Sweden, 2014. (http://www.med.lu.se/bagadilico/news_archive/ppp_event; https://www.youtube.com/watch?v=I7_bJ_5rFyI; <https://www.youtube.com/watch?v=KfH8UIBHTJ8>)
- BAGADILICO:s Parkinsoncafé: Prioriterade områden för personer med Parkinsons sjukdom [Prioritized areas for people with Parkinson's disease]. Lund, Sweden, 2015.
- Nordiskt Parkinsonfördjupningsmöte för sjuksköterskor [Advanced Nordic Meeting on Parkinson's Disease for Nurses]. Sigtuna, Sweden, 2015.
- Nordiskt multidisciplinärt Parkinsonfördjupningsmöte [Advanced Nordic Multidisciplinary Meeting on Parkinson's Disease]. Sigtuna, Sweden, 2016.

AWARDS

1999 The Neuroscience Nursing Foundation Award for Achievements in Advancing the Specialty of Neuroscience Nursing through Leadership and Devoted Service (USA).

2000 The Swedish Parkinson's Disease Association's Bronze Medal of Honor.

2000 Honorary Member of the Swedish Parkinson's Disease Association in Western Sweden.

2001 Agnes Marshall Research Award, World Federation of Neuroscience Nurses.

2006 New Investigator Award, International Society for Quality of Life Research.

2015 Nominee for Article of the year award (best peer-reviewed original health-related quality of life paper 2014), International Society for Quality of Life Research.

PROFESSIONAL LEADERSHIP

1995-2000 President of the Movement Disorder Caring Society, Sweden.

1997-2000 Chairman of the International Steering Committee of Movement Disorder Nursing Societies.

1998-1999 Member of the Board of Directors of the World Federation of Neuroscience Nurses.

1999-2001 Secretary of the World Federation of Neuroscience Nurses.

2000-2001 Vice President of the Movement Disorder Caring Society, Sweden.

2001-2005 Board member, the Movement Disorder Caring Society, Sweden.

2001-2005 Vice President of the World Federation of Neuroscience Nurses.

2005-2009 Member of the Board of Directors of the World Federation of Neuroscience Nurses.

2009-2010 Treasurer of the World Federation of Neuroscience Nurses.

2009- Vice President of the Movement Disorder Caring Society, Sweden.

(www.vfmd.se)

2013- Coordinator of the Swedish national network for psychometrics in the health sciences (PMhealth) (www.hkr.se/forskning/forskningsmiljoer/procare/nationellt-psykometrinatverk/).

13

APPOINTMENTS

1997-1998 Member of the Scientific Committee of the 3rd European Conference on Parkinson's Disease, Barcelona, Spain, 1998.

1997-2000 Editorial Board member, *EPDA Magazine*, the European Parkinson's Disease Association.

1998-2001 International Editor and Editorial Board member, the *Journal of Neuroscience Nursing*.

1999-2001 Editor, *International Brain Waves* (newsletter of the World Federation of Neuroscience Nurses).

2001-2005 Scientific Chair of the World Federation of Neuroscience Nurses.

2003 Member of task force group for implementation and evaluation of clinical research, Lund University Hospital, Lund, Sweden.

2003-2004 Member of the Scientific Committee of the 11th Annual Conference of the International Society for Quality of Life Research, Hong Kong, 2004.

2004-2006 Representative of the Faculty of Medicine on the board of the program "Medicine & the Humanics", Faculties of Medicine and of the Humanities and Theology, Lund University, Lund, Sweden.

2004-2006 Member of the Scientific Committee of the World Parkinson Congress, Washington, D.C., USA, 2006.

2004-2009 Member of the International Benefit Assessment Taskforce for Outcome Measurement in Multiple Sclerosis.

2005-2007 Member of the Scientific Advisory Board for Parkinson's disease, H. Lundbeck Pharmaceuticals, Sweden.

2006 Member of the working group on future research strategies of the Faculty of Medicine, Lund University.

2006-2008 Board member, Future Faculty, Faculty of Medicine, Lund University.
2007-2010 Member of the Neurology Advisory Board, H. Lundbeck Pharmaceuticals, Sweden.
2007- Member of the Steering Committee for the Swedish Parkinson's Disease Academy.
2008-2010 Member of the Scientific Committee of the World Parkinson Congress, Glasgow, UK, 2010.
2008-2010 Member of the Movement Disorder Society's Fatigue Scales Task force.
2009- Editorial Board member for the journal *Parkinson's Disease*.
2009- Editorial Board member for the *European Neurological Journal*.
2010 Expert consultant on assessment scales, the National Board of Health and Welfare (Socialstyrelsen), Stockholm, Sweden.
2010- Editorial Board member for the journal *Neurodegenerative Disease Management*.
2012-2013 Member of the Reference Group for the Parkinson Guide.
2012- Member of the PROM Parkinson task force for the national Swedish Parkinson Registry.
2013- Member of the International Steering Committee for PD Communicate (Working together for effective communications in Parkinson's disease).

14

2014- Member of the Research Board, Kristianstad University, Kristianstad, Sweden.
2014-2015 Member of the International Consortium for Health Outcomes Measurement (ICHOM) Standard Set task force for Parkinson's disease.
2015 Member of the scientific review committee for the development of National Guidelines for Parkinson's disease and Multiple Sclerosis, the National Board of Health and Welfare (Socialstyrelsen), Stockholm, Sweden.
2016- Member of the Steering group for the national Swedish Parkinson Registry.
2017- Member of SWEPAR-net (Swedish research network for Parkinson's disease).

MANUSCRIPT REVIEWER FOR THE FOLLOWING JOURNALS

- Acta Neurologica Scandinavia
- Biogerontology
- Brain
- Clinical Neurology and Neurosurgery
- Drugs & Ageing
- European Journal of Cardiovascular Nursing
- European Journal of Neurology
- European Journal of Neuroscience
- European Journal of Psychological Assessment
- Expert Opinion on Biological Therapy
- Expert Review of Clinical Pharmacology
- Fatigue: Biomedicine, Health and Behavior
- Health and Quality of Life Outcomes
- Internet Journal of Mental Health
- Journal of Advanced Nursing
- Journal of Clinical Nursing
- Journal of Clinical Outcomes Management
- Journal of Investigative Dermatology

- Journal of Medical Economics
- Journal of Mixed Methods Research
- Journal of Neurology
- Journal of Neurology, Neurosurgery & Psychiatry
- Journal of Neuroscience Nursing
- Journal of Pain and Symptom Management
- Journal of Parkinson's Disease
- Journal of Psychosomatic Research
- Lancet Neurology
- Movement Disorders
- Multiple Sclerosis
- Neurodegenerative Disease Management
- Neurology

15

- PLOS One
- Quality of Life Research
- Scandinavian Journal of Primary Health Care
- Trials
- Value in Health

RESEARCH GRANT REVIEWER FOR THE FOLLOWING FUNDING BODIES

- Caring Science Project Grant, Lund University hospital, Lund Sweden (2003-2005)
- Parkinson's Disease Society, United Kingdom (2005-)
- Neuroscience Nursing Foundation, USA (2005-2009)
- The Swedish Parkinson's Disease Academy (2007-)
- Kristianstad University (2014-)
- The Swedish Parkinson Foundation (2017-)

RESEARCH FUNDING (SELECTED)

1999 The Skane County Council Research and Development Foundation
(Outcome Measurement in Parkinson's Disease; SEK 120,000)

P.I.: Peter Hagell

2000 The Skane County Council Research and Development Foundation
(Outcome Measurement in Parkinson's Disease; SEK 60,000)

P.I.: Peter Hagell

2001 The Skane County Council Research and Development Foundation
(Outcome Measurement in Parkinson's Disease; SEK 60,000)

P.I.: Peter Hagell

2001-2003 Rådet för hälso- och sjukvårdsforskning (HSF) [Council of Health care research] (Health Status Measurement in Parkinson's Disease; SEK 50,000)

P.I.: Peter Hagell

2002 The Skane County Council Research and Development Foundation
(Outcome Measurement in Parkinson's Disease; SEK 60,000)

P.I.: Peter Hagell

2002-2003 The Rut och Erik Hardebo Foundation, the Elsa Schmitz Foundation
(Health Economy in Parkinson's Disease; SEK 40,000)

P.I.: Peter Hagell

2003 The Skane County Council Research and Development Foundation
(Outcome Measurement in Parkinson's Disease; SEK 60,000)

P.I.: Peter Hagell

2003-2005 The Parkinson Foundation in Sweden (Effect of Patient Education in

Parkinson's Disease; SEK 300,000)

P.I.: Peter Hagell

2003-2005 The Parkinson Foundation in Sweden (Fatigue in Parkinson's Disease; SEK 150,000)

P.I.: Peter Hagell

2004 The Skane County Council Research and Development Foundation

(Outcome Measurement in Parkinson's Disease; SEK 65,000)

P.I.: Peter Hagell

16

2004 Department of Nursing, Lund University (Measuring and Understanding Outcomes in Parkinson's Disease; SEK 150,000)

P.I.: Peter Hagell

2004-2005 The Vårdal Institute (Measuring and Understanding Outcomes in Parkinson's Disease; SEK 200,000)

P.I.: Peter Hagell

2005 The Skane County Council Research and Development Foundation

(Outcome Measurement in Parkinson's Disease; SEK 70,000)

P.I.: Peter Hagell

2005-2009 The Swedish Research Council (Measuring and Understanding Outcomes in Parkinson's Disease; SEK 3,870,000)

P.I.: Peter Hagell

2005-2007 Galen Research, UK (Adaptation and validation of the Patient Reported Indices of Multiple Sclerosis (PRIMUS) and a modified Fatigue Impact Scale (FIS) for use in Sweden; GBP 13,550)

P.I.: Peter Hagell

2006 The Skane County Council Research and Development Foundation

(Outcome Measurement in Parkinson's Disease; SEK 70,000)

P.I.: Peter Hagell

2007-2008 The Skane County Council Research and Development Foundation

(Outcome Measurement in Parkinson's Disease; SEK 70,000/year)

P.I.: Peter Hagell

2007-2008 The Parkinson Foundation in Sweden (MAP-PD: Multidimensional outcome Assessment in People with Parkinson's Disease; SEK 100,000)

P.I.: Peter Hagell

2008-2011 Faculty of Medicine, Lund University (ALF) (MAP-PD: Multidimensional outcome Assessment in People with Parkinson's Disease; SEK 789,000)

P.I.: Peter Hagell

2008-2010 AFA Insurance (Early diagnostics and novel therapies for Parkinson's disease; SEK 1,000,000)

P.I.: Oskar Hansson

Co-P.I.: Peter Hagell

2008-2018 Linnaeus Grant, the Swedish Research Council and the Swedish Research Council for Environment, Agricultural Sciences and Spatial Planning

(Bagadilico – a joint initiative for the development of novel therapies for basal ganglia disorders; SEK 75,000,000)

P.I.: Patrik Brundin

Co-P.I.: Peter Hagell

2012-2014 Vårdalstiftelsen (DUNÄT: Datoriserat utbildningsprogram för omvårdnadspersonal med fokus på evidensbaserade nutritionsbedömningar och åtgärder – utveckling, implementering och åtgärder; SEK 1,500,000)

P.I.: Albert Westergren

Co-P.I.: Peter Hagell

2017-2018 Stiftelsen Olle Engkvist Byggmästare (Svenska Parkinsonakademien vid Skånes universitetssjukhus (Lund) - mot en bättre framtid för Parkinsonpatienter i Sverige och internationellt; SEK 4,600,000)

17

P.I.: Per Odin

Co-P.I.: Peter Hagell

2016-2018 The Parkinson Foundation in Sweden (Daytime sleepiness in Parkinson's disease: Associations with other disease aspects and consequences in daily life; SEK 135,000)

P.I.: Peter Hagell

2017 The Skane County Council Research and Development Foundation (Gait and balance problems in Parkinson's disease: Predictive factors and clinical tests; SEK 180,000)

P.I./Supervisor: Peter Hagell

2017 Lions Forskningsfond (Ofrivillig viktförändring vid Parkinsons sjukdom: 5-årsuppföljning och relation till immunologisk aktivering/Unintentional weight change in Parkinson's disease: A 5-year follow-up and relation to immunological activation); SEK 75,000)

P.I.: Klas Sjöberg

Co-P.I.: Peter Hagell

SCIENTIFIC COLLABORATORS

[* = active collaborations]

- * David Andrich, PhD: Graduate School of Education, University of Western Australia, Perth, Australia.
- * Kolbjørn Brønnick, Stavanger University, Stavanger, Norge.
- Lena Brundin, MD PhD: Department of Clinical Sciences, Section of Psychiatry, Lund University, Lund, Sweden.
- Patrik Brundin, MD PhD: Department of Experimental Medical Science, Lund University, Lund, Sweden.
- John Brodersen, MD PhD: Institute of Public Health, University of Copenhagen, Copenhagen, Denmark.
- * Jan-Erik Broman, RN PhD: Department of Neuroscience, Uppsala University Hospital, Uppsala, Sweden.
- David Cella, PhD: Center on Outcomes Research and Education Evanston Northwestern Healthcare/Northwestern University, Evanston, IL, USA.
- Mona Eklund, OT PhD: Department of Health Sciences, Lund University, Lund, Sweden.
- Lena-Karin Erlandsson, OT PhD: Department of Health Sciences, Lund University, Lund, Sweden.
- Lars Forsgren, MD PhD: Department of Pharmacology and Clinical Neuroscience, Umeå University, Umeå, Sweden.
- * Sten Fredrikson, MD PhD: Department of Neurology, Karolinska University Hospital Huddinge, Stockholm, Sweden.
- * Bengt Fridlund, RN PhD: School of Health and Welfare, Jönköping University, Jönköping, Sweden.
- * Gun-Marie Hariz, OT PhD: Department of Community Medicine and Rehabilitation, Umeå University, Umeå, Sweden.

18

- * Oskar Hansson, MD PhD: Department of Clinical Sciences, Lund University, Lund, Sweden.
 - * Jeremy Hobart, MD PhD: Peninsula Medical School, Plymouth, UK.
 - Markus Idvall, PhD: Department of Arts and Cultural Sciences, Ethnology, Lund University, Lund, Sweden.
 - Ulf Jakobsson, RN PhD: Department of Health Sciences, Lund University, Lund, Sweden.
 - Jan-Petter Larsen, MD PhD: Stavanger University Hospital, Stavanger, Norge.
 - Olle Lindvall, MD PhD: Section of Restorative Neurology, Skåne University Hospital, Lund, Sweden.
 - * Stephen P. McKenna, PhD: Galen Research, Manchester, UK.
 - * Maria H. Nilsson, PT PhD: Department of Health Sciences, Lund University, Lund, Sweden.
 - Per Nyberg, PhD: Department of Health Sciences, Lund University, Lund, Sweden.
 - Lennart Nyberg, PhD: Department of English, Lund University, Lund, Sweden.
 - * Per Odin, MD PhD: Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
 - Richard Osborne, PhD: Centre for Rheumatic Diseases, University of Melbourne, Melbourne, Australia.
 - * Ulf Persson, PhD: The Swedish Institute for Health Economics, Lund, Sweden.
 - * Sven Pålhagen, MD PhD: Department of Neurology, Karolinska University Hospital Huddinge, Stockholm, Sweden.
 - Ingalill Rahm Hallberg, RN PhD: Department of Health Sciences, Lund University, Lund, Sweden.
 - * Scott Rosas, PhD: Concept Systems, Inc., Ithaca, NY, USA.
 - Karin Samuelson, RN PhD: Department of Health Sciences, Lund University, Lund, Sweden.
 - Bengt Sivberg, PhD: Department of Health Sciences, Lund University, Lund, Sweden.
 - * Klas Sjöberg, MD PhD: Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden.
 - * Stephen Smith, RN MPhil: University of East Anglia, Norwich, UK.
 - * A. Jackson Stenner, PhD: University of North Carolina/MetaMetrics Inc., Chapel Hill, NC, USA.
 - * Catharina Sjö Dahl Hammarlund, PT PhD: Department of Health Sciences, Lund University, Lund, Sweden.
 - * Christine Wann-Hansson, RN PhD: Faculty of Health and Society, Malmö University, Malmö, Sweden.
 - * Albert Westergren, RN PhD: School of Health and Society, Kristianstad University, Kristianstad, Sweden.
 - Lena Wettergren, RN PhD: Department of Neurobiology, Care Science and Society, Karolinska Institutet, Stockholm, Sweden.
 - * Klas Wictorin, MD PhD: Department of Neurology, University Hospital, Lund, Sweden.
- 19
- Håkan Widner, MD PhD: Department of Neurology, Skåne University Hospital, Lund, Sweden.
 - Ania Willman RN PhD: Faculty of Health and Society, Malmö University, Malmö, Sweden.
 - Sophia Zackrisson, MD PhD: Diagnostic Centre for Imaging and Functional

Medicine, Skåne University Hospital, Malmö, Sweden.

□ * Kristofer Årestedt, RN PhD: Department of Medical and Health Sciences, Linköping University, Linköping, Sweden.

INTERNATIONAL PUBLICATIONS

h-index: 37 (Publish or Perish, April 2017)

Average citations/paper: 31.89

PhD Thesis

□ Hagell P. Assessment of graft effects and function in cell replacement therapy for Parkinson's disease. Section of Restorative Neurology, Division of Neurology, Department of Clinical Neuroscience, Faculty of Medicine, Lund University, 2002.

Original Research Articles

[* = included in PhD-thesis]

□ Wenning G, Odin P, Morrish P, Rehncrona S, Widner H, Brundin P, Rothwell JC, Brown R, Gustavii B, Hagell P, Jahanshahi M, Sawle G, Björklund A, Brooks DJ, Marsden CD, Quinn NP, Lindvall O. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. *Annals of Neurology* 1997; 42: 95-107.

□ Pietz K, Hagell P, Odin P. Subcutaneous apomorphine in late stage Parkinson's disease: A long-term follow-up. *Journal of Neurology Neurosurgery and Psychiatry* 1998; 65: 709-716.

□ Hagell P, Odin P, Vinge E. Pregnancy in Parkinson's disease: A review of the literature and a case report. *Movement Disorders* 1998; 13: 34-38.

□ * Hagell P, Widner H. Clinical rating of dyskinesias in Parkinson's disease: Use and reliability of a new rating scale. *Movement Disorders* 1999; 14: 448-455.

□ * Hagell P, Schrag A, Piccini P, Jahanshahi M, Brown R, Rehncrona S, Widner H, Brundin P, Rothwell JC, Odin P, Wenning GK, Morrish P, Gustavii B, Björklund A, Brooks DJ, Marsden CD, Quinn NP, Lindvall O. Sequential bilateral transplantation in Parkinson's disease: Effects of the second graft. *Brain* 1999; 122: 1121-1132.

□ * Piccini P, Brooks D, Björklund A, Gunn RN, Grasby PM, Rimoldi O, Brundin P, Hagell P, Rehncrona S, Widner H, Lindvall O. Dopamine release from nigral transplants visualized *in vivo* in a Parkinson's patient. *Nature Neuroscience* 1999; 2: 1137-1140.

□ * Hagell P, Crabb L, Pogarell O, Schrag A, Widner H, Brooks DJ, Oertel WH, Quinn NP, Lindvall O. Health-related quality of life following bilateral intrastriatal transplantation in Parkinson's disease. *Movement Disorders* 2000; 15: 224-229.

20

□ Brundin P, Pogarell O, Hagell P, Piccini P, Widner H, Schrag A, Kupsch A, Crabb L, Odin P, Gustavii B, Björklund A, Brooks DJ, Marsden CD, Oertel WH, Quinn NP, Rehncrona S, Lindvall O. Bilateral caudate and putamen grafts of lazardoid-treated embryonic mesencephalic tissue in Parkinson's disease. *Brain* 2000; 123(Pt 7): 1380-1390.

□ Piccini P, Lindvall O, Björklund A, Brundin P, Hagell P, Cerevalo R, Oertel W, Quinn N, Samuel M, Rehncrona S, Widner H, Brooks D. Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. *Annals of Neurology* 2000; 48(5): 689-695.

□ * Hagell P, Piccini P, Björklund A, Brundin P, Rehncrona S, Widner H, Crabb L, Oertel WH, Quinn N, Brooks DJ, Lindvall O. Dyskinesias following neural transplantation in Parkinson's disease. *Nature Neuroscience* 2002; 5(7): 627-628.

□ Hagell P, Nordling S, Reimer J, Grabowski M, Persson U. Resource use and costs in a Swedish cohort of patients with Parkinson's disease. *Movement Disorders* 2002;

17(6): 1213-1220.

- * Hagell P, Whalley D, McKenna SP, Lindvall O. Health status measurement in Parkinson's disease: Validity of the PDQ-39 and Nottingham Health Profile. *Movement Disorders* 2003; 18(7): 773-783.
 - Masferrer R, Prendergast V, Hagell P. Colored pain drawings: Preliminary observations in a neurosurgical practice. *European Journal of Pain* 2003; 7(3): 213-217.
 - Hagell P, McKenna SP. International use of health status questionnaires in Parkinson's disease: Translation is not enough. *Parkinsonism & Related Disorders* 2003; 10(2): 89-92.
 - Reimer J, Grabowski M, Lindvall O, Hagell P. Use and interpretation of on/off diaries in Parkinson's disease. *Journal of Neurology Neurosurgery & Psychiatry* 2004; 75: 396-400.
 - Piccini P, Pavese N, Hagell P, Reimer J, Björklund A, Oertel WH, Quinn NP, Brooks DJ, Lindvall O. Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. *Brain* 2005; 128: 2977-2986.
 - Kim MY, Dahlberg A, Hagell P. Respondent burden and patient perceived validity of the PDQ-39. *Acta Neurologica Scandinavica* 2006; 113(2): 132-137.
 - Hagell P, Westergren A. The significance of importance: An evaluation of Ferrans and Powers' Quality of Life Index. *Quality of Life Research* 2006; 15(5): 867-876.
 - Hjelmgren J, Ghatnekar O, Reimer J, Grabowski M, Lindvall O, Persson U, Hagell P. Estimating the value of novel interventions for Parkinson's disease: An early decision-making model with application to dopamine cell replacement. *Parkinsonism & Related Disorders* 2006; 12(7): 443-452.
 - Hagell P, Höglund A, Reimer J, Eriksson B, Knutsson I, Widner H, Cella D. Measuring fatigue in Parkinson's disease: A psychometric study of two brief generic fatigue questionnaires. *Journal of Pain and Symptom Management* 2006; 32(5): 420-432.
 - Westergren A, Hagell P. Initial validation of the Swedish version of the London Handicap Scale. *Quality of Life Research* 2006; 15(7): 1251-1256.
- 21
- Hagell P, Broman JE. Measurement properties and hierarchical item structure of the Epworth Sleepiness Scale in Parkinson's disease. *Journal of Sleep Research* 2007; 16(1): 102-109.
 - Lindskov S, Westergren A, Hagell P. A controlled trial of an educational programme for people with Parkinson's disease. *Journal of Clinical Nursing* 2007; 16(11c): 368-376.
 - Hagell P, Nygren C. The 39-item Parkinson's disease questionnaire (PDQ-39) revisited: implications for evidence-based medicine. *Journal of Neurology Neurosurgery & Psychiatry* 2007; 78(11): 1191-1198.
 - Hagell P. Nursing and multidisciplinary interventions for Parkinson's disease: What is the evidence? *Parkinsonism & Related Disorders* 2007; 13(Suppl 3): S501-S508.
 - Hagell P, Törnqvist AL, Hobart J. Testing the SF-36 in Parkinson's disease: Implications for reporting rating scale data. *Journal of Neurology* 2008; 255(2): 246-254.
 - Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, Lashley T, Quinn NP, Rehncrona S, Björklund A, Widner H, Revesz T, Lindvall O, Brundin P. Lewy bodies in grafted neurons in Parkinson patients suggest host to graft disease propagation. *Nature Medicine* 2008; 14(5): 501-503.
 - Wann-Hansson C, Hagell P, Willman A. Risk factors and prevention among patients

with hospital-acquired and pre-existing pressure ulcers in an acute care hospital.

Journal of Clinical Nursing 2008; 17(13): 1718-1727.

□ Hübel M, Hagell P, Sivberg B. Development and initial testing of a questionnaire version of the Environmental Rating Scale (ERS) for assessment of residential programs for individuals with autism. *Journal of Autism and Developmental Disorders* 2008; 38(6): 1178-1183.

□ Wann-Hansson C, Klevsgård R, Hagell P. Cross-diagnostic validity of the Nottingham Health Profile index of Distress (NHPD). *Health and Quality of Life Outcomes* 2008; 6: 47.

□ Bolejko A, Sarvik C, Hagell P, Brinck A. Meeting patient information needs prior to magnetic resonance imaging: development and evaluation of an information booklet. *Journal of Radiology Nursing* 2008; 27(3): 96-102.

□ Eklund M, Erlandsson LK, Persson D, Hagell P. Rasch analysis of an instrument for measuring occupational value: implications for theory and practice. *Scandinavian Journal of Occupational Therapy* 2009; 16(2): 118-128.

□ Hagell P, Brundin L. Towards an understanding of fatigue in Parkinson's disease. *Journal of Neurology Neurosurgery & Psychiatry* 2009; 80(5): 489-492.

□ Hagell P, Reimer J, Nyberg P. Whose quality of life? Ethical implications in patient-reported

health outcome measurement. *Value in Health* 2009; 12(4): 613-617.

□ Lindqvist D, Janelidze S, Hagell P, Erhardt S, Samuelsson M, Minthon L, Hansson O, Björkqvist M, Träskman-Bendz L, Brundin L. Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. *Biological Psychiatry* 2009; 66(3): 287-292.

□ Hagell P, Nilsson MH. The 39-item Parkinson's disease questionnaire (PDQ-39): Is it a unidimensional construct? *Therapeutic Advances in Neurological Disorders* 2009; 2(4): 205-214.

22

□ Prendergast V, Rahm Hallberg I, Jahnke H, Kleiman C, Hagell P. Oral health, ventilator-acquired pneumonia, and ICP among intubated neuroscience ICU patients. *American Journal of Critical Care* 2009; 18(4): 368-376.

□ Nilsson MH, Hagell P. Freezing of Gait Questionnaire: validity and reliability of the Swedish version. *Acta Neurologica Scandinavica* 2009; 120: 331-334.

□ Friedman JH, Alves G, Hagell P, Marinus J, Marsh L, Martinez-Martin P, Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins G, Schrag A. Fatigue rating scales: Critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease. *Movement Disorders* 2010; 25(7): 805-822.

□ Knutsson I, Rydström H, Reimer J, Nyberg P, Hagell P. Interpretation of response categories in patient-reported rating scales: a controlled study among people with Parkinson's disease. *Health and Quality of Life Outcomes* 2010; 8: 61.

□ Nilsson MH, Westergren A, Carlsson G, Hagell P. Uncovering indicators of the International Classification of Functioning, Disability, and Health from the 39-item Parkinson's Disease Questionnaire. *Parkinson's Disease* 2010: Article ID 984673 (doi:10.4061/2010/984673).

□ Hagell P, Hedin PJ, Meads DM, Nyberg L, McKenna SP. Effects of method of translation of patient-reported health outcome questionnaires: A randomized study of the translation of the Rheumatoid Arthritis Quality of Life (RAQoL) instrument for Sweden. *Value in Health* 2010; 13(4): 424-430.

□ Doward LC, Meads DM, Fisk J, Twiss J, Hagell P, Oprandi NC, Grand'Maison F, Bhan V, Arbizu T, Kohlmann T, Brassat D, Eckert BT, McKenna SP. International

development of the Unidimensional Fatigue Impact Scale (U-FIS). *Value in Health* 2010; 13(4): 463-468.

□ Nilsson MH, Hariz GM, Wictorin K, Miller M, Forsgren L, Hagell P. Development and testing of a self administered version of the Freezing of Gait Questionnaire. *BMC Neurology* 2010; 10: 85.

□ af Sandeberg M, Johansson EM, Hagell P, Wettergren L. Psychometric properties of the DISABKIDS Chronic Generic Module (DCGM-37) when used in children undergoing treatment for cancer. *Health and Quality of Life Outcomes* 2010; 8: 109.

□ Nilsson MH, Holmbäck AM, Hagell P. Assessment of fall-related self-efficacy and activity avoidance in people with Parkinson's disease. *BMC Geriatrics* 2010, 10: 78.

□ Hellström A, Hagell P, Fagerström C, Willman A. Measurement properties of the Minimal Insomnia Symptom Scale (MISS) in an elderly population in Sweden. *BMC Geriatrics* 2010; 10: 84.

□ Hübel M, Hagell P, Sivberg B. Psychometric properties of the of the questionnaire version (ERS-Q) of the Environmental Rating Scale (ERS) for assessment of residential programs for individuals with autism. *Scandinavian Journal of Disability Research* 2010; 12(4): 245-256.

□ McKenna SP, Doward LC, Twiss J, Hagell P, Oprandi NC, Fisk J, Grand'Maison F, Bhan V, Arbizu T, Brassat D, Kohlmann T, Meads DM, Eckert BJ. International development of the Patient Reported Outcome Indices for Multiple Sclerosis (PRIMUS). *Value in Health* 2010; 13(8): 946-951.

□ Vallén C, Hagell P, Westergren A. Validity and user-friendliness of the minimal eating observation and nutrition form – version II (MEONF – II) for undernutrition

23
risk screening. *Food & Nutrition Research* 2011; 55: 5801. (doi: 10.3402/fnr.v55i0.5801)

□ Prendergast V, Hagell P, Rahm Hallberg I. Electric vs. manual tooth brushing among neuroscience ICU patients: Is it safe? *Neurocritical Care* 2011; 14(2):281-286.

□ Westergren A, Norberg E, Vallén C, Hagell P. Cut-off scores for the Minimal Eating Observation and Nutrition Form – Version II (MEONF-II) among hospital inpatients. *Food & Nutrition Research* 2011; 55: 7289. (doi: 10.3402/fnr.v55i0.7289)

□ Hagell P, Westergren A. Measurement properties of the SF-12 Health Survey in Parkinson's disease. *Journal of Parkinson's Disease* 2011; 1(2): 185-196.

□ Westergren A, Norberg E, Hagell P. Diagnostic performance of the Minimal Eating Observation and Nutrition Form - Version II (MEONF-II) and Nutritional Risk Screening 2002 (NRS 2002) among hospital inpatients - a cross-sectional study. *BMC Nursing* 2011; 10: 24. (doi:10.1186/1472-6955-10-24)

□ Nilsson MH, Hariz GM, Iwarsson S, Hagell P. Walking ability is a major contributor to fear of falling in people with Parkinson's disease: Implications for rehabilitation. *Parkinson's Disease* 2012: Article ID 713236 (doi: 10.1155/2012/713236).

□ Sjö Dahl Hammarlund C, Hagell P, Nilsson MH. Motor and non-motor predictors of illness-related distress in Parkinson's disease. *Parkinsonism & Related Disorders* 2012; 18(3): 299-302.

□ Sjö Dahl Hammarlund C, Nilsson MH, Hagell P. Measuring outcomes in Parkinson's disease: A multi-perspective concept mapping study. *Quality of Life Research* 2012; 21(3): 453-463.

□ Hagell P, Rosblom T, Pålhagen S. A Swedish version of the 16-item Parkinson Fatigue Scale (PFS-16). *Acta Neurologica Scandinavica* 2012; 125(4): 288-292.

□ Bladh S, Nilsson MH, Hariz GM, Westergren A, Hobart J, Hagell P. Psychometric performance of a generic walking scale (Walk-12G) in multiple sclerosis and

Parkinson's disease. *Journal of Neurology* 2012; 259(4): 729-738.

□ Jakobsson U, Westergren A, Lindskov S, Hagell P. Construct validity of the SF-12 in three different samples. *Journal of Evaluation in Clinical Practice* 2012; 18(3): 560-566.

□ Eklund M, Erlandsson LK, Hagell P. Psychometric properties of a Swedish version of the Pearlin Mastery Scale in people with mental illness and healthy people. *Nordic Journal of Psychiatry* 2012; 66(6): 380-388.

□ Bala SV, Samuelson K, Hagell P, Svensson B, Fridlund B, Hesselgard K. The experience of care at nurse-led rheumatology clinics. *Musculoskeletal Care* 2012; 10(4): 202-211.

□ Westergren A, Edfors E, Hedin G, Hagell P. Improving nursing students research knowledge through participation in a study about nutrition, its associated factors and assessment. *Journal of Nursing Education and Practice* 2013; 3(8): 50-58.

□ Bolejko A, Wann-Hansson C, Zackrisson S, Brodersen J, Hagell P. Adaptation to Swedish and further development of the "Consequences of Screening – Breast Cancer" questionnaire: a multi-method study. *Scandinavian Journal of Caring Sciences* 2013; 27(2): 475-486.

24

□ Knutsson I, Samuelson K, Hagell P. Stability of rating scale response category interpretations in neurological disorders. *Acta Neurologica Scandinavica* 2013; 128(4): 265–272.

□ Steen Krawczyk R, Hagell P, Sjö Dahl Hammarlund C. Danish translation and psychometric testing of the Rivermead Mobility Index. *Acta Neurologica Scandinavica* 2013; 128(4): e20-e25. (doi: 10.1111/ane.12144)

□ Hagell P, Smith S. A psychometric comparison of two carer quality of life questionnaires in Huntington's disease: Implications for neurodegenerative disorders. *Journal of Huntington's Disease* 2013; 2(3): 315-322.

□ Nilsson MN, Bladh S, Hagell P. Fatigue in Parkinson's disease: Measurement properties of a generic and a condition-specific rating scale. *Journal of Pain and Symptom Management* 2013; 46(5): 737-746.

□ Westergren A, Hagell P. Measurement properties of the SF-12 Health Survey in stroke. *Journal of Neuroscience Nursing* 2014; 46(1): 34-45.

□ Lindholm B, Hagell P, Hansson O, Nilsson MH. Factors associated with fear of falling in people with Parkinson's disease. *BMC Neurology* 2014; 14: 19. (doi:10.1186/1471-2377-14-19)

□ Sjö Dahl Hammarlund C, Nilsson MH, Idvall M, Rosas SR, Hagell P. Conceptualizing and prioritizing clinical trial outcomes from the perspectives of people with Parkinson's disease vs. health care professionals: A concept mapping study. *Quality of Life Research* 2014; 23(6): 1687-1700.

□ Westergren A, Torfadóttir Ó, Hagell P. Inter- and intrarater reliability of Minimal Eating Observation and Nutrition Form - version II (MEONF-II) nurse assessments among hospital inpatients. *BMC Nursing* 2014; 13: 8. (doi:10.1186/1472-6955-13-18)

□ Lindskov S, Sjöberg K, Westergren A, Hagell P. Malnutrition risk in Parkinson's disease. *Journal of Aging Research and Clinical Practice* 2014; 3(2): 93-99.

□ Bolejko A, Zackrisson S, Hagell P, Wann-Hansson C. A rollercoaster of emotions and sense – coping with the perceived psychosocial consequences of a false-positive screening mammography. *Journal of Clinical Nursing* 2014; 23(13-14): 2053-2062. (doi: 10.1111/jocn.12426)

□ Hagell P. Testing rating scale unidimensionality using the Principal Component Analysis (PCA)/t-test protocol with the Rasch model: The primacy of theory over statistics. *Open*

- Journal of Statistics* 2014; 4(6): 456-465. (doi: 10.4236/ojs.2014.46044)
- Bolejko A, Brodersen J, Zackrisson S, Wann-Hansson C, Hagell P. Psychometric properties of a Swedish version of the Consequences of Screening – Breast Cancer questionnaire. *Journal of Advanced Nursing* 2014; 70(10): 2373-2388. (doi: 10.1111/jan.12385)
 - Sjö Dahl Hammarlund C, Andersson K, Andersson M, Nilsson MH, Hagell P. The significance of walking from the perspective of people with Parkinson's disease. *Journal of Parkinson's Disease* 2014; 4(4): 657-663.
 - Westergren A, Hagell P, Sjö Dahl Hammarlund C. Malnutrition and risk of falling among elderly without home-help service – a cross sectional study. *The Journal of Nutrition, Health & Aging* 2014; 18(10): 905-911. (doi: 10.1007/s12603-014-0469-5)
 - Westergren A, Torfadóttir Ó, Hagell P. Malnutrition and nutritional care in an Icelandic teaching hospital. *Research* 2014; 1: 1270. (doi: 10.13070/rs.en.1.1270) 25
 - Lindholm B, Hagell P, Hansson O, Nilsson MH. Prediction of falls and/or near falls in people with mild Parkinson's disease. *PLoS One* 2015 Jan 30; 10(1): e0117018. (doi: 10.1371/journal.pone.0117018)
 - Westergren A, Broman JE, Hellström A, Fagerström C, Willman A, Hagell P. Measurement properties of the Minimal Insomnia Symptom Scale as an insomnia screening tool for adults and the elderly. *Sleep Medicine* 2015; 16(3): 379-384. (doi: 10.1016/j.sleep.2014.10.016)
 - Westergren A, Khalaf A, Hagell P. A Swedish version of the SCREEN II for malnutrition screening among community-dwelling elderly. *Scandinavian Journal of Public Health* 2015; 43(6): 667–671. (doi: 10.1177/1403494815575339)
 - Nilsson MH, Hagell P, Iwarsson S. Psychometric properties of the General Self-Efficacy Scale in Parkinson's disease. *Acta Neurologica Scandinavica* 2015; 132(2): 89-96. (doi: 10.1111/ane.12368)
 - Höglund A, Broman JE, Pålhagen S, Fredrikson S, Hagell P. Is excessive daytime sleepiness a separate manifestation in Parkinson's disease? *Acta Neurologica Scandinavica* 2015; 132(2): 97-104. (doi: 10.1111/ane.12378)
 - Bolejko A, Hagell P, Wann-Hansson C, Zackrisson S. Prevalence, long-term development, and predictors of psychosocial consequences of false-positive mammography among women attending population-based screening. *Cancer Epidemiology, Biomarkers & Prevention* 2015; 24(9): 1388-1397. (doi: 10.1158/1055-9965.EPI-15-0060)
 - Blom L, Petersson P, Hagell P, Westergren A. The Situation, Background, Assessment and Recommendation (SBAR) model for communication between health care professionals: A clinical intervention pilot study. *International Journal of Caring Sciences* 2015; 8(3): 530-535.
 - Henriksson A, Hudson P, Öhlen J, Thomas K, Holm M, Carlander I, Hagell P, Årestedt K. Use of the Preparedness for Caregiving Scale in palliative care: A Rasch evaluation study. *Journal of Pain and Symptom Management* 2015; 50(4): 533-541. (doi: 10.1016/j.jpainsymman.2015.04.012)
 - Lindskov S, Sjöberg K, Hagell P, Westergren A. Weight stability in Parkinson's disease. *Nutritional Neuroscience* 2016; 19(1): 11-20.
 - Smith S, Westergren A, Saunders J, Hagell P. Nutritional screening: a user-friendly tool adapted from Sweden. *British Journal of Nursing* 2016; 25(4): 208-211. (doi: 10.12968/bjon.2016.25.4.208)
 - Olsson Y, Clarén L, Alvariza A, Årestedt K, Hagell P. Health and social service access among family caregivers of people with Parkinson's disease. *Journal of Parkinson's Disease* 2016; 6(3): 581-587. (doi: 10.3233/JPD-160811)

- Hagell P, Edfors E, Hedin G, Westergren A, Sjö Dahl Hammarlund C. Group concept mapping for evaluation and development in nursing education. *Nurse Education in Practice* 2016; 20: 147-153. (doi: 10.1016/j.nepr.2016.08.006)
 - Hagell P, Westergren A, Janelidze S, Hansson O. The Swedish SCOPA-SLEEP for assessment of sleep disorders in Parkinson's disease and healthy controls. *Quality of Life Research* 2016; 25(19): 2571-2577. (doi: 10.1007/s11136-016-1318-2)
 - Westergren A, Edfors E, Norberg E, Stubbendorff A, Hedin G, Wetterstrand M, Hagell P. Short-term effects of a computer based nutritional nursing training program for inpatient hospital care. *Journal of Evaluation in Clinical Practice* 2016; 22(5): 799-807. (doi: 10.1111/jep.12545)
 - Sjö Dahl Hammarlund C, Hagell P, Westergren A. Fall risk and its associated factors among older adults without home-help services in a Swedish municipality. *Journal of Community Health Nursing* 2016; 33(4): 181-189. (doi: 10.1080/07370016.2016.1227211)
 - Løvereide L, Hagell P. Measuring life satisfaction in Parkinson's disease and healthy controls using the Satisfaction With Life Scale. *PLoS One* 2016 Oct 24; 11(10): e0163931. (doi: 10.1371/journal.pone.0163931)
 - Westergren A, Hagell P, Wendin K, Sjö Dahl Hammarlund C. Conceptual relationships between the ICF and experiences of mealtimes and related tasks among persons with Parkinson's disease. *Nordic Journal of Nursing Research* 2016; 36(4): 201-208. (doi: 10.1177/2057158516642386)
 - Lindholm B, Nilsson MH, Hansson O, Hagell P. External validation of a 3-Step Falls Prediction Model in mild Parkinson's disease. *Journal of Neurology* 2016; 263(12): 2462-2469. (doi: 10.1007/s00415-016-8287-9)
 - Hagell P, Westergren A. Sample size and statistical conclusions from tests of fit to the Rasch model according to the Rasch Unidimensional Measurement Model (RUMM) program in health outcome measurement. *Journal of Applied Measurement* 2016; 17(4): 416-431.
 - Hagell P, Alvariza A, Westergren A, Årestedt K. Assessment of burden among family caregivers of people with Parkinson's disease using the Zarit Burden Interview. *Journal of Pain and Symptom Management* 2017; 53(2): 272-278. (doi: 10.1016/j.jpainsymman.2016.09.007)
- Accepted for Publication*
- Timpka J, Svensson J, Nilsson MH, Pålhagen S, Hagell P, Odin P. Workforce unavailability in Parkinson's disease. *Acta Neurologica Scandinavica*. (doi: 10.1111/ane.12602)
 - Rosqvist K, Hagell P, Odin P, Ekström H, Iwarsson S, Nilsson MH. Factors associated with life satisfaction in Parkinson's disease. *Acta Neurologica Scandinavica*. (doi: 10.1111/ane.12695)
 - Garmy P, Berg A, Clausson E, Hagell P, Jakobsson U. Psychometric analysis of the Salutogenic Health Indicator Scale (SHIS) in adolescents. *Scandinavian Journal of Public Health*. (doi: 10.1177/1403494816680801)
 - Bala SV, Samuelson K, Hagell P, Fridlund B, Forslind K, Svensson B, Thomé B. Living with persistent rheumatoid arthritis. *Journal of Clinical Nursing*. (doi: 10.1111/jocn.13691)
 - Westergren A, Edfors E, Norberg E, Stubbendorff A, Hedin G, Wetterstrand M, Hagell P. Long-term effects of a computer based nutritional training program for inpatient hospital care. *Journal of Evaluation in Clinical Practice*.
- Submitted for Publication*
- de Roos P, Bloem BR, Kelley TA, Antonini A, Dodel R, Hagell P, Marras C,

Martinez-Martin P, Mehta SH, Odin P, Chaudhuri R, Weintraub D, Wilson B, Uitti RJ. A consensus set of outcomes for Parkinson's disease from the International Consortium for Health Outcomes Measurement.

27

- Persson CU, Linder A, Hagell P. Measurement properties of the Swedish modified version of the Postural Assessment Scale for Stroke Patients (SwePASS) using Rasch analysis.
- Lindholm B, Nilsson MH, Hansson O, Hagell P. The clinical significance of different standardizations of the 10-Meter Walk Test in mild Parkinson's disease.
- Johansson M, Johansson P, Stomrud E, Hagell P, Hansson O. Psychometric testing of a Swedish version of the Apathy Evaluation Scale.
- Hagell P, Westergren A, Årestedt K. Beware of the origin of numbers: Standard scoring of the SF-12 and SF-36 summary measures distorts measurement and score interpretations.
- Hellqvist, Dizdar N, Hagell P, Berterö C, Sund-Levander M. Improving self-management for people with Parkinson's disease: Patients' and relatives' experience of the Swedish National Parkinson School (NPS).
- Westergren A, Edfors E, Norberg E, Stubbendorff A, Hedin G, Wetterstrand M, Rosas SR, Hagell P. Conceptual perspectives on a computer based training in eating and nutrition: a group concept mapping study.
- Kumlien C, Miller M, Fagerström C, Hagell P. Evaluation of self-management program outcomes: Adaptation and testing of a Swedish version of the Health Education Impact Questionnaire (heiQ).

Peer-Reviewed Review Articles

- Hagell P. Restorative neurology in movement disorders. *Journal of Neuroscience Nursing* 2000; 32(5): 256-262.
- Hagell P. Timed tests in clinical assessment of motor function in Parkinson's disease. *Journal of Neuroscience Nursing* 2000; 32(6): 331-336.
- Hagell P, Odin P. Apomorphine in the treatment of Parkinson's disease. *Journal of Neuroscience Nursing* 2001; 33(1): 21-38.
- Hagell P, Brundin P. Cell survival and clinical outcome following intrastriatal transplantation in Parkinson's disease. *Journal of Neuropathology and Experimental Neurology* 2001; 60(8): 741-752.
- Lindvall O, Hagell P. Cell therapy and transplantation in Parkinson's disease. *Clinical Chemistry and Laboratory Medicine* 2001; 39(4): 356-361.
- Brundin P, Hagell P. The neurobiology of cell transplantation in Parkinson's disease. *Clinical Neuroscience Research* 2001; 1(6): 507-520.
- Lindvall O, Hagell P. Cell replacement therapy in human neurodegenerative disorders. *Clinical Neuroscience Research* 2002; 2: 86-92.
- Tennant A, McKenna SP, Hagell P. Application of Rasch analysis in the development and application of quality of life instruments. *Value in Health* 2004; 7(Suppl 1): S22-S26.
- Swaine-Verdier A, Doward LC, Hagell P, Thorsen H, McKenna SP. Adapting quality of life instruments. *Value in Health* 2004; 7(Suppl 1): S27-S30.
- Hagell P. Feasibility and linguistic validity of the Swedish version of the PDQ-39. *Expert Review of Pharmacoeconomics & Outcomes Research* 2005; 5(2): 131-136.
- Hagell P, Cenci MA. Dyskinesias and dopamine cell replacement in Parkinson's disease: A clinical perspective. *Brain Research Bulletin* 2005; 68(1-2): 4-15.

Invited Review Articles, Book Chapters, Editorials, etc.

28

- Hagell P, Swinn L. Diagnosing Parkinson's disease. In: Swinn L (ed.). *Parkinson's*

disease: Theory and practice for nurses. Whurr Publishers Ltd., London, 2005. pp 9-27. [Book chapter]

□ Hagell P. Future developments in the treatment of Parkinson's disease. In: Swinn L (ed.). *Parkinson's disease: Theory and practice for nurses*. Whurr Publishers Ltd., London, 2005. pp 201-214. [Book chapter]

□ Cenci MA, Hagell P. Dyskinesias and neural grafting in Parkinson's disease. In: Brundin P, Olanow CW (eds.). *Restorative therapies in Parkinson's disease*. Springer, New York, 2006. pp 184-224. [Book chapter]

□ Hagell P. Self reported health in people with Parkinson's disease left untreated at diagnosis. *Journal of Neurology Neurosurgery & Psychiatry* 2007; 78(5): 442. [Editorial]

□ Hagell P, Smith S. Why psychometrics is important – A response to: Aubeeluck, Buchanan & Stupple (2013) *Journal of Huntington's Disease* 2(4) 453-454. *Journal of Huntington's Disease* 2013; 2(4): 455-457. [Letter]

Review Articles, Book Chapters, Editorials, etc.

□ Hagell P. Fetal transplantation in Huntington's disease. *Circular in Motion* 1997; 2: 2-3.

□ Hagell P and the International Steering Committee of Movement Disorder Nursing Societies. An introduction to movement disorders for the neuroscience nurse. *International Brain Waves* 1998; 6: 5-7+insert.

□ Pogarell O, Eichhorn T, Kupsch A, Oertel WH, Brundin P, Hagell P, Odin P, Pietz K, Widner H, Lindvall O. Preliminary clinical experience with neural transplantation: Two case reports. In: Hellwig D, Bauer BL (eds.). *Minimally invasive techniques for neurosurgery: Current status and future perspectives*. Springer Verlag, Berlin, 1998. pp 277-280.

□ Hagell P, Hoeck B, Shephard T, O'Brien E, Kadesha K, Bee S, Halberstadt J. Postoperative pain control after craniotomy. *Journal of Neuroscience Nursing* 1999; 31: 47-49.

□ Hagell P, Chen H, Evans V, O'Brien E, Thomas S, Hoeck B, Halberstadt J, Abrefah AF, Kadesha K, Shephard TJ, Schultka S. International perspectives on stroke rehabilitation. *Journal of Neuroscience Nursing* 1999; 31: 110-114.

□ Hagell P, Laupenmahlen-Schemm M, Ubachs H, Eberhardie C, Kadesha K, Schultka S, Hoeck B, Halberstadt J. Pain management. *Journal of Neuroscience Nursing* 1999; 31: 251-253.

□ Hagell P, Wade F, Reimer M, Smith S. Health-related quality of life in clinical practice. *Journal of Neuroscience Nursing* 1999; 31: 366-368.

□ Hagell P, Wade F, O'Brien E, Hoeck B, Eberhardie C, Smith S, Rost-Ruffner E. Should boxing be banned? *Journal of Neuroscience Nursing* 2000; 32(2): 126-128.

□ Hagell P, Welsh M. Quality of life in Parkinson's disease and other movement disorders. Movement Disorder Society 2000.

□ Hagell P, O'Brien E, Goode S, Smith S, Prendergast V, Rost-Ruffner E, Håkansson M. Compliance and noncompliance in neuroscience. *Journal of Neuroscience Nursing* 2000; 32(3): 182-184.

29

□ Lindvall O, Hagell P. Clinical observations after neural transplantation in Parkinson's disease. *Progress in Brain Research* 2000; 127: 299-320.

□ Hagell P, Chen H, Evans V, Baker L, Halberstadt J, Prendergast V, Schultka S, Suner R, Shephard T, Fox S, Abrefah AF. Career opportunities in neuroscience nursing. *Journal of Neuroscience Nursing* 2001; 33(2): 113-118.

□ Lindvall O, Hagell P. Restoring structure and function in the nigrostriatal system in

Parkinson's disease. In: Abramsky O, Compston DAS, Miller A, Said G (eds.). *Brain disease – Therapeutic strategies and repair*. Martin Dunitz Ltd., London, 2002. pp 275-281.

- Lindvall O, Hagell P. Neural and stem cell transplantation. In: Jankovic J, Tolosa E (eds.). *Parkinson's disease and movement disorders, Fourth Edn*. Lippincott Williams and Wilkins, Philadelphia, 2002. pp 663-673.
- Lindvall O, Hagell P. Role of cell therapy in Parkinson's disease. *Neurosurgical Focus* 2002; 13(5): article 2.
- Lindvall O, Hagell P. Status of neural repair clinical trials in brain diseases. In: Selzer ME, Clarke S, Cohen LG, Duncan PW, Gage FH (eds.). *Textbook of neural repair and rehabilitation. Volume I: Neural repair and plasticity*. Cambridge University Press, Cambridge, 2006. pp 615-631.
- Sjö Dahl Hammarlund C, Hagell P, Nilsson MH. Motor and non-motor predictors of illness-related distress in Parkinson's disease. *Focus on Parkinson's Disease* 2012; 23(1): 27-28.
- Hagell P. Testing unidimensionality using the PCA/t-test protocol with the Rasch model: A cautionary note. *Rasch Measurement Transactions* 2015; 28(4): 1487-1489.

Books

- Odin P, Hagell P, Shing M. Apomorphine in Parkinson's disease. UNI-MED Verlag AG, Bremen; 2005.
- Hagell P, Odin P, Shing M. Apomorphin bei Morbus Parkinson. UNI-MED Verlag AG, Bremen; 2005.
- Hagell P, Odin P, Shing M. Apomorphine in Parkinson's disease. 2nd edition. UNIMED Verlag AG, Bremen; 2008.
- Hagell P, Odin P, Shing M. Apomorphin bei Morbus Parkinson. 2. Auflage. UNIMED Verlag AG, Bremen; 2008.
- Hagell P, Odin P. Apomorphine in Parkinson's disease. 3rd edition. UNI-MED Verlag AG, Bremen; 2014. (ISBN: 978-3-8374-1452-3)

Reports, Unpublished Papers, etc.

- Hagell P. Disease-specific measures of health-related quality of life in Parkinson's disease. Centre of Caring Sciences, Lund University, 1999.
- Hagell P. Adaptation of the ASQoL for use in Sweden: Report on the translation process. Department of Nursing, Lund University, 2004.
- Hagell P. Adaptation of PRIMUS for use in Sweden: Report on the translation process. Department of Health Sciences, Lund University, 2005.

30

- Hagell P. Adaptation of the Parkinson Fatigue Scale (PFS-16) for use in Sweden: Report on the translation process. Department of Health Sciences, Lund University, 2006.
- Westergren A, Nilsson M, Hagell P. Adaptation of "Seniors in the community: Risk evaluation for eating and nutrition, Version II" (SCREEN II) for use in Sweden: Report on the translation process. Kristianstad University, Klinisk Patientnära Forskning - 1654-1421:15. 2007.
- Nilsson M, Hagell P, Westergren A. Adaptation of Walk-12G for use in Sweden: Report on the translation process. Department of Health Sciences, Lund University, 2007.
- Hagell P, Nilsson M, Westergren A. Adaptation of the 26-item Parkinson's disease Dyskinesia Scale (PDYS-26) for use in Sweden: Report on the translation process. Department of Health Sciences, Lund University, 2007.
- Hagell P, Hariz GM. Adaptation of the Alzheimer's Carers' Quality of Life Instrument

(ACQLI) for use in Sweden: Report on the translation process. Department of Health Sciences, Lund University and Department of Community Medicine and Rehabilitation, Umeå University, 2007.

□ Hagell P, Smith S, Westergren A. Manual for translation and cultural adaptation of the Minimal Eating Observation and Nutrition Form – Version II (MEONF-II). PROCARE, Högskolan Kristianstad. Kristianstad University Press, ISSN: 1654-1421. 2015.

Abstracts / Conference Presentations

□ Hagell P, Odin P, Vinge E. Pregnancy in Parkinson's disease. The 4th International Congress of Movement Disorders. Vienna, Austria, 1996.

□ Hagell P. The "Lund-model": A multidisciplinary approach to the management of Parkinson's disease. The Royal College of Nursing's Parkinson's Disease Nurse Specialist Weekend Conference. Grantham, UK, 1997.

□ Hagell P and the Lund/London Transplantation Team. Survival and function of unilateral dopaminergic striatal grafts in patients with Parkinson's disease. Neuroscience Day. Lund, Sweden, 1997.

□ Hagell P. Symptoms and signs during the immediate post-operative phase after embryonic transplantations in Parkinson's disease. 7th World Federation of Neuroscience Nurses Congress. Amsterdam, the Netherlands, 1997.

□ Hagell P. Timed tests in clinical assessment of motor function in Parkinson's disease. 7th World Federation of Neuroscience Nurses Congress. Amsterdam, the Netherlands, 1997.

□ Hagell P. Subcutaneous apomorphine in the treatment of Parkinson's disease: results and experiences from a long-term follow-up. The 30th Anniversary Annual Meeting of the American Association of Neuroscience Nurses. Chicago, USA, 1998.

□ Piccini P, Ceravolo R, Hagell P, Samuel M, Rakshi J, Rehncrona S, Brundin P, Pogarell O, Schrag A, Oertel W, Quinn NP, Marsden CD, Lindvall O, Brooks DJ. Task-related cortical function in Parkinson's disease after bilateral dopaminergic grafts. The 5th International Congress of Movement Disorders. New York, USA, 1998. 31

□ Hagell P. Neurosurgery for Parkinson's disease - the role of the specialist nurse. The 3rd European Conference on Parkinson's Disease. Barcelona, Spain, 1998.

□ Hagell P. Clinical rating scales: Rationale, principles and methodology with examples from Parkinson's disease. 31st Annual Meeting of the American Association of Neuroscience Nurses. Philadelphia, USA, 1999.

□ Hagell P. Intra-striatal embryonic transplantation in Parkinson's disease: Experiences from the past decade and possibilities for the next. 31st Annual Meeting of the American Association of Neuroscience Nurses. Philadelphia, USA, 1999.

□ Masferrer R, Prendergast V, Hagell P. Colored pain drawings in the assessment of back pain: A neurosurgical perspective. 31st Annual Meeting of the American Association of Neuroscience Nurses. Philadelphia, USA, 1999.

□ Prendergast V, Hagell P. Colored pain drawings in the assessment of neuroscience patients with lumbar spine pathology. 6th Quadrennial Congress of the European Association of Neuroscience Nurses. Rome, Italy, 1999.

□ Hagell P. Clinical rating of dyskinesias in Parkinson's disease: Development and utility of a new rating scale. 6th Quadrennial Congress of the European Association of Neuroscience Nurses. Rome, Italy, 1999.

□ Hagell P. Restorative neurology in movement disorders. 6th Quadrennial Congress of the European Association of Neuroscience Nurses. Rome, Italy, 1999.

□ Hagell P. Importance of graft survival for clinical outcome following intra-striatal

transplantation of human embryonic dopaminergic tissue in Parkinson's disease. 32nd Annual Meeting of the American Association of Neuroscience Nurses. New Orleans, USA, 2000.

- Hagell P. Health-related quality of life following bilateral intrastriatal transplantation in Parkinson's disease. 32nd Annual Meeting of the American Association of Neuroscience Nurses. New Orleans, USA, 2000.
- Hagell P. Quality of life: Concepts and measurements with examples from Parkinson's disease. 32nd Annual Meeting of the American Association of Neuroscience Nurses. New Orleans, USA, 2000.
- Piccini P, Pavese N, Lindvall O, Hagell P, Gunn RN, Brooks D. Endogenous dopamine release correlates with dopamine storage in patients with Parkinson's disease: An ¹¹C-raclopride and ¹⁸F-dopa PET study. 52nd Annual Meeting of the American Academy of Neurology. San Diego, USA, 2000. *Neurology* 2000; 54(Suppl 3): A329-330.
- Hagell P, Welsh M. Quality of life in Parkinson's disease and other movement disorders. The 6th International Congress of Parkinson's Disease and Movement Disorders. Barcelona, Spain, 2000.
- Hagell P, Sandlund B. Patients' self-assessment of disease and symptom severity in Parkinson's disease. The 7th Annual Conference of the International Society for Quality of Life Research. Vancouver, Canada, 2000. *Quality of Life Research* 2000; 9(3): 285.
- Hagell P. Parkinson's disease nurse specialists: The Swedish experience. The 4th European Conference on Parkinson's Disease. Vienna, Austria, 2000.
- Hagell P, Sandlund B, Reimer J, Grabowski M, Lindvall O. The NHP index of distress in Parkinson's disease. The 8th Annual Conference of the International Society for Quality of Life Research. Amsterdam, Netherlands, 2001. *Quality of Life Research* 2001; 10(3): 237.
- Hagell P. Quality of life in Parkinson's disease [expanded abstract]. 2nd Scandinavian Congress of Neurological Nursing, Reykjavik, Iceland, 2002. *Icelandic Medical Journal* 2002; 88(43): 20-21.
- Hagell P, Whalley D, McKenna SP, Lindvall O. Measurement properties of two common health status questionnaires in Parkinson's disease. The 7th International Congress of Parkinson's Disease and Movement Disorders. Miami, Florida, USA, 2002. *Movement Disorders* 2002; 17(Suppl 5): S124.
- Hagell P. Quality of life in Parkinson's disease: What do we measure and how does it affect our results? The 7th International Congress of Parkinson's Disease and Movement Disorders. Miami, Florida, USA, 2002. *Movement Disorders* 2002; 17(Suppl 5): S240.
- Hjelmgren J, Reimer J, Persson U, Ghatnekar O, Grabowski M, Lindvall O, Hagell P. Early decision-making modeling in Parkinson's disease – The case of neural transplantation in patients with advanced Parkinson's disease. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 6th Annual European Congress. Barcelona, Spain, 2003. *Value in Health* 2003; 6(6): 765-766.
- Hagell P, McKenna SP. International use of health status questionnaires in Parkinson's disease: Translation is not enough. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 6th Annual European Congress. Barcelona, Spain, 2003. *Value in Health* 2003; 6(6): 770.
- Hagell P, Reimer J. Use and interpretation of "on"/"off"-diaries in Parkinson's disease. Advanced Health Care Sciences of Tomorrow, The Vårdal Institute, Lund,

Sweden, 2003.

- Hagell P. Dyskinesias and dopamine cell replacement in Parkinson's disease: A clinical perspective. 14th Annual General Meeting of the Network of European CNS Transplantation and Restoration (NECTAR). Amsterdam, the Netherlands, 2003.
- Hagell P, Dahlberg A, Mi-Young K. Feasibility and linguistic validity of the revised Swedish version of the PDQ-39. The 11th Annual Conference of the International Society for Quality of Life Research. Hong Kong, 2004. *Quality of Life Research* 2004; 13(9): 1545.
- Reimer J, Hagell P. Perceived relevance of generic and disease-specific patient-reported outcome measures in Parkinson's disease. The 11th Annual Conference of the International Society for Quality of Life Research. Hong Kong, 2004. *Quality of Life Research* 2004; 13(9): 1602.
- Hagell P, Hedin PJ, McKenna SP. The effect of method of adaptation on the acceptability of questionnaires in cross-cultural research. The 11th Annual Conference of the International Society for Quality of Life Research. Hong Kong, 2004. *Quality of Life Research* 2004; 13(9): 1510.
- Hagell P, Westergren A. The internal structure of handicap: An evaluation of the London Handicap Scale. The 9th Quadrennial Congress of the World Federation of Neuroscience Nurses. Barcelona, Spain, 2005.
- Hagell P. Measuring fatigue in Parkinson's disease. The 9th Quadrennial Congress of the World Federation of Neuroscience Nurses. Barcelona, Spain, 2005.

33

- Hagell P, Vasilová K. Functionality of rating scales in survey research. The 1st European Association for Survey Research (EASR) Conference. Barcelona, Spain, 2005.
- Hagell P. Health status measurement. The 1st World Parkinson Congress. Washington D.C., USA, 2006. *Movement Disorders* 2006; 21(Suppl 3): S36-S37.
- Hagell P, Törnqvist AL, Hobart J. An assessment of the structure of self-reported health in Parkinson's disease using the SF-36. The 13th Annual Conference of the International Society for Quality of Life Research. Lisbon, Portugal, 2006. *Quality of Life Research* 2006; 15(Suppl 1): A77-78.
- Nygren CK, Hagell P. Analysis of the PDQ-39 in relation to the International Classification of Functioning, Disability and Health (ICF) core concepts. The 13th Annual Conference of the International Society for Quality of Life Research. Lisbon, Portugal, 2006. *Quality of Life Research* 2006; 15(Suppl 1): A77.
- Hagell P, Törnqvist AL, Hobart J. An assessment of the dimensionality of health in Parkinson's disease using the SF-36. The 10th International Congress of Parkinson's Disease and Movement Disorders. Kyoto, Japan, 2006. *Movement Disorders* 2006; 21(Suppl 15): S655.
- Hagell P, Broman JE. Measurement properties and hierarchical item structure of the Epworth Sleepiness Scale in Parkinson's disease. The 10th International Congress of Parkinson's Disease and Movement Disorders. Kyoto, Japan, 2006. *Movement Disorders* 2006; 21(Suppl 15): S658.
- Hagell P. Parkinson's disease nurse specialists: the Swedish experience. The 5th German Congress on Parkinson's Disease: Satellite symposium. Ulm, Germany, 2007.
- Doward LC, Fisk J, Meads DM, McKenna SP, Hagell P, Oprandi N, Grand'Maison F, Bhan V, Gonzalez B, Kohlmann T, Goodman J, Eckert BJ. International development of the Unidimensional Fatigue Impact Scale. The 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Prague, Czech Republic, 2007. *Multiple Sclerosis* 2007; 13(Suppl 2):S219.

- Doward LC, McKenna SP, Meads DM, Twiss J, Hagell P, Oprandi N, Grand'Maison F, Bhan V, Gonzalez B, Txomin A, Kohlmann T, Goodman J, Brassat D, Fisk J, Eckert BJ. Psychometric and scaling properties of the patient reported outcome indices for multiple sclerosis (PRIMUS). The 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Prague, Czech Republic, 2007. *Multiple Sclerosis* 2007; 13(Suppl 2):S219.
- Hagell P. Evidence-based measurement. Nordic Network of Parkinson's Disease nurses (NNPD) conference. Oslo, Norway, 2008.
- Nilsson M, Hagell P. The 39-item Parkinson's disease questionnaire (PDQ-39): Is it a unidimensional construct? The 15th Annual Conference of the International Society for Quality of Life Research. Montevideo, Uruguay, 2008. *Quality of Life Research* 2008; 17(Suppl): A44.
- Nilsson M, Hagell P. Factors associated with patient-reported distress in Parkinson's disease. The 15th Annual Conference of the International Society for Quality of Life Research. Montevideo, Uruguay, 2008. *Quality of Life Research* 2008; 17(Suppl): A116-117.
- Hagell P, Meads D, Hedin PJ, Nyberg L, McKenna SP. Effects of method of questionnaire adaptation in cross-cultural research. The 15th Annual Conference of the International Society for Quality of Life Research. Montevideo, Uruguay, 2008. *Quality of Life Research* 2008; 17(Suppl): A43-44.
- Hagell P, Rosblom T, Pålhagen S. Initial validation of the Swedish version of the 16-item Parkinson Fatigue Scale (PFS-16). The 15th Annual Conference of the International Society for Quality of Life Research. Montevideo, Uruguay, 2008. *Quality of Life Research* 2008; 17(Suppl): A43.
- Smith SM, Hagell P. Internal validity of the Huntington's Disease Quality of Life battery for Carers (HDQOL-C). The 15th Annual Conference of the International Society for Quality of Life Research. Montevideo, Uruguay, 2008. *Quality of Life Research* 2008; 17(Suppl): A73.
- Knutsson I, Rydström H, Nyberg P, Reimer J, Hagell P. Towards an evidence base for selecting rating scale response categories for patient-reported outcome measures in Parkinson's disease. XVIII WFN World Congress on Parkinson's Disease and Related Disorders. Miami Beach, Florida, USA, 2009. *Parkinsonism & Related Disorders* 2009; 15(Suppl 2): S62-63.
- Hagell P, Hariz GM. Assessment of the Alzheimer Carer Quality of Life Instrument (ACQLI) among Swedish Alzheimer's and Parkinson's disease carers. XVIII WFN World Congress on Parkinson's Disease and Related Disorders. Miami Beach, Florida, USA, 2009. *Parkinsonism & Related Disorders* 2009; 15(Suppl 2): S138.
- Hagell P, Hariz GM, Nilsson MN. The Parkinson's Disease Activities of Daily Living Scale (PADLS) revisited. XVIII WFN World Congress on Parkinson's Disease and Related Disorders. Miami Beach, Florida, USA, 2009. *Parkinsonism & Related Disorders* 2009; 15(Suppl 2): S62.
- Westergren A, Nilsson M, Edfors E, Lindskov S, Hagell P. Adaptation of "seniors in the community: risk evaluation for eating and nutrition, version II" (SCREEN II) for use in Sweden: report on the translation process and field test. 32nd ESPEN Congress, Nice, France, 2010.
- Hagell P. Current evidence of PD nursing: Where do we go from here? The 2nd World Parkinson Congress. Glasgow, UK, 2010. *Movement Disorders* 2010; 25(Suppl 3): S589.
- Hagell P. Outcome measures and what these mean to patients The 2nd World

Parkinson Congress. Glasgow, UK, 2010. *Movement Disorders* 2010; 25(Suppl 3): S602.

□ Nilsson MH, Wictorin K, Bladh S, Högstedt Å, Eliasson M, Toreld C, Reimer J, Hagell P. Initial validation of a self administered version of the Freezing of Gait Questionnaire (FOGQsa). The 2nd World Parkinson Congress. Glasgow, UK, 2010. *Movement Disorders* 2010; 25(Suppl 3): S687.

□ Hellström A, Hagell P, Fagerström C, Willman A. How to measure and classify insomnia in elderly persons. Fourth European Nursing Congress - Older Persons: the Future of Care. Rotterdam, the Netherlands, 2010. *Journal of Clinical Nursing* 2010; 19(Suppl 1): 147-148.

□ Hellström A, Hagell P, Fagerström C, Willman A. Usefulness of the Minimal Insomnia Symptom Scale (MISS) in elderly persons. Nordisk Gerontologisk Förening. Reykjavik, 2010.

35

□ Westergren A, Hagell P. Screening for undernutritional risk among home dwelling elderly people without service from the municipality. 33rd ESPEN Congress, Gothenburg, Sweden, 2011.

□ Nilsson MH, Nyberg P, Hariz GM, Forsgren L, Hagell P. Clinic versus patient association sampling of people with Parkinson's disease. The 16th International Congress of Parkinson's Disease and Movement Disorders. Dublin, Ireland, 2012. *Movement Disorders* 2012; 27(Suppl 1): S101-102.

□ Westergren A, Hagell P. Undernutrition, mental and physical factors form a triad of coexisting problems. 34th ESPEN Congress, Barcelona, Spain, 2012. *Clinical Nutrition* 2012; 7(Suppl 1): 117.

□ Hagell P. Effect of recall period on item responses to activity limitation items in multiple sclerosis. The 19th Annual Conference of the International Society for Quality of Life Research. Budapest, Hungary, 2012. *Quality of Life Research* 2012; 21(Suppl 1): 95-96.

□ Hagell P, Knutsson I, Samuelson K. Interpretation of response categories in patientreported rating scales: a test-retest study among people with neurological disorders. The 19th Annual Conference of the International Society for Quality of Life Research. Budapest, Hungary, 2012. *Quality of Life Research* 2012; 21(Suppl 1): 47-48.

□ Lindholm B, Hansson O, Hagell P, Nilsson MH. Prediction of instability in people with Parkinson's disease - clinical balance and gait tests. The 17th International Congress of Parkinson's Disease and Movement Disorders. Sydney, Australia, 2013. *Movement Disorders* 2013; 28(Suppl 1). S163.

□ Lindholm B, Hansson O, Hagell P, Duzynski W, Nilsson MH. Future falls and/or near falls in people with Parkinson's disease: Sensitivity and specificity of two retropulsion tests. The 17th International Congress of Parkinson's Disease and Movement Disorders. Sydney, Australia, 2013. *Movement Disorders* 2013; 28(Suppl 1). S163.

□ Lindskov S, Sjöberg K, Westergren A, Hagell P. Weight loss in Parkinson's disease? 35th ESPEN Congress, Leipzig, Germany, 2013.

□ Hagell P. Testing for unidimensionality using the principal component analysis (PCA)/t-test protocol in Rasch analysis: A cautionary note. The 20th Annual Conference of the International Society for Quality of Life Research. Miami, Florida, USA, 2013. *Quality of Life Research* 2013; 22(Suppl 1): 63-64.

□ Hagell P, Knutsson I. Single-item assessment of perceived health in neurological disorders: Verbal response categories vs visual analog scale. The 20th Annual Conference of the International Society for Quality of Life Research. Miami, Florida, USA, 2013. *Quality of Life Research* 2013; 22(Suppl 1): 116-117.

□ Lindholm B, Hansson O, Hagell P, Nilsson MH. Walking difficulties is the strongest contributing factor to fear of falling among people with mild Parkinson's disease. The 3rd World Parkinson Congress, Montreal, Canada, 2013. *Journal of Parkinson's Disease* 2013; 3(Suppl 1): 150.

□ Ljusbäck AM, Hagell P, Nilsson MH, Sperens M, Forsgren L, Hariz GM. Psychometric properties of a modified self-rating version of the ADL taxonomy for people with Parkinson's disease. The 18th International Congress of Parkinson's Disease and Movement Disorders. Stockholm, Sweden, 2014. *Movement Disorders* 2014; 29(Suppl 1): S187.

36

□ Höglund A, Broman JE, Pålhagen S, Fredrikson S, Hagell P. Excessive Daytime Sleepiness in Parkinson's Disease – relationship to motor and non-motor symptoms. The 18th International Congress of Parkinson's Disease and Movement Disorders. Stockholm, Sweden, 2014. *Movement Disorders* 2014; 29(Suppl 1). S292.

□ Hagell P. Towards end-user centered outcome measurement: An example from Parkinson's disease. The 2nd International Congress on Nursing & Healthcare. Chicago, IL, USA, 2014. *Journal of Nursing & Care* 2014; 3(7): 71. (doi: 10.4172/2167-1168.S1.006)

□ Hagell P, Broman JE, Hellström A, Fagerström C, Willman A, Westergren A. Measurement properties of the Minimal Insomnia Symptom Scale (MISS) as an insomnia screening tool among adults and the elderly. The 6th International Conference on Probabilistic Models for Measurement in Education, Psychology, Social Science and Health. Cape Town, South Africa, 2015.

□ Hagell P, Westergren A. Sample size and statistical conclusions from tests of fit to the Rasch measurement model according to the RUMM2030 program. The 4th International Outcome Measurement Conference. Chicago, Illinois, USA, 2015.

□ Lindholm B, Hansson O, Hagell P, Nilsson MH. Prediction of falls and/or near falls by using tandem gait performance in people with mild Parkinson's disease. The 19th International Congress of Parkinson's Disease and Movement Disorders. San Diego, California, USA, 2015. *Movement Disorders* 2015; 30(Suppl 1): S100-101.

□ Mehta SH, De Roos P, Bloem BR, Kelley TA, Angelo A, Dodel R, Hagell P, Marras C, Martinez-Martin P, Odin P, Chaudhuri KR, Weintraub D, Uitti R. Standard set measuring patient-centred outcomes in Parkinson's disease: An international, crossdisciplinary

effort. The 140th Annual Meeting of the American Neurological Association. Chicago, Illinois, USA, 2015. *Annals of Neurology* 2015; 78(S19): S54.

□ Rosqvist K, Hagell P, Odin P, Iwarsson S, Ekström H, Nilsson MH. Life satisfaction in Parkinson's disease – associated factors. The 20th International Congress of Parkinson's Disease and Movement Disorders. Berlin, Germany, 2016. *Movement Disorders* 2016; 31(Suppl 2): S166.

□ Løvereide L, Larsen JP, Hagell P. Measuring life satisfaction in people with Parkinson's disease and healthy controls using the Satisfaction With Life Scale. The 23rd Annual Conference of the International Society for Quality of Life Research. Copenhagen, Denmark, 2016. *Quality of Life Research* 2016; 25(Suppl 1): 150.

□ Johansson M, Johansson P, Stomrud E, Hagell P, Hansson O. Psychometric testing of a Swedish version of the Apathy Evaluation Scale in three clinical cohorts. The 13th International Conference on Alzheimer's & Parkinson's Diseases. Vienna, Austria, 2017.

□ Nilsson MH, Jonasson SB, Lindholm B, Hagell P. Walking difficulties is the main contributor to fear of falling in people with Parkinson's disease. The 21st IAGG World

Congress of Gerontology and Geriatrics. San Francisco, California, USA, 2017.

□ Persson CU, Linder A, Hagell P. Measurement properties of the Swedish modified version of the Postural Assessment Scale for Stroke Patients (SwePASS) using Rasch analysis. World Confederation of Physical Therapy Congress. Cape Town, South Africa, 2017.

□ Hagell P, Hariz GM, Sandlund B. Direct dopaminergic responsiveness of activity performance. The 21st International Congress of Parkinson's Disease and Movement Disorders. Vancouver, Canada, 2017.

Disorders. Vancouver, Canada, 2017.

□ Hellqvist, Dizdar N, Hagell P, Berterö C, Sund-Levander M. A national Swedish selfmanagement

program for people with Parkinson's disease - patients and relatives

view. The 21st International Congress of Parkinson's Disease and Movement

Disorders. Vancouver, Canada, 2017.

□ Hagell P, Nilsson MH, Chaudhuri R, Odin P. The Non-Motor Symptoms Questionnaire and Non-Motor Symptoms Scale for use in Sweden. The 21st International Congress of Parkinson's Disease and Movement Disorders. Vancouver, Canada, 2017.

□ Rosqvist K, Horne M, Hagell P, Iwarsson S, Nilsson MH, Odin P. Levodopa effect and motor function in late stage Parkinson's disease. The 21st International Congress of Parkinson's Disease and Movement Disorders. Vancouver, Canada, 2017.

□ Hagell P, Höglund A, Hellqvist C, Johansson EL, Löwed B, Sjöström AC, Karlberg C, Lundgren M, Dizdar N, Johansson A, Willows T, Rådberg J, Bergquist F.

Apomorphine formulation influences subcutaneous complications in continuous apomorphine pump therapy for Parkinson's disease. (Late-Breaking Abstract) The 21st International Congress of Parkinson's Disease and Movement Disorders. Vancouver, Canada, 2017.

38

PUBLICATIONS IN SWEDISH

Original Research Articles

□ Petersson U, Sobiecki D, Hagell P, Samuelson K. Intensivvård ur ett genusperspektiv – en registerstudie. *Vård i Norden [Nordic Journal of Nursing Research]* 2012; 32 (2): 51-55.

Peer-Reviewed Review Articles

□ Hagell P, Odin P, Freccero-Rosman K, Träskman-Bendz L, Lindvall O. Depression vanlig vid Parkinsons sjukdom - Begränsade studier kring symtom och behandling. *Läkartidningen* 1994; 91: 4270-4276.

Invited Review Articles, Book Chapters, Editorials, etc.

□ Hagell P. Omvårdnadsaspekter. In: Odin P (ed.). *Parkinsons sjukdom - Vårdprogram för södra sjukvårdsregionen 1996-98*. Lund, Sweden, 1996.

□ Hagell P. Utmaningar i utvecklingen: Nya behandlingsmetoder vid Parkinsons sjukdom. In: Lundin S (ed.). *En ny kropp*. Nordic Academic Press, Lund, 2004. pp 77-102.

□ Sjö Dahl Hammarlund C, Hagell P, Nilsson MH. Motoriska och icke-motoriska prediktorer för patientrapporterad distress vid Parkinsons sjukdom. *BestPractice Psykiatri/Neurologi* 2012; 3(12): 12-15.

□ Westergren A, Hagell P, Sjö Dahl Hammarlund C. Undernäring och fallrisk - ett förestående folkhälsoproblem bland yngre pensionärer? *Svensk Geriatrik* 2014; 1: 11-14.

Review Articles, Book Chapters, Editorials, etc.

- Hagell P. Parkinsonbehandling - Apomorfin utökar terapiarsenalen. *Vårdfacket* 1994; 18: xxii-xxiv.
- Hagell P. Trötthet vid Parkinsons sjukdom: Går det att mäta? *ParkinsonJournalen* 2006; 14(1): 14-15.
- Lindskov S, Westergren A, Hagell P. Hälsoeffekter av patientundervisning. *ParkinsonJournalen* 2006; 14(1): 10-11.
- Lindskov S, Westergren A, Hagell P. Patientundervisning vid Parkinsons sjukdom. *iVården* 2010; 1(4): 28-30.
- Lindskov S, Hagell P, Westergren A. Viktförändring – ett problem vid Parkinsons sjukdom. *iVården* 2010; 1(4): 24-26.
- Hagell P. Behandlingsmål vid Parkinson: Vad är viktigt för patientens livskvalitet? *ParkinsonJournalen* 2015; 22(2): 40-42.

Books

- Hagell P, Widner H. Neurologisk terminologi med inriktning mot movement disorders. Vårdföreningen Movement Disorders, Lund, Sweden, 1997.
- Hagell P, Victorin K. Icke-motoriska symtom vid Parkinsons sjukdom. GlaxoSmithKline AB, Stockholm, Sweden, 2010.

39

Reports, Unpublished Papers, etc.

- Nordling S, Grabowski M, Hagell P, Reimer J, Persson U. Samhällsekonomiska kostnader till följd av Parkinsons sjukdom. IHE Arbetsrapport 2001:2.
- Westergren A, Hagell P, Lindgren E. Sömnsvårigheter inom vård och omsorg – En studie genomförd med hjälp av studenter i sjuksköterskeprogrammet. PRO-CARE, Högskolan Kristianstad. Kristianstad University Press, ISSN: 1654-1421:35. 2012.
- Westergren A, Hedin G, Lindgren E, Hagell P. Gångsvårigheter, tilltro till balansförmåga, fallrisk och relaterade faktorer på sjukhus och i särskilt boende – En studie genomförd med hjälp från studenter i sjuksköterskeprogrammet. PRO-CARE, Högskolan Kristianstad. Kristianstad University Press, ISSN: 1654-1421:36. 2013.
- Westergren A, Hedin G, Hagell P. 10 år med forskargruppen PRO-CARE – Jubileumsskrift. PRO-CARE, Högskolan Kristianstad. Kristianstad University Press, ISSN: 1654-1421-40. 2014.
- Hedin G, Westergren A, Hagell P. Smärta – En studie genomförd med hjälp från studenter i sjuksköterskeprogrammet. PRO-CARE, Högskolan Kristianstad. Kristianstad University Press, ISSN: 1654-1421. 2014.

Abstracts / Conference Presentations

- Hagell P. Klinisk skattning av drog-inducerade dyskinesier vid Parkinsons sjukdom. 3rd Annual Conference of the Swedish Movement Disorders Caring Society. Stockholm, Sweden, 1998.
- Ekvall K, Johansson Å, Johansson O, Hagell P, Midgren B, Berg S. Hälsorelaterad livskvalitet vid cpapbehandling. The 11th Scandinavian Sleep Research Congress. Lund, Sweden, 2005.

CV Martin Ingelsson

Office Address: Uppsala University, Rudbeck Laboratory, Dag Hammarskjölds väg 20, 751 85 Uppsala. Sweden
Home Address: Norbyvägen 44B, 752 39 Uppsala, Sweden
Work Phone: +46184714107
Work Email: martin.ingelsson@pubcare.uu.se
Work Phone: +464714808
FAX:
Place of Birth: Husie, Sweden

Education

1995: MD; Karolinska Institutet
2001: PhD; Karolinska Institutet

Postdoctoral Training

09/01-12/04: Post-doctoral Fellowship; Harvard Medical School/ Massachusetts General Hospital

Faculty Academic Appointments

12/09-ongoing: Associate Professor; Uppsala University
08/14-07/15: Visiting Associate Professor; Harvard Medical School

Appointments at Hospitals/Affiliated Institutions

05/98-05/01: Internship at Karolinska University Hospital
01/05-12/12: Clinical Residency at the Geriatric Dept, Uppsala University Hospital
12/12 - ongoing: Specialist in Geriatrics; Uppsala University Hospital
14/08- ongoing: Research Sabbatical / Massachusetts General Hospital

Major Administrative Leadership Positions

Local

12/09- : Member of the Research Committee at the Geriatric Department; Uppsala University Hospital
12/09- : Member of the Steering Committee at the Geriatric Laboratory; Uppsala University

Professional Societies

06/95- : Member of the Swedish Society of Medicine
01/97- : Member of the Society for Neuroscience

Grant Review Activities

01/10- : Alzheimer's Association; Grant Reviewer

Report of Local Teaching and Training

Teaching of Students in Courses

PhD student supervision

2005-2008: Supervision of PhD student (Elin Blom); Uppsala University
2005-2009: Supervision of PhD student (Lena Skoglund); Uppsala University
2007-2011: Supervision of PhD student (Thomas Näsström); Uppsala University
2008-2013: Supervision of PhD student (Therese Fagerqvist); Uppsala University
2012-2015 :Supervision of PhD student (Gabriel Westman); Uppsala University
2012- : Supervision of PhD student (Gabriel Gustafsson); Uppsala University
2013- : Supervision of PhD student (Leire Almandoz-Gil); Uppsala University

Formal Teaching of Residents, Clinical Fellows and Research Fellows (post-docs)

2009- : Supervision of post-doctoral fellow (Veronica Lindström); Uppsala University
2010-2013: Supervision of post-doctoral fellow (Hedvig Welander); Uppsala University
2013- : Supervision of post-doctoral fellow (Elisabet Ihse); Uppsala University
2014- : Supervision of post-doctoral fellow (Sara Ekmark-Lewén); Uppsala University

Clinical Supervisory and Training Responsibilities

2011-2012: Supervision of MD students for their training in Geriatric medicine; Uppsala University Hospital

Laboratory and Other Research Supervisory and Training Responsibilities

2003: Supervision of an Honor's Thesis student (Jung Lee) (2 semesters); Harvard College
2005: Supervision of a Master's thesis student (Johan Fredriksson) (20 weeks); Linköping University
Supervision of a Master's thesis student (Thomas Näsström) (20 weeks); Mälardalen University
2006: Supervision of a Master's thesis student (Jayashree Viswanathan) (20 weeks); Skövde University
Supervision of an M.D. student- project work (Sara Sylvén) (5 weeks); Uppsala University
2007: Supervision of a Master's thesis student (Therese Wahlberg) (20 weeks); Uppsala University
Supervision of a Master's thesis student (Yijing Wang) (20 weeks); Uppsala University
Supervision of a Biomedical student- project work (Kristin Sandberg) (10 weeks); Uppsala University
2008: Supervision of a Master's thesis student (Vanessa Silva) (20 weeks); Uppsala University

Main supervisor of a Master's thesis student (Anna Börjesson) (20 weeks);
Chalmers University
2010: Supervision of an M.D. student – project work (Mikael Barbu) (20 weeks);
Uppsala University
2012: Supervision of an M.D. student – project work (Xingjian Su) (20 weeks);
Uppsala University

Report of Regional, National and International Invited Teaching and Presentations

National

2006: Invited speaker at the symposia “Biobanking in the 21st century”, The Swedish National Biobank Program; Uppsala, Sweden
2007: Invited speaker at the “Annual Meeting for The Swedish Society for Cognitive Illnesses”; Uppsala, Sweden
2007: Invited symposia speaker at SwedenBIOS Key Scientist Day; Stockholm, Sweden
2008: Invited symposia speaker at the “National Dementia Day”, Stockholm, Sweden
2008: Invited speaker at the symposia “Pharmacological treatment of Alzheimer's disease”; Uppsala, Sweden (arranged by The Swedish Society for Cognitive Illnesses)
2011: Invited speaker at the symposia “Pharmacological treatment of Alzheimer's disease”; Uppsala, Sweden (arranged by The Swedish Society for Cognitive Illnesses)
2013: Invited speaker at the “Swedish Neurology Association's Spring meeting”; Falun, Sweden
2013: Invited speaker at the “National Dementia Day”; Stockholm, Sweden

International

2008: Invited speaker at “Reunión del Grupo de Estudio de Conductas y Demencias de la Sociedad Española de Neurología”; Barcelona, Spain
2008: Invited speaker at the “Springfield symposium on advances in AD therapy”; Geneva, Switzerland
2009: Organizer and speaker at the “Firat International Conference on Neurodegenerative Disorders: Immunotherapy and Biomarkers”; Uppsala, Sweden
2011: Organizer and speaker at the “Second International Conference on Neurodegenerative Disorders: Immunotherapy and Biomarkers”; Uppsala, Sweden
2013: Organizer and speaker at the “Third International Conference on Neurodegenerative Disorders: Immunotherapy and Biomarkers”; Uppsala, Sweden
2013: Invited speaker at the “TRANS MED meeting” at the Academy of Athens; Athens, Greece
2013: Invited speaker at the “13th Scandinavian Meeting on Parkinson's Disease”; Stockholm, Sweden
2014: Invited speaker at the “American Academy of Neurology”, Philadelphia, USA
2015: Invited speaker at the “15th Scandinavian Meeting on Parkinson's disease and Related disorders”; Stockholm, Sweden

Report of Clinical Activities and Innovations

Current Licensure and Certification

1995: Medical license
2012: Specialty license in Geriatric Medicine

Practice Activities

1996-1998: Clinical training at the Geriatric Department/ Karolinska University Hospital; 50%
1998-2001: Internship at Karolinska University Hospital; 50%
2005-2012: Residency at the Geriatric Department/ Uppsala University Hospital; 75%

Report of Technological and Other Scientific Innovations

Patents:

Lars Lannfelt, Joakim Bergström, Martin Ingelsson, Pär Gellerfors. Antibodies and vaccines for use in therapeutic and diagnostic methods for Parkinson's disease, dementia with Lewy bodies and other neurodegenerative disorders, 61/048,865

The patent describes the generation and characterization of monoclonal antibodies that have been raised in our laboratory together with researchers at BioArctic Neuroscience and that such antibodies can be used both as novel therapeutics and diagnostics for patients with Lewy body brain pathology.

Report of Education of Patients and Service to the Community

Activities

2005- : Planning and implementation of several lecture program and information meetings with patients and caregivers

Educational Material for Patients and the Lay Community

Books, monographs, articles and presentations in other media:

Ingelsson, M. Behandling av Alzheimers sjukdom- en del nytt under solen, Medikament nr. 3 2000, 99-102 (Swedish).

Landahl, P. Kilander, L., **Ingelsson, M.** O, min man- om den förbryllande sjukdomen frontallobsdemens; Gothia 2009 (Swedish).

Educational material or curricula developed for non-professional students:

Ingelsson, M., Lilius, L., Forsell, C., Shin, Y., Irizarry, M., Graff, C., Hyman, B.T. Genotyping of apolipoprotein E- comparative evaluation of different protocols. Curr Prot Hum Genet 2003, Unit 9.14 (9.14.1.-9.14.14).

Report of Scholarship

Research investigations

1. **Ingelsson, M.**, Vanmechelen, E., Lannfelt, L., Microtubule-associated protein tau in human fibroblasts with and without the Swedish mutation. Neurosci Lett 1996; 220(1):9-12.

2. Forsell, C., Froelich, S., Axelman, K., Vestling, M., Cowburn, R.F., Lilius, L., Johnston, J.A., Engvall, B., Dahlkild, Å., **Ingelsson, M.**, St George-Hyslop, P.H., Lannfelt, L., A novel pathogenic mutation (Leu262Phe) found in the presenilin 1 gene in early-onset Alzheimer's Disease. Neurosci Lett 1997;234:1-4.

3. Bronge, L., Ferneus, S-E., Blomberg, M., **Ingelsson, M.**, Isberg, L., Lannfelt, L., Wahlund, L-O., White matter lesions in Alzheimer patients are influenced by Apolipoprotein E genotype. Dement Geriatr Cogn Disord 1999; 10:89-96.

- # 4. **Ingelsson, M.**, Blomberg, M., Benedikz, E., Karlsson, E., Vanmechelen, E., Lannfelt, L., Tau immunoreactivity in human plasma but no obvious increase in dementia. *Dement Geriatr Cogn Disord* 1999; 10:442-5.
- # 5. **Ingelsson, M.**, Froelich Fabre, S., Lilius, L., Andersen, C., Almkvist, O., Viitanen, M., Wahlund, L-O., Lannfelt, L., Increased risk for frontotemporal dementia through interaction between tau polymorphisms and apolipoprotein E e4. *Neuroreport* 2001; 12(5):905-9.
- # 6. Fukumoto, H., **Ingelsson, M.**, Gårevik, N., Wahlund, L-O., Nukina, N., Hyman, B.T., Rebeck, G.W., Irizarry, M. The proportion of apolipoprotein E4 levels in APOE e3/e4 heterozygotes is elevated in CSF relative to plasma, independent of Alzheimer disease diagnosis. *Exp Neurol* 2003; 183:249-253.
- # 7. Dombek, DA., Kasischke KA., Vishwasrao HD., **Ingelsson M.**, Hyman, B.T., Webb, W.W. Uniform polarity microtubule assemblies imaged in native brain tissue by second harmonic generation. *Proc Natl Acad Sci USA* 2003; 100 (12):7081-86.
- # 8. **Ingelsson, M.**, Fukumoto, H., Newell, K., Growdon, J.H. Hedley-Whyte, T.E., Albert, M.S., Frosch, M.P., Hyman, B.T., Irizarry, MC. Early A[beta] accumulation and progressive synaptic loss, gliosis and tangle formation in AD brain. *Neurology* 2004; 62(6):925-31.
- # 9. **Ingelsson, M.**, Jesneck, J., Irizarry, M.C., Hyman, B.T., Rebeck, G.W. Lack of association of the cholesterol 24-hydroxylase (CYP46) intron 2 polymorphism with Alzheimer's disease. *Neurosci Lett* 2004; 367:228-31.
- # 10. Bertram, L., Hiltunen, M., Parkinson, M., **Ingelsson, M.**, Lange, C., Ramasamy, K., Mullin, K., Menon, R., Sampson, A.J., Hsiao, M.Y., Elliot, K.J., Velicelebi, G., Moscarillo, T., Hyman, B.T., Wagner, S.L., Becker, K.D., Blacker, D., Tanzi, R.E. Family-based association between Alzheimer's disease and variants in UBQLN1. *N Engl J Med* 2005; 352:884-94.
- # 11. Lee, J., Fukumoto, H., Orne, J., Klucken, J., Raju, S., Vanderburg, C., Irizarry, M., Hyman, B.T., **Ingelsson, M.** Decreased levels of BDNF protein in Alzheimer temporal cortex, independent of BDNF polymorphisms. *Exp Neurol* 2005; 194:91-96.
- # 12. SantaCruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., **Ingelsson, M.**, Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E., Forster, C., Yu, M., Orne, J., Janus, C., Mariash, A., Kuskowski, M., Hyman, B.T., Hutton, M., Ashe, K.H. Tau suppression in a neurodegenerative mouse model improves memory function. *Science* 2005; 309:476-81.
- # 13. Huang, W., Dobberfuhl, A., Filippopoulos, T., **Ingelsson, M.**, Fileta, J.B., Poulin, N.R. Grosskreutz, C.L. Transcriptional up-regulation and activation of initiating caspases in experimental glaucoma. *Am J Pathol* 2005; 167, 3:673-81.
- # 14. Cantuti-Castelvetri, I., Klucken, J., **Ingelsson, M.**, Ramasamy, K., McLean, P.J., Frosch, M.P., Hyman, B.T., Standaert, D.G. Alpha-synuclein and chaperones in dementia with Lewy bodies. *J Neuropathol Exp Neurol* 2005; 6 (12):1058-66.

- # 15. Klucken, J., Ingelsson, M., Shin, Y., Irizarry, M.C., Hedley-Whyte, E.T., Frosch, M., Growdon, J., McLean, P., Hyman, B.T. Clinical and biochemical correlates of insoluble alpha-synuclein in dementia with Lewy bodies. *Acta Neuropathol* 2006; 111(2):101-8.
- # 16. Matsui, T., Ramasamy, K., **Ingelsson, M.**, Fukumoto, H., Conrad, C., Frosch, M.P., Irizarry, M.C., Yuan, J., Hyman, B.T. Coordinated expression of caspase 8, 3 and 7 mRNA in temporal cortex of Alzheimer's disease: relationship to formic acid extractable A β 42 levels. *J Neuropathol Exp Neurol* 2006; 65(5):508-15.
- # 17. Ingelsson, M., Ramasamy, K., Cantuti-Castelvetri, I., Skoglund, L., Matsui, T., Orne, J., Kowa, H., Augustinack, J.C., de Silva, R., Lees, A.J., Lannfelt, L., Vanderburg, C.R., Growdon, J.H., Frosch, M.P., Standaert, D.G., Irizarry, M.C., Hyman, B.T. No alteration in tau exon 10 alternative splicing in tangle-bearing neurons of the Alzheimer's disease brain. *Acta Neuropathol* 2006; 112(4):439-49.
- #18. Kim, M., Hersh, L., Leissring, M.A., **Ingelsson, M.**, Matsui, T., Farris, W., Lu, A., Hyman, B.T., Selkoe, D.J., Bertram, L., Tanzi, R.E. Decreased catalytic activity of the insulin degrading enzyme in chromosome 10-linked Alzheimer's disease families. *J Biol Chem* 2007; 282(11):7825-32.
- # 19. Wollmer, M.A., Slegers, K., **Ingelsson, M.**, Zekanowski, C., Brouwers, N., Maruszak, A., Brunner, F., Huynh, K-D., Kilander, L., Brundin, R-M., Hedlund, M., Giedraitis, V., Glaser, A., Kapaki, E., Tsolaki, M., Molyva, D., Paraskevas, G.P., Thal, D., Barcikowska, M., Kuznicki, J., Lannfelt, L., van Broeckhoven, C., Nitsch, R.M., Hock, C., Papassotiropoulos, A. Association Study on Cholesterol-related Genes in Alzheimer's disease. *Neurogenetics* 2007; 8(3):179-88.
- # 20. Matsui, T., **Ingelsson, M.**, Fukumoto, H., Ramasamy, K., Kowa, H., Frosch, M.P., Irizarry, M.C., Hyman, B.T., Expression of APP pathway mRNAs and proteins in Alzheimer's disease. *Brain Res* 2007, 1161:116-23.
- # 21. **Ingelsson, M.**, Ramasamy, K., Russ, C., Freeman, S., Orne, J., Raju, S., Matsui, T., Growdon, J.H., Frosch, M.P., Ghetti, B., Brown, R.H., Irizarry, M., Hyman, B.T. Increase in the relative expression of tau with four microtubule binding repeat regions, but diminished total tau protein, in frontotemporal dementia and progressive supranuclear palsy brains. *Acta Neuropathol* 2007; 114(5):471-9.
- # 22. Conrad, C., Zhu, J., Conrad, C., Schoenfeld, D., Fang, Z., **Ingelsson, M.**, Stamm, S., Church, G., Hyman, B.T. Single Molecule Profiling of Tau Gene Expression in Alzheimer's Disease. *J Neurochem* 2007; 103(3):1228-36.
- # 23. Giedraitis, V., Sundelöf, J., Irizarry, M.C., Gårevik, N., Hyman, B.T., Wahlund, L-O., **Ingelsson, M.**, Lannfelt, L. Amyloid beta levels in CSF and plasma are correlated in non-demented individuals. *Neurosci Lett* 2007; 427(3):127-31.
- # 24. Blom, E., Viswanathan, J., Kilander, L., Helisalmi, S., Soininen, H., Lannfelt, L., **Ingelsson, M.**, Glaser, A., Hiltunen, M. Low prevalence of *APP* duplications in

Swedish and Finnish patients with early onset Alzheimer's disease. *Eur J Hum Genet* 2008; 16(2):171-5.

25. Skoglund, L., Viitanen, M., Kalimo, H., Lannfelt, L., Eriksdotter Jönhagen, M., **Ingelsson, M.**, Glaser, A., Herva, R. The *tau S305S* mutation causes frontotemporal dementia with parkinsonian features. *Eur J Neurology* 2008; 15(2):156-61.

26. Sundelöf, J., Giedraitis, V., Irizarry, MC., Sundström, J., Ingelsson, E., Rönnemaa, E., Ärnlov, J., Wiberg, B., Degerman Gunnarsson, M., Hyman, BT., Basun, H., **Ingelsson, M.**, Lannfelt, L., Kilander, L. High plasma A β 40 is associated with reduced Alzheimer's disease risk in elderly men. *Arch Neurol* 2008; 65(2):256-63.

27. Basun, H., Bogdanovic, N., **Ingelsson, M.**, Almkvist, O., Näslund, J., Axelman, K., Bird, T.D., Nochlin, D., Schellenberg, G.D., Wahlund, L-O. Lannfelt, L. Clinical and neuropathological features of the *Arctic APP* mutation causing early onset Alzheimer's disease. *Arch Neurol* 2008; 65(4):499-505.

28. O'Callaghan, P., Sandwall, E., Li, J-P., Yu, H., Guan, Z-Z., Ravid, R., van Kuppevelt, T.H., Nilsson, L.N.G., **Ingelsson, M.**, Hyman, B.T., Kalimo, H., Lindahl, U., Lannfelt, L., Zhang, Z. Accumulation of Heparan Sulfate with A β Deposits in Alzheimer's Disease and Tg2576 Mice; Implications for Glial Cells. *Brain Pathol* 2008; 18(4):548-61.

29. Bertram, L., Schjeide, BM., Hooli, B., Mullin, K., Hiltunen, M., Soininen, H., **Ingelsson, M.**, Lannfelt, L., Blacker, D., MD, Tanzi, R. No association between CALHM1 and Alzheimer's disease risk. *Cell* 2008; 135:993-4.

30. Philipson, O., Hammarström, P., Nilsson, K.P.R., Portelius, E., Olofsson, T., **Ingelsson, M.**, Hyman, B.T., Blennow, K., Lannfelt, L., Kalimo, H., Nilsson, L.N.G. The Highly Insoluble State of A-beta in Alzheimer's Disease Brain is Recreated in APP Transgenic Mice with the Arctic Mutation. *Neurobiol Aging* 2009; 30:1393-1405.

31. Näsström, T., Wahlberg, T., Karlsson, M., Nikolajeff, F., Lannfelt, L., **Ingelsson, M.**, Bergström J. The lipid peroxidation metabolite 4-oxo-2-nonenal cross-links alpha-synuclein and causes rapid formation of stable oligomers. *Biochem Biophys Res Commun* 2009;23:872-6.

32. Skoglund, L., Brundin, RM., Olofsson, T., Kalimo, H., Ingvast, S., Blom, E., Giedraitis, V., **Ingelsson, M.**, Lannfelt, L., Basun, H., Glaser, A. Frontotemporal dementia in a large Swedish family is caused by a progranulin null mutation, *Neurogenetics* 2009; 10(1):27-34.

33. Blom, ES., Giedraitis, V., Fukumoto, H., Zetterberg, H., Blennow, K., Hyman, BT., Irizarry, MC., Wahlund, LO., Lannfelt, L., **Ingelsson, M.** Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE ϵ 4/ ϵ 4 genotype. *Dement Ger Cogn Disord* 2009; 27(5):458-64.

34. Skoglund, L., Ingvast, S., Matsui, T., Brundin, RM., Giedraitis, V., Freeman, SH., Growdon, JH., Frosch, MP., Hyman, BT., Lannfelt, L., **Ingelsson, M.**, Glaser, A. No evidence of *PGRN* or *MAPT* gene dosage alterations in a collection of patients with frontotemporal lobar degeneration. *Dement Ger Cogn Disord* 2009; 28(5):471-5.

35. Fukumoto, N., Fujii, T., Combarros, O., Kamboh, MI., Tsai, SJ., Matsushita, S., Nacnias, B., Comings, DE., Arboleda, H., **Ingelsson, M.**, Hyman, BT., Akatsu, H., Grupe, A., Nishimura, AL., Zatz, M., Mattila, KM., Got, Y., Asada, T., Nakamura, S., Kunugi, H. Sexually dimorphic effect of the *BDNF* Val66Met polymorphism on susceptibility to Alzheimer's disease: new data and meta-analysis. *Am J Med Genet* 2010; 153B(1):235-42.

36. Wirths, O., Bethge, T., Marcello, A., Harmeier, A., Jawahr, S., Lucassen, P., Multhaup, G., Brody, D., Esparza, T., **Ingelsson, M.**, Kalimo, H., Lannfelt, L., Bayer, T. Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases. *J Neural Transm* 2010; 117(1):85-96.

37. Petzold A, Altintas A, Andreoni L, Bartos A, Berthele A, Blankenstein MA, Buee L, Castellazzi M, Cepok S, Comabella M, Constantinescu CS, Deisenhammer F, Deniz G, Erten G, Espiño M, Fainardi E, Franciotta D, Freedman M, Giedraitis V, Gilhus NE, Giovannoni G, Glabinski A, Grieb P, Hartung HP, Hemmer B, Herukka SK, Hintzen R, **Ingelsson M**, Jackson S, Jacobsen S, Jafari N, Jalosinski M, Jarius S, Kapaki E, Kieseier BC, Koel-Simmelink MJ, Kornhuber J, Kuhle J, Kurzepa J, Lalive P, Lannfelt L, Lehmensiek V, Lewczuk P, Livrea P, Marnetto F, Martino D, Menge T, Norgren N, Papuc E, Paraskevas GP, Pirttilä T, Rajda C, Rejdak K, Ricny J, Ripova D, Rosengren L, Ruggieri M, Schraen S, Shaw G, Sindic C, Siva A, Stigbrand T, Stonebridge I, Topcular B, Trojano M, Tumani H, Twaalfhoven HA, Vécsei L, Van Pesch V, Vanderstichele H, Vedeler C, Verbeek MM, Villar LM, Weissert R, Wildemann B, Yang C, Yao K, Teunissen C. Neurofilament ELISA validation. *J Immun Methods* 2010; 352:23-31.

38. Giedraitis, V., Glaser, A., Sarajärvi, T., Brundin, RM, Degerman Gunnarsson, M., Tanzi, RE, Helisalmi, S., Pirttilä, T., Kilander, L., Lannfelt, L., Soininen, H., Bertram, L., **Ingelsson, M.**, Hiltunen, M. The *CALHM1 P86L* polymorphism does not alter the levels of amyloid-beta, total tau or phospho-tau in cerebrospinal fluid. *Neurosci Lett* 2010; 469(2):265-7.

39. Sehlin D, Sölvander S, Paulie S, Brundin R, **Ingelsson M**, Lannfelt L, Pettersson FE, Englund H. [Interference from heterophilic antibodies in amyloid-beta oligomer ELISAs](#). *J Alzheimers Dis* 2010; 21(4):1295–1301.

40. Faux, NG., Ritchie, CW, Gunn A., Rembach, A., Tsatsanis, A., Bedo, J., Harrison, J., Lannfelt, L., Blennow, K., Zetterberg, H., **Ingelsson, M.**, Masters, CL., Tanzi, RE., Cummings, JL., Herd, CM., Bush, AI., PBT2 rapidly improves cognition in Alzheimer's disease: additional phase 2 analyses. *J Alzheimers Dis* 2010; 20(2):509-16.

41. Soccia, SJ., Kirby, JE., Washicosky, KJ., Tucker, SM., **Ingelsson, M.**, Hyman, BT., Burton, MA, Goldstein, LE, Duong, S., Tanzi, RE., Moir, RD. The Alzheimer's

disease-associated amyloid beta-protein is an antimicrobial peptide. PLoS One 2010; 5:3:e9505.

42. Sundelöf, J., Sundström, J., Hansson, O., Eriksdotter-Jönhagen, M., Giedraitis, V., Larsson, A., Degerman-Gunnarsson, M., **Ingelsson, M.**, Minthon, L., Blennow, K., Kilander, L., Basun, H., Lannfelt, L. Cystatin C levels are positively correlated with both A β 42 and Tau Levels in CSF in subjects with Alzheimer's Disease, Mild Cognitive Impairment and Healthy Controls. J Alzheimers Dis 2010 1; 21(2):471-8.

43. Beyer, A-S., von Einem, B., Schwanzar, D., Keller, IE., Hellrung, A., Thal, DR., **Ingelsson, M.**, Makarova, A., Deng, M., Chhabra, ES., Pröpper, C., Böckers, TM., Hyman, BT., von Arnim, CAF. Engulfment adaptor PTB domain containing 1 interacts with and affects processing of the amyloid-beta precursor protein. Neurobiol Aging 2012; 33(4):732-43

44. Lambert, J-C., Slegers, K., **Ingelsson, M.**, Beecham, G.W., Hiltunen, M., Combarros, O., Bullido, MJ., Brouwers, N., Bettens, K., Berr, C., Pasquier, F., Richard, F. DeKosky, ST., Hannequin, D., Haines, JL., Fiévet, N., Dartigues, J-F., Tzourio, C., Engelborghs, S., Arosio, B., Coto, E., De Deyn, P., Del Zompo, M., Mateo, I., Epelbaum, J., Michaud Schjeide, B-M.M., Frank-Garcia, A., 25, Giedraitis, V., Helisalimi, S., Porcellini, E., Pilotto, A., Forti, P., Ferri, R., Zelenika, D., Lathrop, M., Scarpini, E., Siciliano, G., Solfrizzi, V., Sorbi, S., Spalletta, G., Ravaglia, G., Valdivieso, F., Vepsäläinen, D., Alvarez, V., Bosco, P., Tanzi, R., lo Mancuso, M., Panza, F., Nacmias, B., Bossù, P., Hanon, O., Piccardi, P., Annoni, G., Mann, D., Marambaud, P., Seripa, D., Galimberti, D., Bertram, L., Lendon, C., Lannfelt, L., Licastro, F., Campion, D., Pericak-Vance, M., Soininen, H., Van Broeckhoven, C., Alperovitch, A., Ilyas Kamboh, M., Amouyel, P. [The CALHM1 P86L Polymorphism is a Genetic Modifier of Age at Onset in Alzheimer's Disease: a Meta-Analysis Study.](#) J Alzh Dis. 2010; 22(1):247-55.

45. Sundelöf, J., Sundström, J., Hansson, O., Eriksdotter-Jönhagen, M., Giedraitis, V., Larsson, A., Degerman-Gunnarsson, M., **Ingelsson, M.**, Minthon, L., Blennow, K., Kilander, L., Basun, H., Lannfelt, L. Higher Cathepsin B Levels in Plasma in Alzheimer's Disease Compared to Healthy Controls. J Alzh Dis. 2010; 22(4):1223-30.

46. Wirths, O., Erck, C., Martens, H., Harmeier, A., Geumann, C., Jawahr, S., Kumar, S., Multhaup, G., Walter, J., **Ingelsson, M.**, Degerman-Gunnarsson, M., Kalimo, H., The Netherlands Brain Bank, Lannfelt, L., Bayer, T. Identification of low molecular weight pyroglutamate A β oligomers in Alzheimer disease: a novel tool for therapy and diagnosis. J Biol Chem. 2010; 285(53):41517-24.

47. Skoglund, L., Matsui, T., Freeman, SH., Wallin, A., Blom, E., Frosch, MP., Growdon, JH., Hyman, BT., Lannfelt, L., **Ingelsson, M.**, Glaser, A. [Novel Progranulin Mutation Detected in Two Patients With FTL D.](#) Alzheimer Dis Assoc Disord. 2011; 25(2):173-8.

48. Näsström, T., Wahlberg, T., Barbu, M., Karlsson, M., Nikolajeff, F., Kasrayan, A., Ekenberg, M., Lannfelt, L., **Ingelsson, M.** Bergström, J. The lipid peroxidation products 4-oxo-2-nonenal and 4-hydroxy-2-nonenal promote the formation of alpha-synuclein oligomers with distinct biochemical, morphological and functional properties. Free Rad Biol Med 2011; 50(3):428-37.

49. Blom ES., Wang, Y., Skoglund, L., Hansson, A., Ubaldi, M., Lourdasamy, A., Sommer, W., Mielke, M., Hyman, BT., Heilig, M., Lannfelt, L., Nilsson, LNG., **Ingelsson, M.** Increased mRNA levels of *TCF7L2* and *MYC* of the Wnt pathway in tgAPP-ArcSwe mice and in Alzheimer's disease brain. *Int J Alzh Dis* 2011; 22:936580.

50. Welander, H., Bontha, SV., Näsström, T., Karlsson, M., Nikolajeff, F., Danzer, K., Kalimo, H., Lannfelt, L., **Ingelsson, M.**, Bergström, J. Gelsolin co-occurs with Lewy bodies and accelerates α -synuclein aggregation *in vitro*. *Biochem Biophys Res Commun* 2011; 19:412(1):32-8.

51. Näsström, T., Gonçalves, S., Sahlin, C., Nordström, E., Screpanti Sundquist, V., Lannfelt, L., Bergström, J., Outeiro, T.F., **Ingelsson, M.** Antibodies against alpha-synuclein reduce oligomerization in living cells. *PLoS One* 2011; 6(10):e27230.

52. Philipson, O., Lord, A., Lalowski, M., Soliymani, R., Baumann, M., Thyberg, J., Bogdanovic, N., Olofsson, T., Tjernberg, L., Ingelsson, M., Lannfelt, L., Kalimo, H., Nilsson, LNG. The Arctic *A β PP* mutation results in distinct plaques and accumulation of N- and C-truncated A β . *Neurobiol Aging* 2012; 33(5):1010.e1-1010.e13.

53. Forsberg, LA., Rasi, C., Razzaghian, HR., Pakalapati, G., Thibeault, C., Waite, L., Ronowicz, A., Wineinger, NE., Tiwari, HE., Boomsma, D., Westerman, MP., Harris, J., Essand, M., Eriksson, F., ADVANCE cohort, Strachan, E., O'Hanlon, TP., Rider, LG., Miller, FW., Giedraitis, V., Lannfelt, L., **Ingelsson, M.**, Piotrowski, A., Pedersen, NL., Absher, D., Dumanski, JP. Accumulation of structural variation with age in nuclear genome of normal human blood cells *in vivo*. *Am J Hum Genet* 2012; 10:90(2):217-28.

54. Sehlin, D., Englund, H., Simu, B., Karlsson, M., **Ingelsson, M.**, Nikolajeff, F., Lannfelt, L., Ekholm Pettersson, F. Large aggregates are the major soluble Abeta species in AD brain fractionated with density gradient ultracentrifugation. *PLoS One* 2012; 7(2):e32014.

55. Diógenes, MJ., Dias, RA., Rombo, DM., Vicente Miranda, H., Maiolino, F., Guerreiro, P., Näsström, T., Franquelim, HG., Oliveira, LM., Castanho, M., Lannfelt, L., Bergström, J., **Ingelsson, M.**, Quintas, A., Sebastião, AM., Lopes, LV, Outeiro, TF. Extracellular alpha-synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation. *J Neurosci* 2012; 32(34):11750-62.

56. Lambert, JC., Grenier-Boley, B., Harold, D., Zelenika, D., Chouraki, V., Kamatani, Y., Slegers, K., Ikram, A., Hiltunen, M., Reitz, C., Mateo, I., Feulner, T., Bullido, M., Galimberti, D., Concari, L., Alvarez, V., Sims, R., Gerrish, A., Chapman, J., Deniz-Naranjo, C., Solfrizzi, V., Sorbi, S., Arosio, B., Spalletta, G., Siciliano, G., Epelbaum, J., Hannequin, H., Dartigues, J-F., Tzourio, C., Berr, C., Schrijvers, EMC., Rogers, R., Tosto, G., Pasquier, F., Bettens, K., Van Cauwenberghe, C., Fratiglioni, L., Graff, C., Delepine, M., EADI consortium, GERAD consortium, Ferri, R., Reynolds, CA., Lannfelt, L., **Ingelsson, M.**, Prince, JA., Chillotti, C., Greco, A., Seripa, D., Boland, A., Mancuso, M., Bossù, P., Annoni, G., Nacmias, B., Bosco, P., Panza, F., Sanchez-Garcia, F., Del Zompo, M., Coto, E., Owen, M., O'Donovan, M., Valdivieso, F., Caffara, P., Scarpini, E., Combarros, O., Buée, L., Champion, D., Soininen, H., Breteler, M., Riemenschneider, M., Van Broeckhoven, C., Alperovitch,

A., Lathrop, M., Trégouët, D-A., Williams, J., Amouyel, P. Genome-wide haplotype association study identifies the *FRMD4A* gene as a risk locus for Alzheimer's disease. *Nature Genet* 2013;18(4):461-70.

57. Fagerqvist, T., Lindström, V., Nordström, E., Lord, A., Tucker, S.M.E., Sahlin, C., Kasrayan, A., Andersson, J., Welander, H., Näsström, T., Holmquist, M., Schell, H., Kahle, P., Kalimo, H., Möller, C., Gellerfors, P., Lannfelt, L., Bergström, J., **Ingelsson, M.** [Monoclonal antibodies selective for \$\alpha\$ -synuclein oligomers/protofibrils recognize brain pathology in Lewy body disorders and \$\alpha\$ -synuclein transgenic mice with the disease-causing A30P mutation.](#) *J Neurochem* 2013; 126(1):131-44.

58. Fagerqvist, T., Näsström, T., Sahlin, C., Tucker, S., Lindström, V., Karlsson, M., Nikolajeff, F., Schell, H., Kahle, P., Kasrayan, A., Ekenberg, M., Lannfelt, L., **Ingelsson, M.**, Bergström J. Off-pathway α -synuclein oligomers seem to alter α -synuclein turnover in a cell model but lack seeding capability *in vivo*. *Amyloid* 2013; 20(4):233-44.

59. Rubio-Moscardo, F., Seto-Salvia, N., Pera, M., Bosch-Morato, M., Plata, C., Belbin, O., Gene, G., Dols-Icardo, O., Ingelsson, M., Helisalmi, S., Soininen, H., Hiltunen, M., Giedraitis, V., Lannfelt, L., Frank, A., Bullido, M.J., Combarros, O., Sanchez-Juan, P., Boada, M., Tarraga, L., Pastor, P., Perez-Tur, J., Baquero, M., Molinuevo, J.L., Sanchez-Valle, R., Fuentes-Prior, P., Fortea, J., Blesa, R., Munoz, F.J., Lleo, A., Valverde, M.A., and Clarimon, J. (2013). Rare variants in calcium homeostasis modulator 1 (CALHM1) found in early onset Alzheimer's disease patients alter calcium homeostasis. *PLoS one* 8, e74203.

60. Kalimo, H., Lalowski, M., Bogdanovic, N., Philipson, O., Bird, T.D., Nochlin, D., Schellenberg, G.D., Brundin, R.M., Olofsson, T., Lalowski, M., Baumann, M., Wirths, O., Bayer, T., Nilsson, L.N.G., Basun, H., Lannfelt, L. **Ingelsson, M.** The *Arctic APP* mutation leads to Alzheimer's disease pathology with highly variable topographic deposition of differentially truncated Ab. *Acta Neuropathol Commun* 2013; 1(1):60.

61. Degerman Gunnarsson, M., Lannfelt, L., **Ingelsson, M.**, Basun, H., Kilander, L. High tau levels in cerebrospinal fluid predict poor prognosis in Alzheimer's disease. *Dement Geriatr Cogn Disord* 2013; 37(3-4):196-206.

62. Antonios, G., Saiepour, N., Bouter, Y., Richard, B., Paetau, A., Verkkoniemi, A., Lannfelt, L., **Ingelsson, M.**, Kovacs, G.G., Pillot, T., Wirths, O., Bayer, T.A. N-truncated A β starting with position four: early intraneuronal accumulation and rescue of toxicity using NT4X-167, a novel monoclonal antibody. *Acta Neuropathol Commun* 2013; 1(1):56.

63. Westman, G., Lidhall, A-K., Magnusson, P., **Ingelsson, M.**, Kilander, L., Lannfelt, L., Korsgren, O., Eriksson, B-M. Decreased proportion of cytomegalovirus specific CD8 T-cells but no signs of general immunosenescence in Alzheimer's disease. *PLoS One* 2013;8(10):e77921.

64. Reinert, J., Martens, H., Huettenrauch, M., Lannfelt, L., **Ingelsson, M.**, Paetau, A., Verkkoniemi, A., Bayer, T.A., Wirths, O. Ab38 in the brains of sporadic and

familial Alzheimer's disease and transgenic mouse models. *J Alzh Dis* 2014 ;39(4):871-81.

65. Lambert, J-C., ...**Ingelsson, M.**, ...Amouyel, P. (182 authors) Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. *Nat Genet.* 2013 Oct 27. doi: 10.1038/ng.2802.

66. Musunuri, S., Wetterhall, M., **Ingelsson, M.**, Lannfelt, L., Artemenko, K., Bergquist, J., Kultima, K., Shevchenko, G. Quantification of brain proteome in Alzheimer's disease using multiplexed mass spectrometry: Focus on biomarkers. *J Proteome Res.* 2014 Apr 4;13(4):2056-68. doi: 10.1021/pr401202d. Epub 2014 Mar 19

67. Escott-Price, V., ...**Ingelsson, M.**, ...Williams, J. (188 authors) Gene-wide analysis detects two new susceptibility genes for Alzheimer's disease. *PLoS One.* 2014 Jun 12;9(6):e94661.

68. Guzmán, EA., Bouter, Y., Richard, BC., Lannfelt, L., **Ingelsson, M.**, Paetau, A., Verkkoniemi, A., Wirths, O., Bayer, TA. Abundance of A β _{5-x} in transgenic 5XFAD, APP/PS1KI and 3xTG mice, sporadic and familial Alzheimer's Disease. *Mol Neurodegener.* 2014 Apr 2;9:13

69. Westman, G., Berglund, D., Widén, J., **Ingelsson, M.**, Korsgren, O., Lannfelt, L., Sehlin, D., Lidehall A-K., Eriksson, B-M. Increased Inflammatory Response in Cytomegalovirus Seropositive Patients with Alzheimer's Disease. *PLoS One* 2014 May 7;9(5):e96779.

70. Pannee J, Törnqvist U, Westerlund A, **Ingelsson M**, Lannfelt L, Brinkmalm G, Persson R, Gobom J, Svensson J, Johansson P, Zetterberg H, Blennow K, Portelius E. [The amyloid- \$\beta\$ degradation pattern in plasma - a possible tool for clinical trials in Alzheimer's disease.](#) *Neurosci Lett.* 2014 Jun 24;573:7-12.

71. Lindström, V., Fagerqvist, T., Nordström, E., Lord, A., Tucker, S., Andersson, J., Johannesson, M., Schell, H., Kahle, P., Möller, C., Gellerfors, P., Bergström J., Lannfelt, L., **Ingelsson, M.** Reduced pathology in transgenic mice following immunotherapy with oligomer/protofibril selective α -synuclein antibodies. *Neurobiol Dis.* 2014 Sep;69:134-43.

72. Watts, JC., Condello, C., Stöhr, J., Oehler, A., Lee, J., DeArmond, SJ., Lannfelt, L., **Ingelsson, M.**, Giles, K., Prusiner, SB. The Arctic Alzheimer's disease mutation enciphers a distinct strain of A β prions. *Proc Natl Acad Sci U S A.* 2014 Jul 15;111(28):10323-8.

73. Kvartsberg, H., Duits, FH., **Ingelsson, M.**, Andreasen N., Öhrfelt, A., Andersson, K., Brinkmalm, G., Lannfelt, L., Minthon, L., Hansson, O., Andreasson, U., Teunissen, CE., Scheltens, P., Van der Flier, WM., Zetterberg, H., Portelius, E., Blennow, K. Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. *Alzh Dem* 2014 Dec 19. pii: S1552-5260(14)02863-5.

74. International Genomics of Alzheimer's Disease Consortium (IGAP). [Convergent genetic and expression data implicate immunity in Alzheimer's disease](#). *Alzheimers Dement*. 2014 Dec 20. pii: S1552-5260(14)02492-3.

75. Dumanski, JP., Rasi, C., Lönn, M., Davies, H., **Ingelsson, M.**, Giedraitis, V., Magnusson, P., Lindgren, CM., Morris, AP., Cesarini, D., Johannesson, M., Tiensuu Jansson, E., Lind, L., Pedersen, NP., Ingelsson, E., Forsberg, LA. [Mutagenesis. Smoking is associated with mosaic loss of chromosome Y](#). *Science* 2015 Jan 2;347(6217):81-3.

76. Musunuri, S., Kultima, K., Richard, BC., **Ingelsson, M.**, Lannfelt, L., Bergquist, J., Shevchenko, G. Micellar extraction possesses a new advantage for the analysis of Alzheimer's disease brain proteome. *Anal Bioanal Chem* 2015 Feb;407(4):1041-57.

77. Oskarsson, M., Paulsson, JF., Schultz, SW., **Ingelsson, M.**, Westermark, P., Westermark, GT *In vivo* seeding and cross-seeding of localized amyloidosis: A molecular link between type 2 diabetes and Alzheimer's disease. *Am J Pathol* 2015 Mar;185(3):834-46

78. Jun G, Ibrahim-Verbaas CA, Vronskaya M, Lambert JC, Chung J, Naj AC, Kunkle BW, Wang LS, Bis JC, Bellenguez C, Harold D, Lunetta KL, Destefano AL, Grenier-Boley B, Sims R, Beecham GW, Smith AV, Chouraki V, Hamilton-Nelson KL, Ikram MA, Fievet N, Denning N, Martin ER, Schmidt H, Kamatani Y, Dunstan ML, Valladares O, Laza AR, Zelenika D, Ramirez A, Foroud TM, Choi SH, Boland A, Becker T, Kukull WA, van der Lee SJ, Pasquier F, Cruchaga C, Beekly D, Fitzpatrick AL, Hanon O, Gill M, Barber R, Gudnason V, Champion D, Love S, Bennett DA, Amin N, Berr C, Tsolaki M, Buxbaum JD, Lopez OL, Deramecourt V, Fox NC, Cantwell LB, Tarraga L, Dufouil C, Hardy J, Crane PK, Eiriksdottir G, Hannequin D, Clarke R, Evans D, Mosley TH Jr, Letenneur L, Brayne C, Maier W, De Jager P, Emilsson V, Dartigues JF, Hampel H, Kamboh MI, de Bruijn RF, Tzourio C, Pastor P, Larson EB, Rotter JI, O'Donovan MC, Montine TJ, Nalls MA, Mead S, Reiman EM, Jonsson PV, Holmes C, St George-Hyslop PH, Boada M, Passmore P, Wendland JR, Schmidt R, Morgan K, Winslow AR, Powell JF, Carasquillo M, Younkin SG, Jakobsdóttir J, Kauwe JS, Wilhelmsen KC, Rujescu D, Nöthen MM, Hofman A, Jones L; **IGAP Consortium**, Haines JL, Psaty BM, Van Broeckhoven C, Holmans P, Launer LJ, Mayeux R, Lathrop M, Goate AM, Escott-Price V, Seshadri S, Pericak-Vance MA, Amouyel P, Williams J, van Duijn CM, Schellenberg GD, Farrer LA. [A novel Alzheimer disease locus located near the gene encoding tau protein](#). *Mol Psych*. 2015 Mar 17. doi: 10.1038/mp.2015.23. [Epub ahead of print]

79. [Quantitative Interaction Proteomics of Neurodegenerative Disease Proteins](#). Hosp F, Vossfeldt H, Heinig M, Vasiljevic D, Arumughan A, Wyler E; the Genetic and Environmental Risk for Alzheimer's Disease (GERAD1) Consortium, Landthaler M, Hubner N, Wanker EE, Lannfelt L, **Ingelsson M**, Lalowski M, Voigt A, Selbach M. *Cell Rep*. 2015 May 6. pii: S2211-1247

80. Cai, Y., Lendel, C., Österlund, L., Lannfelt, L., **Ingelsson, M.**, Nikolajeff, F., Karlsson, M., Bergström, J. Changes in secondary structure of α -syn during oligomerization induced by reactive aldehydes. *Biochem Biophys Res Commun*. 2015

Jun 27. pii: S0006-291X(15)30212-6. doi: 10.1016/j.bbrc.2015.06.154. [Epub ahead of print].

Other peer-reviewed publications

- # 1. **Ingelsson, M.**, Hyman, B.T., Disordered proteins in dementia. *Ann Med* 2002; 34:1-13.
- # 2. **Ingelsson, M.**, Fukumoto, H. Newell, K., Hyman, BT., Irizarry, MC. Lack of correlation between biochemical and neuropathological amyloid measures in the Alzheimer brain. *Ana Aslan International Academy of Aging* 2003; 191-8.
- # 3. Klucken, J., McLean, P.J. Gomez-Tortosa, E., **Ingelsson, M.**, Hyman, B.T. Neuritic alterations and neural system dysfunction in Alzheimer's disease and Lewy body dementia. *Neurochem Res* 2003; 11:1683-91.
- # 4. Hyman, B.T., Augustinack, J.C., **Ingelsson, M.**, Transcriptional and conformational changes of the tau molecule in Alzheimer's Disease. *Biochim Biophys Acta* 2005; 1739 (2-3):150-7.
- # 5. **Ingelsson, M.**, Nilsson, L., Basun, H., Aquilonius, S-M., Lannfelt, L. Conformationally altered proteins cause neurodegenerative disorders. *Läkartidningen* 2005; 0547 (102):3542-51 (Swedish).
- # 6. **Ingelsson, M.**, Hyman, B.T. The molecular basis of Alzheimer's disease. Chapter 16, p.p. 241-55. In: *Molecular Neurology 2007*. Elsevier Academic Press, Burlington, MA. Editor: Stephen G. Waxman.
- # 7. Kilander, L., Landahl, P. **Ingelsson, M.** O, min man- om den förbryllande sjukdomen frontallobsdemens; Gothia 2009.
- # 8. **Ingelsson, M.**, Basun, H., Ekholm Pettersson, F., Kilander, L., Nilsson, LNG., Lannfelt, L. Alzheimer's disease- [rare](#) mutations aim toward future treatment. *Läkartidningen* 2009; 20:1396-1400 (Swedish)..
- # 9. **Ingelsson, M.**, Fagius, J. Synpunkter på åldrandets neurologi. In: *Neurologi*, 5:th edition, Stockholm, Liber, 2013.
- # 10. Lindström, V., Ihse, E., Fagerqvist, T., Bergström, J., Nordström, E., Möller, C., Lannfelt, L., **Ingelsson, M.** Immunotherapy targeting α -synuclein – with relevance for future treatment of Parkinson's disease and other Lewy body disorders. *Immunotherapy* 2014; 6(2):141-53.

Abstracts, Poster Presentations and Exhibits Presented at Professional Meetings

- # 1. **Ingelsson, M.**, Lannfelt, L., Tau in fibroblasts with and without the Swedish APP 670/671 mutation. *Neurobiology of Aging*, 1996, 17 (4S), S 101.

2. **Ingelsson, M.**, Benedikz, E., Karlsson, E., Lannfelt, L., Evidence for the presence of the microtubule-associated protein tau in human plasma. Poster/ Society for Neuroscience 27th Annual Meeting, New Orleans October 25-30 1997.

3. Forsell, C., Froelich, S., Axelman, K., Vestling, M., Cowburn, R.F., Lilius, L., Johnston, J.A., Engvall, B., Dahlkild, Å., **Ingelsson, M.**, St George-Hyslop, P.H., Lannfelt, L., A novel pathogenic mutation (Leu262Phe) found in the Presenilin 1 gene in early-onset Alzheimer's Disease. Fondation IPSEN, Présénilines et Maladie D'Alzheimer, Paris April 28 1997.

4. **Ingelsson, M.**, Blomberg, M., Benedikz, E., Karlsson, E., Vanmechelen, E., Lannfelt, L. Evidence for the presence of tau-like proteins in human plasma. *Neurobiology of Aging*, 1998, 19 (4S), S 58.

5. **Ingelsson, M.**, Froelich, S., Lilius, L., Wahlund, L.O., Lannfelt, L., Investigation of a dinucleotide repeat polymorphism in the tau gene in a clinical population with frontotemporal dementia. Colloques médecine et recherche; Poster/ Paris April 12 1999.

6. **Ingelsson, M.**, Froelich Fabre, S., Lilius, L., Andersen, C., Viitanen, M., Wahlund, L.O., Lannfelt, L., No association with tau polymorphisms in a clinical population with frontotemporal dementia. Poster/ Society for Neuroscience 29th Annual Meeting, Miami October 23-29 1999.

7. Lannfelt, L., Froelich Fabre, S., Lilius, L., Andersen, C., Viitanen, M., Almkvist, O., Wahlund, L.-O., **Ingelsson, M.** Increased risk for frontotemporal lobar degeneration through interaction between the tau intron 9 polymorphism and APOE *e4*. Talk/ Society for Neuroscience 30th Annual Meeting, New Orleans November 4-9 2000

8. **Ingelsson, M.**, Froelich Fabre, S. Volkman, I., Basun, H., Näslund, J., Lannfelt, L., Bogdanovic, N. Tau with three and four microtubule-binding repeats in human brain of Alzheimer's disease and frontotemporal dementia. Poster/ World Alzheimer Congress, Washington D.C. 2000

9. **Ingelsson, M.**, Froelich Fabre, S, Volkman, I., Sundström, E., Näslund, J., Lannfelt, L., Bogdanovic, N. Three microtubule-binding repeat tau (3R tau) are the major tau isoforms in Alzheimer neuropathology. Poster/ Society for Neuroscience 31st Annual Meeting, San Diego November 10-15 2001

10. Fukumoto, H., Newell, K., **Ingelsson, M.**, Hyman, B.T., Irizarry, M.C. Biochemical measures in Alzheimer brain. Correlation of synaptophysin loss but not Ab levels with duration of illness. Massachusetts Alzheimer's Disease Research Center 15th Annual Scientific Poster Session 2002

11. **Ingelsson, M.**, Dombeck, D.A., Kasischke, K.A., Vishwasrao, H.D., Hyman, B.T. Webb, W.W. Second Harmonic Imaging of Axonal Microtubules in the Hippocampus. Poster/ Society for Neuroscience 32d Annual Meeting, Orlando 2002

- # 12. **Ingelsson M.**, Fukumoto H, Newell K, Hyman BT, Irizarry MC. Biochemical and neuropathological measures in Alzheimer brain: correlation of synaptophysin loss but not A β levels with duration of disease. Alzheimer Association 2002 (Stockholm). Neurobiol Aging; 23 (1529):S416.
- # 13. Huang, W., Dobberfuhr, A., **Ingelsson, M.**, Filippopoulos, T., Grosskreutz, C. Detection of gene expression changes of caspase 8 and Thy1 in rat retinal ganglion cells after optic nerve crush using laser capture microdissection with real-time PCR. Poster/ The association for research in vision and ophthalmology. Fort Lauderdale 2003
- # 14. Lawler, S., **Ingelsson, M.**, Augustinack, J., Saeki, Y., Hyman, B., Bhide, P.G., Chiocca, E.A. Wade-Martins, R. Examination of tau splicing using an HSV amplicon expression system. Poster/ Society for Neuroscience 33rd Annual Meeting, New Orleans 2003
- # 15. **Ingelsson, M.**, Cantuti-Castelvetri, I., Augustinack, J.C., Vanderburg, C.R., Growdon, J.H. Frosch, M.P. Irizarry, M.C., Standaert, D.G., Hyman, B.T. Quantitative PCR-analysis of tau with three and four microtubule-binding repeat regions from Alzheimer temporal lobe tissues. Talk/ Society for Neuroscience 33rd Annual Meeting, New Orleans 2003
- # 16. Lawler, S., **Ingelsson, M.**, Augustinack, J., Saeki, Y., Hyman, B., Chiocca, E.A. Wade-Martins, R. Examination of the Pathological Mechanism of the Microtubule Associated Protein Tau Using an HSV Amplicon Based Neuronal Gene Delivery System. Poster/ American Society of Gene Therapy, 6th Annual Meeting (Washington D.C.) June 4-8 2003
- # 17. Dombeck, DA., Kasischke KA., Vishwasrao HD., **Ingelsson M.**, Hyman, B.T, Webb, W.W. Second harmonic imaging of axonal microtubules in the hippocampus. 2003 Biophysical Society meeting, San Antonio 2003
- # 18. Levene, M.J., Dombeck, D.A., Williams, R.M., Skoch, J, Hickey, G.A., Kasischke, K.A., Molloy, R.P., **Ingelsson, M.**, Stern, E.A., Klucken, J., Bacskai, B.J., Zipfel, W.R., Hyman, B.T., Webb, W.W. In vivo multiphoton microscopy of deep tissue with gradient index lenses. Photonics West. San José 2004 and published in [Proc. SPIE Vol. 5323](#), p. 291-296, Multiphoton Microscopy in the Biomedical Sciences IV; Ammasi Periasamy, Peter T. So; Eds.
- # 19. Kim, M.J., Bertram, L., **Ingelsson, M.**, Lu, A., Hyman, B.T., Tanzi, R.E. Functional Analysis of the Insulin Degrading Enzyme in Genetically-Associated AD Families. Poster/ Alzheimer Association 2004 (Philadelphia)
- # 20. **Ingelsson, M.**, Cantuti-Castelvetri, I., Ramasamy, K., Orne, J., Augustinack, J.C., Vanderburg, C.R., Growdon, J.H., Frosch, M.P., Irizarry, M.C., Standaert, D.G., Hyman, B.T. Analysis of gene expression in the Alzheimer's disease brain. Poster/ Alzheimer Association 2004 (Philadelphia)

- # 21. SantaCruz, K.S., Lewis, J., Paulson, J., **Ingelsson, M.**, Kotilinek, L., Forster, C., Guimaraes, A., Mariash, A., Hyman, B.T., Hutton, M., Ashe, K.H. Cognitive impairment in transgenic mice with abnormal intraneuronal tau phosphorylation but little silver positive neurofibrillary pathology. *J Neuropathol Exp Neurol* 2004, 63 (5), 554.
- # 22. Cantuti-Castelvetri, I., **Ingelsson, M.**, Klucken, J., Ramasamy, K., Hyman, B.T., Standaert, D.G. Dysregulation of chaperone proteins in Dementia with Lewy bodies. Poster/ The Movement Disorder Society 2004 (Rome)
- # 23. Giedraitis, V., Kilander, L., Degerman-Gunnarsson, M., Sundelöf, J., Berglund, L., Blom, E., Ingelsson, M., Glaser, A. and Lannfelt, L. Genetic analysis of Alzheimer's disease in the ULSAM cohort. Poster/ Wallenberg Consortium Nord Annual Conference 2005
- # 24. Giedraitis, V., Sundelöf, J., Irizarry, M.C., Degermann Gunnarsson, M., Kilander, L., Glaser, A., **Ingelsson, M.**, Hyman, B.T., Basun, H. Lannfelt, L. Regulation of A β levels in human plasma. Poster/ Wallenberg Consortium Nord Annual Conference 2005
- # 25. Matsui, T., Ramasamy, K., **Ingelsson, M.**, Conrad, C., Frosch, M.P., Irizarry, M.C., Yuan, J., Hyman, B.T. Elevated mRNA Expression of Caspase-7 and 8 are Associated with Insoluble A β 42 Levels in AD Brain. Poster/ Society for Neuroscience 35th Annual Meeting, Washington D.C. 2005
- # 26. Lannfelt, L., Skoglund, L., Glaser, A., Kilander, L., Brundin, R., Basun, H., **Ingelsson, M.** Advances in Genetics of Frontotemporal Dementia. Poster/ Annual meeting for the International Psychiatric Association, Stockholm 2005
- # 27. **Ingelsson, M.**, Russ, C., Ramasamy, K., Orne, J., Skoglund, L., Raju, S., Growdon, J.H., Frosch, M.P., Ghetti, B., Brown Jr., R.H., Irizarry, M., Hyman, B.T. Characterization of tau in human frontal cortex on a neuropathological cohort of tauopathies. Poster/ Society for Neuroscience 35th Annual Meeting, Washington D.C. 2005
- # 28. Conrad, C., Zhu, J., Conrad, C., **Ingelsson, M.**, Church, C., Hyman, B. Single Molecule Exon and Haplotype Profiling of Tau Gene Expression in Alzheimer's disease. Poster/ Society for Neuroscience 35th Annual Meeting, Washington D.C. 2005
- # 29. Zhang, X., O'Callaghan, P., Hong, Y., **Ingelsson, M.**, Hyman, BT, Li, J-P., Lindahl, U., Lannfelt, L. Comparative analysis of heparan sulfate co-localization with A β 40 and A β 42 in different A β deposits in APP transgenic and Alzheimer's disease brain tissue. Poster/ Alzheimer's Association International Conference on Alzheimer's Disease (ICAD) Madrid 2006
- # 30. Sundelöf, J., Giedraitis, V., Irizarry, MC. Hyman, BT., Sundström, J., Ingelsson, E., Rönnekaa, E., Degerman-Gunnarsson, M., Basun, H., **Ingelsson, M.**, Kilander, L., Lannfelt, L. Plasma amyloid-b protein (Ab) in the Uppsala Longitudinal Study of

Adult Men (ULSAM). Poster/ Alzheimer's Association International Conference on Alzheimer's Disease (ICAD) Madrid 2006

31. Giedraitis, V., Gårevik, N., Sundelöf, J., Irizarry, MC., **Ingelsson, M.**, Lannfelt, L. Amyloid beta levels in plasma and CSF are correlated in healthy individuals. Poster/ Alzheimer's Association International Conference on Alzheimer's Disease (ICAD) Madrid 2006

32. Blom, E., Sommer, W., Heilig, M., Lannfelt, L., **Ingelsson, M.**, Nilsson, L. Analysis of gene expression in brains of a transgenic mouse model for Alzheimer's disease. Poster/ Alzheimer's Association International Conference on Alzheimer's Disease (ICAD) Madrid 2006

33. Skoglund, L., Kalimo, H., Herva, R., **Ingelsson, M.**, Lannfelt, L., Glaser, A., Viitanen, M. Frontotemporal dementia and parkinsonism: another phenotype of the tau S305S mutation. Poster/ Alzheimer's Association International Conference on Alzheimer's Disease (ICAD) Madrid 2006

34. Glaser, A., Giedraitis, V., Kilander, L., Degerman-Gunnarsson, M., Sundelöf, J., Berglund, L., Blom, E., **Ingelsson, M.**, Lannfelt, L., Genetic analysis of Alzheimer's disease in the ULSAM cohort. Poster/ Alzheimer's Association International Conference on Alzheimer's Disease (ICAD) Madrid 2006

35. Fredriksson, J., Skoglund, L., Bergström, J., Lannfelt, L., **Ingelsson, M.** *In vitro* characterization of tau aggregational properties. Poster/ Alzheimer's Association International Conference on Alzheimer's Disease (ICAD) Madrid 2006

36. **Ingelsson, M.**, Blom, E., Fukumoto, H., Gårevik, N., Wahlund, L-O., Lannfelt, L., Hyman, B.T., Irizarry, M. Effect of *APOE* genotype on CSF Ab levels in Alzheimer's disease and mild cognitive impairment. Poster/ Alzheimer's Association International Conference on Alzheimer's Disease (ICAD) Madrid 2006

37. **Ingelsson, M.**, Fredriksson, J., Irizarry, M., Lannfelt, L., Hyman, B.T. Function and regulation of tau- in vivo and in vitro lessons of FTDP17 mutations. Talk/ Springfield Conference Geneva 2006 (Neurobiol Aging 27S1 (2006) S11)

38. O'Callaghan, P., Li, J-P., Yu, H., Nilsson, LNG., Hyman, BT., Kalimo, H., **Ingelsson, M.**, Lindahl, U., Lannfelt, L., Zhang, X. Differential co-localization of heparan sulfate with A β 40 and A β 42 deposits in APP-transgenic mice and Alzheimer's disease. Poster/ AD/PD Salzburg, 2007

39. Giedraitis, V., Irizarry, M., Sundelöf, J., Degerman Gunnarsson, M., Kilander, L., Glaser, A., **Ingelsson, M.**, Hyman, BT., Basun, H., Lannfelt, L. Genetic regulation of A β levels in human plasma. Poster/ Alzheimer's Association International Conference on Alzheimer's Disease (ICAD) Chicago 2008

40. Nilsson, LNG., Lord, A., Philipson, O., Englund, H., Gumucio Gatics, A., Sehlin, D., Clausen, F., Hillered, L., **Ingelsson, M.**, Gordon, M., Ekholm Pettersson, F., Kalimo, H., Lannfelt, L. Transgenic mice with the Arctic APP mutation as animal models of Alzheimer's disease. Poster/ Alzheimer's Association International Conference on Alzheimer's Disease (ICAD) Chicago 2008

- # 41. Englund, H., Sehlin, D., Degerman Gunnarsson, M., Lord, A., Brundin, R-M., **Ingelsson, M.**, Kilander, L., Nilsson, LNG., Ekholm Pettersson, F., Lannfelt, L. Increased levels of CSF A β oligomers in AD- combination of techniques allows indirect estimates. Poster/ Alzheimer's Association International Conference on Alzheimer's Disease (ICAD) Chicago 2008
- # 42. Näsström, T., Wahlberg, T., Karlsson, M., Nikolajeff, F., Lannfelt, L., Bergström, J., **Ingelsson, M.** Oligomeric amorphous species of alpha-synuclein induce toxicity in a cellular model. Poster/ Alzheimer's Association International Conference on Alzheimer's Disease (ICAD) Chicago 2008
- # 43. Wahlberg, T., Näsström, T., Hedlund, M., Ekholm Pettersson, F., Lannfelt, L., **Ingelsson, M.**, Bergström, J. Development of oligomer-specific alpha-synuclein antibodies. Poster/ Alzheimer's Association International Conference on Alzheimer's Disease (ICAD) Chicago 2008
- # 44. Bergström, J., Näsström, T., Wahlberg, T., Lannfelt, L., **Ingelsson, M.** Characterization of early events in the alpha-synuclein aggregation pathway. Poster/ Alzheimer's Association International Conference on Alzheimer's Disease (ICAD) Chicago 2008
- # 45. **Ingelsson, M.**, Blom, ES., Zetterberg, H., Fukumoto, H., Hyman, BT., Irizarry, MC., Blennow, K., Wahlund, L-O., Lannfelt, L. CSF tau levels and APOE ϵ 4 carriership predict the progression of mild cognitive impairment to Alzheimer's disease. Poster/ Alzheimer's Association International Conference on Alzheimer's Disease (ICAD) Chicago 2008
- # 46. Blom, ES, Wang, Y., Hansson, A., Sommer, W., Hyman, BT., Heilig, M., Lannfelt, L., Nilsson, LNG, **Ingelsson, M.** Poster/ Upregulation of genes in the Wnt pathway in tg-ArcSwe mice and Alzheimer's disease brain Poster/ Alzheimer's Association International Conference on Alzheimer's Disease (ICAD) Chicago 2008
- # 47. Bergström, J., Näsström, T., Wahlberg, T., Karlsson, M., Nikolajeff, F., Lannfelt, L., **Ingelsson, M.** The Effect of the Lipid Peroxidation Metabolite 4-oxo-2-nonenal on the Structure and Function of Alpha-Synuclein. Poster/ International meeting on alpha-synuclein, Copenhagen 2009
- # 48. Bergström, J., Näsström, T., Wahlberg, T., Karlsson, M., Nikolajeff, F., Lannfelt, L., **Ingelsson, M.** Effects of lipid peroxidation metabolites on alpha-synuclein aggregation. Talk/ Society for Neuroscience 39th Annual Meeting, Chicago 2009
- # 49. Näsström, T., Wahlberg, T., Karlsson, M., Nikolajeff, F., Lannfelt, L., **Ingelsson, M.**, Bergström, J. Morphological and functional properties of aldehyde-induced alpha-synuclein oligomers. Poster/ Alzheimer's Association International Conference on Alzheimer's Disease (ICAD) Honolulu 2010
- # 50. Wahlberg, T., Näsström, T., Sahlin, C., Ingvast, S., Karlsson, M., Nikolajeff, F., Ekberg, M., Kasrayan, A., Schell, H., Kahle, P., Lannfelt, L., Bergström, J., **Ingelsson, M.** Seeding of cross linked alpha-synuclein oligomers *in vitro* and *in vivo*. Poster/

Alzheimer's Association International Conference on Alzheimer's Disease (ICAD)
Honolulu 2010

51. Wahlberg, T., Näsström, T., Sahlin, C., Ingvast, S., Karlsson, M., Nikolajeff, F., Ekberg, M., Kasrayan, A., Schell, H., Kahle, P., Lannfelt, L., Bergström, J., **Ingelsson, M.** Alpha-synuclein protofibrils can seed fibril formation *in vitro*. Poster/ Society for Neuroscience 40th Annual Meeting, San Diego 2010

52. Welander, H., Bontha, SV., Näsström, T., Lannfelt, L., **Ingelsson, M.**, Bergström, J. Alpha-synuclein aggregation is influenced by gelsolin in a cell culture model. Poster/ AD/PD Barcelona, 2011

53. Näsström, T., Gonçalves, S., Sahlin, C., Nordström, E., Sundquist, V., Möller, C., Gellerfors, P., Lannfelt, L., Bergström, J., Outeiro, J., **Ingelsson, M.** Treatment with monoclonal antibodies reduces intracellular dimerization/oligomerization of alpha-synuclein in a cell culture model. Poster/ AD/PD Barcelona, 2011

54. **Ingelsson, M.**, Fagerqvist, T., Näsström, T., Ihse, E., Lindström, V., Sahlin, C., Tucker, S., Kasrayan, A., Karlsson, M., Nikolajeff, F., Nath, S., Agholme, L., Outeiro, T.F., Hallbeck, M., Lannfelt, L., Bergström, J. Alpha-synuclein oligomers can act as seed in a fibrillization assay but do not cause increased aggregation in living cells. Poster/ AAIC Boston 2013

55. **Ingelsson, M.**, Gustafsson, G., Fonseca, T.L., Lazaro, D., Nordström, E., Ihse, E., Nath, S., Agholme, L., Möller, C., Hallbeck, M., Outeiro, T.F., Lannfelt, L., Bergström, J. Alpha-synuclein oligomers/protofibrils as immunotherapeutic targets in cell models of aggregation and propagation. Talk/ Poster/ Society for Neuroscience 43rd Annual Meeting, San Diego 2013

56. Lindström, V., Sigvardson, J., Kasrayan, A., Lannfelt, L., **Ingelsson, M.**, Bergström, J., Erlandsson, A. Alpha-synuclein oligomers are engulfed primarily by astrocytes in a co-culture system with primary neurons and glia. Poster/ Nanonet Training School and Research Conference, Gothenburg 2014

57. **Ingelsson, M.**, Gustafsson, G., Eriksson, F., Nordström, E., Möller, C., Lannfelt, L. Characterization of the cellular uptake of α -synuclein oligomer/protofibril selective antibodies. Poster/ Society for Neuroscience 44th Annual Meeting, Washington 2014

58. Hallbeck, M., Sinha, MS., Ansell, A., Falk, A., Sackmann, C., Severinsson, E., **Ingelsson, M.**, Bergström, J., Marcusson, J. [Mechanisms for neuron-to-neuron transmission of neurodegenerative proteins](#). Poster/ Society for Neuroscience 44th Annual Meeting, Washington 2014

59. Bergström, J., Almandoz-Gil, L., Sigvardsson, J., Lannfelt, L., **Ingelsson, M.** [Characterization of surface-exposed epitopes of *in vitro* and *in vivo* formed alpha-synuclein aggregates](#). Talk (Bergström) / Society for Neuroscience 44th Annual Meeting, Washington 2014

60. Gustafsson, G., Eriksson, F., Möller, C., Outeiro, T.F., Lannfelt, L., Bergstrom, J., **Ingelsson, M.** Characterisation of the cellular uptake of alpha-synuclein oligomer/protofibril selective antibodies. Poster / AD/PD Nice 2015

61. Eriksson, F., Ramberg, V., Sigvardson, J., Kasrayan, A., **Ingelsson, M.**, Kahle, P., Lannfelt, L., Osswald, G., Möller, C., Nordström, E. Alpha-synuclein protofibril-selective antibody prevents motor related death in alpha-synuclein A30P tg mice. Poster / AD/PD Nice 2015

62. Almandoz-Gil, L., Sigvardsson, J., Lannfelt, L., **Ingelsson, M.**, Bergström, J. Epitope mapping of aggregated forms of alpha-synuclein. Poster / AD/PD Nice 2015

63. Lindström, V., Gustafsson, G., Sigvardsson, J., Kasrayan, A., Lannfelt, L., **Ingelsson, M.**, Bergström, J., Erlandsson, A. Extensive uptake of alpha-synuclein oligomers in primary astrocytes – a central pathological mechanism in Parkinson's disease? Poster / AD/PD Nice 2015

Thesis

Ingelsson, M.: “Molecular Aspects of Tau Proteins in Alzheimer's Disease and Frontotemporal Dementia”. Karolinska Institute, Stockholm, Sweden, defended on 09/28/2001. Faculty Opponent: Dr. Simon Lovestone, King's College, London, UK.

Narrative Report

Being a specialist in Geriatric Medicine at Uppsala University Hospital and an Associate Professor of Experimental Geriatrics at Uppsala University, Martin Ingelsson is dedicated to the care of patients with various neurodegenerative disorders and to the advancement of novel therapies and diagnostic methods for this patient group. His current position allows him to spend approximately 60% of his time in the laboratory doing translational molecular research, 20% in the Memory Disorder Unit seeing patients and 20% teaching clinical skills to medical students as well as supervising his PhD students in their respective research projects.

Among his achievements, Dr. Ingelsson has published more than 70 original papers, reviews and book chapters. He has studied amyloid-beta, tau and alpha-synuclein, proteins involved in the pathogenesis of Alzheimer's disease and Parkinson's disease. He has characterized the presence of soluble and insoluble forms of aggregated amyloid-beta and alpha-synuclein and described the regulation of the corresponding genes in brains from patients with the respective disorders. Different cell and animal models are now being used to explore the aggregation behavior of these proteins, with the focus of understanding neurotoxic mechanisms. Among other studies, seeding and propagation properties of amyloid-beta are currently being investigated in a collaborative study with Dr. Stanley Prusiner. Moreover, monoclonal antibodies that are selective against toxic forms of alpha-synuclein have been generated and are now being evaluated as tools for diagnostic and immunotherapeutic applications. In a recently concluded study, Dr. Ingelsson was able to show that peripheral treatment with an oligomer-selective antibody against alpha-synuclein could lower the levels of toxic alpha-synuclein in the CNS of a transgenic Parkinson's disease mouse model.

Apart from investigating and treating patients with different cognitive and motor symptoms, Dr. Ingelsson has been the PI of several clinical trials, aimed at exploring the use of monoclonal antibodies as disease-modifying treatment in Alzheimer's disease. In an ongoing trial, the effect of an antibody that was developed in the

Uppsala laboratory and which is selectively targeting toxic protofibrillar forms of amyloid-beta, is being evaluated in a phase II b clinical trial on Alzheimer patients.

In order to improve the scientific understanding among medical students, Dr. Ingelsson has organized a laboratory course that has been integrated in the curriculum. In addition, he has served as a well appreciated mentor during the clinical training periods for medical students in their fourth year.

Taken together, Dr. Ingelsson has been able to successfully integrate his preclinical and clinical activities in a translational setting with the clear aim of utilizing research results from the laboratory to increase our understanding of these devastating diseases. Such novel knowledge will be essential for the development of the next generation of disease-modifying drugs against these disorders.

CV Anders Johansson, MD, PhD

Silverdalsvägen 31, lgh 1004

191 38 Sollentuna

Sweden

Phone numbers:

office: 0046-8-51773424, mobile: 0046-73-6130611, home: 0046-8-50906369

Email address: anders.c.johansson@karolinska.se

Education and Medical Training

Fellowship / Residency, Department of Neurology 04/01/1998—10/12/2003

University Hospital, Uppsala, Sweden

Internship

08/01/1995—04/30/1997

Arvika Hospital, Arvika, Sweden

Departments of Internal medicine, Surgery, Psychiatry and General Practice

Doctor of Philosophy, Faculty of Medicine

06/13/2009

Department of Neuroscience, Uppsala University, Uppsala, Sweden

University Medical Degree

21/07/1995

Uppsala University, Faculty of Medicine, Uppsala, Sweden

Professional Work History

Consultant Physician, Department of Neurology

05/16/2011—

Karolinska University Hospital

Solna, Stockholm, Sweden

Consultant Physician, Department of Neurology

06/01/2010—05/15/2011

University Hospital, Uppsala, Sweden

Responsibilities: Deep brain stimulation, Dystonia treatment with botulinum toxin, Huntington disease, Parkinson disease

Neurologist, Department of Neurology

10/14/2003—05/31/2010

University Hospital, Uppsala, Sweden

Licensure and Certifications

License to Practice 05/21/1997

Specialist of Neurology 10/13/2003

Professional Memberships

The Movement Disorder Society (MDS)

The Swedish Movement Disorder Society (SWEMODIS)

Uppsala Medical Society

Swedish Medical Association

Swedish Neurological Society

International Physicians for the Prevention of Nuclear War

Honors

The Hwasserska Prize (Uppsala Medical Society) for meritorious scientific work 2010

The Åke Ljungdahl Prize (The Research Foundation of The Swedish Parkinson's Disease Association) 2011

CV Cecilia Lundberg

BIOGRAPHICAL SKETCH

Provide the following information for the key personnel in the order listed for Form Page 2. Follow the sample format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Cecilia Lundberg		POSITION TITLE Professor		
EDUCATION/TRAINING (<i>Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.</i>)				
INSTITUTION AND LOCATION	DEGREE (if applicable)	YEAR(S)	FIELD OF STUDY	
Porthälla gymnasium, Sweden	baccalaureate	1986	Natural sciences	

Lund University, Sweden	B.Sc.	1990	Medicine
Lund University, Sweden	Ph. D.	1996	Neurobiology
Harvard Medical School, Boston	Post-doc	1996-1998	Gene therapy
Lund University, Sweden	Docent	2002	Neurobiology

NOTE: The Biographical Sketch may not exceed four pages. Items A and B (together) may not exceed two of the four-page limit. Follow the formats and instructions on the attached sample.

3. Positions and Honors.

Professional Positions

- 1990-1996 PhD student in Prof Anders Björklund's lab at the Dept. Medical Cell Research, Lund University Sweden.
- 1996-1998 Post-doctoral Fellow in Prof Richard C Mulligan's lab at Children's Hospital, Harvard Medical School, Boston.
- 1999-2002 Assistant professor at the Wallenberg Neuroscience Center, Dept Physiological Sciences, Lund University, Sweden.
- 1999-present Head of independent research group at Wallenberg Neuroscience Center. Main supervisor of 6 PhD students.
- 2002 Associate professor (Docent).
- 2003-2004 Lecturer in biomedicine (half-time)
- 2007-2009 Deputy chairman Dept Experimental Medical Sciences, Lund University
- 2009-2010 Lecturer in Neurobiology, tenured full time
- 2011-present Professor in Neurobiology, Lund University
- 2012-present Vice dean Medical faculty, Lund University

Honors, Awards, Other Professional Activities

- 1998 Awarded Wenner-Gren Post Doctoral Fellowship 5 years of funding for post-doctoral training
- 2000-present Secretary Neurobiological Club at Lund University
- 2001 Member of the organizing committee for the Gene Therapy Network meeting, 26-27 March 2001 at the Wenner-Gren Center, Stockholm
- 2001-2005 Director of graduate studies at the Dept Physiological Sciences, Lund University
- 2002-2005 Editor of Basic Science on Lund Virtual Medical Journal (LVMJ) ISSN 1652-0971
- 2002-2007 Treasurer Swedish Society for Gene Therapy
- 2006-present Evaluation committee member of the Swedish Research Council
- 2007-present Evaluation committee member of the Norwegian Research Council

Ad hoc referee for different journals, including:

Experimental Neurology, Proceedings of the National Academy of Science USA, Neuroscience, Experimental Cell Research, Brain Research, Cell Transplantation, Gene Therapy, Stem Cells, Journal of Neurochemistry, Molecular Therapy

4. **Selected peer-reviewed publications (in chronological order).** (Selected from approx. 75 peer-reviewed publications and 15 book chapter and reviews)

1. C.Lundberg, S.J. Jungles and R.C. Mulligan, "Increased efficacy of leptin by intracranial gene transfer in obese mice using recombinant adeno-associated vectors." Nature Biotechnology February 2001 Volume 19 Number 2 pp 169 - 172
2. U Englund, R.A Fricker-Gates, C Lundberg, A Björklund and K Wictorin "Transplantation of Human Neural Progenitor Cells into the Neonatal Rat Brain: Extensive Migration and Differentiation with Long-distance Axonal Projections" Exp Neurol. 2002 Jan; 173(1): 1-21.
3. Lundberg, U. Englund, D. Trono, A. Björklund, K. Wictorin "Differentiation of the RN33B cell line into forebrain projection neurons after transplantation into the neonatal rat brain" Exp Neurol. 2002 Jun;175(2):370-87
4. Ericson, K Wictorin and C Lundberg "Ex vivo and in vivo studies of transgene expression in rat astrocytes transduced with lentiviral vectors. Exp Neurol. 2002 Jan; 173(1): 1-21.
5. Georgievskaja, D Kirik, C Rosenblad, C Lundberg, A Björklund. "Overexpression of GDNF in the striatum by a recombinant lentiviral vector provides preservation and sprouting of the nigrostriatal dopamine pathway in the 6-hydroxydopamine lesion model." Neuroreport. 2002 Jan 21;13(1):75-82.
6. Kirik, C Rosenblad, C Burger, C Lundberg, TE Johansen, N Muzyczka, RJ Mandel, A Björklund "Parkinson-like neurodegeneration induced by overexpression of alpha-synuclein in the nigrostriatal system. J Neurosci. 2002 Apr 1;22(7):2780-91.

7. Lotharius J, Barg S, Wiekop P, Lundberg C, Raymon HK, Brundin P. "Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line." *J Biol Chem*. 2002 Oct 11;277(41):38884-94.
8. J Jakobsson, C Ericson, M Jansson, E Björk and C Lundberg "Targeted transgene expression in rat brain using lentiviral vectors". *J Neurosci Res*. 2003 Sep 15;73(6):876-85.
9. Arvidsson A, Kirik D, Lundberg C, Mandel RJ, Andsberg G, Kokaia Z, Lindvall O. "Elevated GDNF levels following viral vector-mediated gene transfer can increase neuronal death after stroke in rats." *Neurobiol Dis*. 2003 Dec;14(3):542-56.
10. Jakobsson J, Georgievskaja B, Ericson C, Lundberg C. "Lesion-dependent regulation of transgene expression in the rat brain using a human glial fibrillary acidic protein-lentiviral vector." *Eur J Neurosci*. 2004 Feb;19(3):761-5.
11. Jakobsson J, Rosenqvist N, Thompson L, Lundberg C "Dynamics of transgene expression in a neural stem cell line transduced with lentiviral vectors incorporating the cHS4-insulator." *Exp Cell Res*. 2004 Aug 15;298(2):611-23.
12. Georgievskaja B, Jakobsson J, Persson E, Ericson C, Kirik D, Lundberg C "Regulated delivery of GDNF in the rat striatum using a tetracycline-dependent lentiviral vector" *Hum Gene Ther*. 2004 Oct;15(10):934-44.
13. Jakobsson J, Lundberg C. *Lentiviral Vectors for Use in the Central Nervous System*. *Mol Ther*. 2006 Jan 2;
14. Jakobsson J, Nielsen TT, Staflin K, Georgievskaja B, Lundberg C. Efficient transduction of neurons using Ross River glycoprotein-pseudotyped lentiviral vectors. *Gene Ther*. 2006 Jun;13(12):966-73. Epub 2006 Mar 2.
15. Jakobsson J, Rosenqvist N, Marild K, V Agoston D, Lundberg C. Evidence for disease-regulated transgene expression in the brain with use of lentiviral vectors. *J Neurosci Res*. 2006 Jul;84(1):58-67.
16. Rogelius N, Jensen JB, Lundberg C, Parmar M. Retrovirally delivered Islet-1 increases recruitment of Ng2 expressing cells from the postnatal SVZ into the striatum. *Exp Neurol*. 2006 Jun 23; [Epub ahead of print]
17. Rogelius N, Hebsgaard JB, Lundberg C, Parmar M. "Reprogramming of neonatal SVZ progenitors by islet-1 and neurogenin-2." *Mol Cell Neurosci*. 2008 Jul;38(3):453-9. Epub 2008 Apr 24.
18. Lundberg C, Björklund T, Carlsson T, Jakobsson J, Hantraye P, Déglon N, Kirik D. "Applications of lentiviral vectors for biology and gene therapy of neurological disorders." *Curr Gene Ther*. 2008 Dec;8(6):461-73.
19. Nielsen TT, Marion I, Hasholt L, Lundberg C. "Neuron-specific RNA interference using lentiviral vectors." *J Gene Med*. 2009 Jul;11(7):559-69.
20. Tønnesen J, Sørensen AT, Deisseroth K, Lundberg C, Kokaia M. "Optogenetic control of epileptiform activity." *Proc Natl Acad Sci U S A*. 2009 Jul 21;106(29):12162-7. Epub 2009 Jul 6.
21. Horvath L, van Marion I, Tai K, Nielsen TT, Lundberg C. Knockdown of GAD67 protein levels normalizes neuronal activity in a rat model of Parkinson's disease. *J Gene Med*. 2011 Mar;13(3):188-97. doi: 10.1002/jgm.1555.
22. Tønnesen J, Parish CL, Sørensen AT, Andersson A, Lundberg C, Deisseroth K, Arenas E, Lindvall O, Kokaia M.
23. Functional integration of grafted neural stem cell-derived dopaminergic neurons monitored by optogenetics in an in vitro Parkinson model. *PLoS One*. 2011 Mar 4;6(3):e17560.
24. Sørensen AT, Rogelius N, Lundberg C, Kokaia M. Activity-dependent long-term plasticity of afferent synapses on grafted stem/progenitor cell-derived neurons. *Exp Neurol*. 2011 Jun;229(2):274-81. Epub 2011 Feb 12.
25. Lindgren N, Francardo V, Quintino L, Lundberg C, Cenci A A Model of GDNF Gene Therapy in Mice with 6-Hydroxydopamine Lesions: Time Course of Neurorestorative Effects and ERK1/2 Activation *Journal of Parkinson's Disease*, 2012; 2: 333-47.
26. Wettergren EE, Gussing F, Quintino L, Lundberg C Novel disease-specific promoters for use in gene therapy for Parkinson's disease. *Neurosci Lett* 2012 Nov 14;530(1):29-34. Epub 2012 Oct 12.
27. Tai K, Quintino L, Isaksson C, Gussing F, Lundberg C. Destabilizing domains mediate reversible transgene expression in the brain. *PLoS One*. 2012;7(9):e46269. Epub 2012 Sep 28.
28. Quintino L, Baudet A, Larsson J, Lundberg C FACS binding assay for analysing GDNF interactions *J Neurosci Methods*. 2013 Aug 15;218(1):25-8

29. Quintino L, Manfre G, Elgstrand Wettergren E, Namislo A, Isaksson C, Lundberg C Functional neuroprotection and efficient regulation of GDNF using destabilizing domains in a rodent model of Parkinson's Disease Mol Ther. 2013 Jul 24.
30. Åkerblom M, Sachdeva R, Quintino L, Elgstrand Wettergren E, Chapman K Z, Manfre G, Lindvall O, Lundberg C, Jakobsson J Visualization and genetic modification of resident brain microglia using lentiviral vectors regulated by microRNA-9 Nature Communications 4, Article number: 1770. Published 23 April 2013.

CV Johan Lökk (1951-06-18)

1. Higher education degree(s)

MD 1976 Authorised MD 1978

2. Doctoral degree

1991, Karolinska Institutet, "On the effects of an autonomous daycare unit"

3. Postdoctoral positions

N/A

4. Docent level

1998 Karolinska Institutet, Clinical neuroscience

5. Specialist certification or equivalent

Geriatrics 1983, Internal medicine 1988

6. Present position

Senior consultant, Head physician, Geriatric Dept, Karolinska University Hospital; Professor of Geriatrics at the Department of Neurobiology, Care Sciences and Society, Karolinska Institutet.

7. Previous positions and periods of appointment

2000-2010 Senior lecturer, Karolinska Institutet
1992-2000 Senior consultant, section head of rehabilitation unit, Geriatric Dept, Karolinska University Hospital
1988-1992 Senior consultant, Dalens Hospital, Stockholm
1985-1988 Consultant, Danderyds Hospital, Stockholm
1983-1985 Physician, Stureby Hospital, Stockholm

8. Interruption in research

N/A

9. Supervision

Main supervisor (completed): Mats Nilsson (2008), Sylvia Annerbo (2009), Ahmad Delbari (2011); (Ongoing): Örjan Skogar (2008-), Mohamad Fereshtehnejad(2011-). Co-supervisor: Lena Flodin, Katja Samuelsson, Frida Göthe, David Conradsson, Ingrid Claesson

10. Others

- Accountant of Parkinsonföreningen 1999
- Member of the board of Research and Development at NVS, KI, 2001--
- Member of the Committee for doctoral education (FoUK) at the Department of Neurobiology, Care Sciences and Society, 2002—
- Board member Geriatric Dept, Karolinska University Hospital 2002-
- Board member FoUU-committee, NVS-dept, Karolinska Institutet 2005-
- Board member Swedish Parkinson Foundation 2010-
- Member of Regional Ethical Committee, Karolinska Institutet 2009-

- Board Member Swedish Movement Disorder Society (SWEMODIS) 2012-
- Member of Medical Advisory Boards for Lundbecks, Boehringer-Ingelheim, Pfizer, Ferring

My research is focused on neurodegenerative diseases with special interest in Parkinson's disease and currently a project about Parkinson's disease on how different forms of physical treatment affect function and psycho-endocrinology. I have also extended the research to epidemiological issues and have a joint program with the University of Teheran and the University of Sabzewar. Moreover, I have cooperation with researchers in Alzheimer's disease and is currently investigating predictive factors for developing dementia in MCI and SCI patients. I have a total of 28 years in the geriatric field, of which 26 years as consultant or senior, giving me a unique expertise in the field of neurogeriatrics.

CV Åsa Mackenzie

Name: Åsa Mackenzie

Home address: Ekolnsvägen 13A, 756 53 Uppsala, Phone: +46-18-314030, +46-725326755

Work address: Dept of Comparative Physiology, Norbyvägen 18A, 752 36 Uppsala, SWEDEN, Phone: +46-18-471 6419, Fax: +46-18-471 6425

Home page: <http://www.iob.uu.se/forskning/jamforande-fysiologi/mackenzie-lab/>

E-mail: asa.mackenzie@neuro.uu.se

Date and place of birth: August 28, 1971, Uppsala, Sweden

Nationality: Swedish

Marital status: Married to Nicholas Mackenzie. Children: Stella (11 ys), Peggy (9 ys) and Amy (4 ys). Total maternity leave 2 years 8 months.

Education and Positions

- 1991-1996 MSc1996, Biochemistry, Uppsala University (UU).
1997-2002 PhD in Medicine, Cell and Molecular Biology at Karolinska Institutet: "Some aspects of nuclear receptor function in the CNS – Novel roles of Nurr1 and RXR in developing and mature neurons". Supervisor Prof. *Thomas Perlmann*. Faculty opponent: Prof. *Kenneth Campbell*, US.
2002-2005 Post-doc at AstraZeneca Transgenics/Comparative Genomics and Molecular Neurobiology, AstraZeneca, Gothenburg.
2005-2008 Post-doc Uppsala University, Dept of Neuroscience.
2008-2010 Assistant Prof and Group Leader, UU, Dept of Neuroscience.
2010-2014 Associate Prof and Group Leader, UU, Dept of Neuroscience.
2014-2015 Associate Prof and Head, Unit of Functional Neurobiology, UU.
2015- Professor at Dept of Comparative Physiology; Chair in Molecular Physiology

Appointments, Honor, Evaluation & Board participation

- 2013- V. Chairman *Expert Board for Lab Animal Science* Swedish Research Council.
2009- Member of board for the main seminar series at the Biomedical center, UU.
2009-2011 Member of Faculty board for anti-discrimination policy, UU.
2014 Awarded "Scientist of the month" for my work on basic research around Parkinson's disease by the Swedish Brain Foundation.
2014 Evaluation report for the Chair in Molecular Physiology at UU: "*Clearly potential researcher with international visibility. Potential candidate to this position due to highly competitive research program ... Can be considered as a very promising "rising star". Own funding. Strong publications.*" "*Mackenzie has published 20 articles in internationally very well recognized journals. Promising scientist*".
2015 Recruited to the position as Chair in Molecular Physiology.

Funding (Main PI in all)

Current:

- 2014-2017 Swedish Research Council (SMRC; Vetenskapsrådet (VR)); Category: "Natural Sciences";
2015-2017 SMRC (VR); Category: "Medicine";
2014 The Swedish Parkinson Foundation (Parkinsonfonden);
2014, 2015 The Swedish Brain Foundation (Hjärnfonden),

Previous:

- 2008-2011 SMRC (VR)-"Medicine" + a number of private foundations, incl Wiberg, Åhlén, Bergwall.
2011-2014 SMRC (VR) -"Medicine" + private brain foundations.
2008-2013 The Swedish Parkinson Foundation (Parkinsonfonden).
2009, 2012 The Swedish Brain Foundation (Hjärnfonden).

Funded networks

Current:

2014-2016 ERA-NET Neuron "Mental disorders": EU network on Addiction headed by Prof El Mestikawy; ranked 2 out of all proposals.

Previous:

2009-2012 Nordic Co-transmission Network (STINT-funded): Mackenzie Initiative/head.

2009-2013 Dopamine diseases (VR-funded): Mackenzie Initiative, Prof Lars Olson head.

2012-2014 Joint Brazilian-Swedish Collaboration (STINT-funded): Mackenzie co-applicant.

Invited speaker at international meetings

1. Labex 2014: "From Synapses to Psychiatric Disorders", Nov 7, 2014, Collège de France, Paris, France.
2. SFN mini-convention org:d by NIH/NIDA, "Emerging and Novel Aspects of Neuronal Transmission" Nov 8, 2013, San Diego, USA. *Only speaker invited outside US top-ranked universities*. Cancelled due to the temporary close-down of NIH.
3. Dopamine 2013, May 24-28, 2013, Sardinia, Italy.
4. French Neuroscience Meeting, May 21-23, 2013, Lyon, France.
5. ECNP: Eur College Neuropsychopharmacol, October 14-17, 2012, Vienna, Austria.
6. The Scandinavian Physiological Society, Aug 14-16, 2009, Uppsala.
7. Imaging, Genetics and Other Nifty Techniques in Neurophysiology", Jan 18-20, 2010, Natal, Brazil

Organizer of international meetings

1. A Christmas Neuroscience Symposium (CNS) on Glutamate Transporters (Dec 2011).
2. A Christmas Neuroscience Symposium (CNS) on Parkinson's disease (Dec 2013).
3. Organizer of session at IBANGS in Uppsala 2015 ("Cotransmission in the basal ganglia").

Thesis evaluations

Sweden: Anna Lord, UU, 2009; Jenny Häggkvist, UU, 2009; Helena Åkerberg, UU, 2009; Linda Järdestad, UU, 2011; Thomas Näsström, UU, 2011; Carly Kiselyczyk, KI, 2012; Richard Andersson, KI, 2012; Jenny Johansson, UU, 2013; Alfhild Grönblad, UU, 2013;
International: Diana Yae Sakae, Paris, Université Pierre et Marie Curie, April 11, 2014.

Leadership and pedagogical training

1. Project Management – Wenell (UU), 2007
2. Supervision of Case studies at the Medical Faculty (UU), 2008.
3. Pedagogy for University Lecturers (UU), 2008.
4. Pedagogy for PhD student supervisors (UU), 2009-10.
5. Media-training course at SMRC/VR 2010.
6. Leadership course for women employed at Uppsala Universitet, UU, 2013.
7. More than 250 hours of teaching, incl Biomedical and Medical programs.
8. Course head Neurobiology with Pharmacology (15 hp, Biomedical Program) 2012-14.

Supervision (postdocs and doctors and for whom I have been main supervisor):

Doctoral degree:

1. Karin Nordenankar, April 20, 2012: *Functional Analysis of the Vesicular Glutamate Transporter 2 in Specific Neuronal Circuits of the Brain*, Faculty opponent Prof. Rainer Spanagel, Heidelberg, Germany;

2. Emma Arvidsson, Oct 3, 2014: *Motion and Emotion. In Vivo Analysis of the Mouse Basal Ganglia*. Faculty opponent: Prof Cecilia Flores, Montreal, Canada;
3. Stefano Pupe, March 24, 2015, Natal (Brazil)-Uppsala Joint PhD degree.
4. Planned defences: Nadine Schweizer, March 2016; Thomas Viereckel, Dec 2017; Julia Pedersen, Jan 2018.

Postdocs:

Current:

Maria Papathanou 2015-2017; Stéfano Pupe 2015, Emma Arvidsson 2015.

Previous:

Hillevi Englund 2009, Tobias Johansson 2010, Johan Alsiö* 2010, Carolina Birgner 2009-11, Casey Smith 2009-12, Aparna Rajagopalan 2010-11, Ernesto Restrepo-Leidefors 2011-2013.
**Together with Trevor Robbins at Cambridge Univ, England, I am supervisor for Dr Johan Alsiö, International postdoc supported by VR-M 2012-current.*

International and national collaborations:

I have been fortunate to come in contact with prominent scientists worldwide who have been interested in my work and I have thereby been able to form a substantial and meaningful network. ***In Sweden and Switzerland:*** Christian Luscher (AMPA/NMDA recordings Geneva), Sylvie Dumas (Quantitative in situ hybridization, Paris), Richardson Leao (electrophysiology/optogenetics, UU), Malin Lagerström (mouse genetics, UU), Martin Lundblad (optogenetic-*in vivo* amperometry, Lund). ***In the US and Canada:*** Louis-Eric Trudeau* (cotransmission, Université de Montréal, UdeM), Daniel Levesque (biochemistry, UdeM), Salah El Mestikawy* and Bruno Giros (VGLUT3/VMAT2, McGill, Montreal), Marisela Morales (*in situ* hybridization, NIH, Baltimore), Satoshi Ikemoto (optogenetic tetrode electrophysiology, NIH, Baltimore), Trevor Robbins (reinforcement, Cambridge; *cosupervisor and host at Cambridge for Johan Alsiö, International postdoc supported by VR-M.*) *Together with Trudeau and El Mestikawy, I formed the scientific network “Nordic Cotransmission Network” (supported by STINT 2009-2013); our first joint article was published in Nature Reviews Neuroscience 2011 and together with Trudeau and senior colleagues, I published a new review earlier this year: The multilingual nature of dopamine neurons, Prog. Brain Res. 2014.*

PUBLICATION LIST

1. [Cre-driven optogenetics in the heterogeneous genetic panorama of the VTA.](#)

Pupe S, Wallén-Mackenzie Å. *Trends Neurosci.* 2015 May 8. pii: S0166-2236(15)00083-1. doi: 10.1016/j.tins.2015.04.005. Review. PMID: 25962754

2. [Targeted deletion of Vglut2 expression in the embryonal telencephalon promotes an anxiolytic phenotype of the adult mouse.](#) Nordenankar K, Bergfors A, Wallén-Mackenzie Å. *Ups J Med Sci.* 2015 Apr 9:1-13. PMID: 25857802

3. [Reply to Konsolaki and Skalióra: Habituation, hyperlocomotion, and "genuine hyperlocomotion"](#). Pupe S, Schweizer N, Wallén-Mackenzie Å. *Proc Natl Acad Sci U S A*. 2015 Jan 6;112(1):E5. doi: 10.1073/pnas.1417574112. PMID: 25540419
4. [SLC10A4 is a vesicular amine-associated transporter modulating dopamine homeostasis](#). Larhammar M, Patra K, Blunder M, Emilsson L, Peuckert C, Arvidsson E, ..., Jahn R, Wallén-Mackenzie Å, Kullander K. *Biol Psychiatry*. 2015 Mar 15;77(6):526-36. doi: 10.1016/j.biopsych.2014.07.017. PMID: 25176177
5. [Reduced gene expression levels of Munc13-1 and additional components of the presynaptic exocytosis machinery upon conditional targeting of Vglut2 in the adolescent mouse](#). Rajagopalan A, Schweizer N, Nordenankar K, Nilufar Jahan S, Emilsson L, Wallén-Mackenzie A. *Synapse*. 2014 Aug 19. doi: 10.1002/syn.21776. PMID: 25139798
6. [The multilingual nature of dopamine neurons](#). Trudeau LE, Hnasko TS, Wallén-Mackenzie A, Morales M, Rayport S, Sulzer D. *Prog Brain Res*. 2014;211:141-64. doi: 10.1016/B978-0-444-63425-2.00006-4. Review. PMID: 24968779
7. [Haplotype-tag single nucleotide polymorphism analysis of the vesicular glutamate transporter \(VGLUT\) genes in severely alcoholic women](#). Comasco E, Hallman J, Wallén-Mackenzie A. *Psychiatry Res*. 2014 Oct 30;219(2):403-5. doi: 10.1016/j.psychres.2014.05.052. Epub 2014 Jun 6. PMID: 24953423
8. [Age- and sex-dependence of dopamine release and capacity for recovery identified in the dorsal striatum of C57/Bl6J mice](#). Arvidsson E, Viereckel T, Mikulovic S, Wallén-Mackenzie Å. *PLoS One*. 2014 Jun 12;9(6):e99592. doi: 10.1371/journal.pone.0099592. PMID: 24925086
9. [Limiting glutamate transmission in a Vglut2-expressing subpopulation of the subthalamic nucleus is sufficient to cause hyperlocomotion](#). Schweizer N, Pupe S, Arvidsson E, Nordenankar K, Smith-Anttila CJ, Mahmoudi S, Andrén A, Dumas S, Rajagopalan A, Lévesque D, Leão RN, Wallén-Mackenzie Å. *Proc Natl Acad Sci U S A*. 2014 May 27;111(21):7837-42. doi: 10.1073/pnas.1323499111. PMID: 24821804
10. [Increased hippocampal excitability and impaired spatial memory function in mice lacking VGLUT2 selectively in neurons defined by tyrosine hydroxylase promoter activity](#). Nordenankar K, Smith-Anttila CJ, Schweizer N, Viereckel T, Birgner C, Mejia-Toiber J, Morales M, Leao RN, Wallén-Mackenzie A. *Brain Struct Funct*. 2014 May 7. PMID: 24802380
11. [Glutamate corelease promotes growth and survival of midbrain dopamine neurons](#). Fortin GM, Bourque MJ, Mendez JA, Leo D, Nordenankar K, Birgner C, Arvidsson E, Rymar VV, Bérubé-Carrière N, Claveau AM, Descarries L, Sadikot AF, Wallén-Mackenzie Å, Trudeau LÉ. *J Neurosci*. 2012 Nov 28;32(48):17477-91. doi: 10.1523/JNEUROSCI.1939-12.2012. PMID: 23197738
12. [Ultrastructural characterization of the mesostriatal dopamine innervation in mice, including two mouse lines of conditional VGLUT2 knockout in dopamine neurons](#).

Bérubé-Carrière N, Guay G, Fortin GM, Kullander K, Olson L, Wallén-Mackenzie Å, Trudeau LE, Descarries L. *Eur J Neurosci*. 2012 Feb;35(4):527-38. doi: 10.1111/j.1460-9568.2012.07992.x. PMID: 22330100

13. [Enhanced sucrose and cocaine self-administration and cue-induced drug seeking after loss of VGLUT2 in midbrain dopamine neurons in mice.](#) Alsjö J, Nordenankar K, Arvidsson E, Birgner C, Mahmoudi S, Halbout B, Smith C, Fortin GM, Olson L, Descarries L, Trudeau LÉ, Kullander K, Lévesque D, Wallén-Mackenzie A. *J Neurosci*. 2011 Aug 31;31(35):12593-603. doi: 10.1523/JNEUROSCI.2397-11.2011. PMID: 21880920

14. [From glutamate co-release to vesicular synergy: vesicular glutamate transporters.](#) El Mestikawy S, Wallén-Mackenzie A, Fortin GM, Descarries L, Trudeau LE. *Nat Rev Neurosci*. 2011 Apr;12(4):204-16. doi: 10.1038/nrn2969. Review. PMID: 21415847

15. [A sensory subpopulation depends on vesicular glutamate transporter 2 for mechanical pain, and together with substance P, inflammatory pain.](#) Lagerström MC, Rogoz K, Abrahamsen B, Lind AL, Olund C, Smith C, Mendez JA, Wallén-Mackenzie Å, Wood JN, Kullander K. *Proc Natl Acad Sci U S A*. 2011 Apr 5;108(14):5789-94. doi: 10.1073/pnas.1013602108. Epub 2011 Mar 17. PMID: 21415372

16. [VGLUT2-dependent sensory neurons in the TRPV1 population regulate pain and itch.](#) Lagerström MC, Rogoz K, Abrahamsen B, Persson E, Reinius B, Nordenankar K, Olund C, Smith C, Mendez JA, Chen ZF, Wood JN, Wallén-Mackenzie A, Kullander K. *Neuron*. 2010 Nov 4;68(3):529-42. doi: 10.1016/j.neuron.2010.09.016. PMID: 21040852

17. [Genetic inactivation of the vesicular glutamate transporter 2 \(VGLUT2\) in the mouse: what have we learnt about functional glutamatergic neurotransmission?](#) Wallén-Mackenzie A, Wootz H, Englund H. *Ups J Med Sci*. 2010 Feb;115(1):11-20. doi: 10.3109/03009730903572073. Review. PMID: 20187846

18. [VGLUT2 in dopamine neurons is required for psychostimulant-induced behavioral activation.](#) Birgner C, Nordenankar K, Lundblad M, Mendez JA, Smith C, le Grevès M, Galter D, Olson L, Fredriksson A, Trudeau LE, Kullander K, Wallén-Mackenzie A. *Proc Natl Acad Sci U S A*. 2010 Jan 5;107(1):389-94. doi: 10.1073/pnas.0910986107. Epub 2009 Dec 14. PMID: 20018672

In press 2015:

Bagchi S, Fredriksson R, Wallén-Mackenzie Å. The Proximity Ligation Assay in cells and tissue; ELISA – Methods and Protocols, Publisher: Springer Science and Business Media; Book Series: *Methods in Molecular Biology: Springer protocols*, Series Editor JM Walker, Book Editor RM Hnasko. *Methods in Molecular Biology 1318*; 2015; ISBN 978-1-4939-2741-8.

Curriculum Vitae Malin Parmar

Name **Malin Pernilla Parmar**
Date of birth: 1973-12-11
Citizenship: Swedish
Telephone, work: + 46 46 222 0620
Mobile phone: + 46 709 823901
E-mail: Malin.Parmar@med.lu.se
Web: [Developmental Neurobiology](#)

Higher education degree
1998 Bachelor of Science, Simon Fraser University, Canada

Doctoral degree
2003 PhD in Medical Sciences, developmental biology.
Medical Faculty, Lund University. Degree awarded 2003-09-26.

Postdoctoral positions
2005-2006 **Postdoc position, financed by Swedish Research Council**
Faculty of Science, Institute of Stem Cell Research
Edinburgh University, Scotland, UK.
2003-2005 **PostDoc Position**
Faculty of Medicine, Lund University, Sweden

Docent level
2008 Docent in Neurobiology
Medical Faculty Lund University

Specialist Certification
N/A

Current position
Associate professor (Lektor) at the Department of Experimental Medical Science: Wallenberg Neuroscience Centre and Lund Stem Cell Centre, Medical Faculty, Lund University

Previous Positions (excl postdoc positions that are listed above)

2012-2014 **Senior Researcher.**
Faculty of Medicine, Lund University, Sweden
2007-2012 **Assistant Professor (Forskarassistent). Fully financed by the Swedish Research Council**
Faculty of Medicine, Lund University, Sweden
1999-2003 **PhD Position, financed by National network in Neuroscience, SSF.**
Faculty of Medicine, Lund University, Sweden
1998-1999 **Project Student**, Terry Fox Laboratory, University of British Columbia, BC, Canada

Career breaks

Since my Phd was awarded I have had two careers breaks (total 488 days) for parental leave when my children were born (2004 and 2008)

Supervision as main supervsor:

Completed Phd students:

Jenny Nelande: 12/12-2013

Olof Torper: 28/2-2014

Ongoing Phd students:

Ulrich Pfisterer: Booked dissertation date 19/9-2014

Maria Pereira: Registered Jan 1, 2013

Main supervisor Postdocs:

Audrey Dufour 2009-2011

Daniel Wolf 2010-2012

Agnete Kirkeby 2010 - 2013

Shane Grealish 2011 - currently

Shong Lau 2012 - currently

Daniella Rylander 2013 - currently

Andreas Heuer 2013 - currently

National and International awards:

2012 ERC Starting Grant

Other significant activities

2013 – 2016 Board member, “Membership committee”, International Society for Stem Cell Research, ISSCR

2014 – Currently: Swedish Parkinson Foundation Scientific Committee

2013-2015: Editorial Board for Experimental Neurology

2009 – 2013 Training and Networking Director for 7th framework EU program NeuroStemcell: responsible for activities and training of PhD students and postdocs within the network, organizing scientific workshops and meeting as well as communication with other EU networks and public.

1999 – Currently: Involved in teaching (PBL tutor, lecturer, examination and course leader) at the medical, biomedical programs and PhD program at Lund University

2008 - Currently: Co-Director of Research School in Stem Cell Biology, LU

2009 – Currently: External expert and writer for the Swedish National Encyclopaedia (NE)

Curriculum Vitae för Per Svenningsson

Born: Lund, Sweden, December 19, 1968.

Home address: Observatoriegatan 23
SE-113 29 Stockholm
Sweden

Work address: Department of Neurology
Karolinska University Hospital
SE-141 86 Stockholm
and
Department of Clinical Neuroscience
Center for Molecular Medicine L8:01
Karolinska Institutet
SE-171 77 Stockholm

Sweden
Phone: +46 (0)8 51774614/ +46 70 7498522
Fax: +46 (0)8 51774614
e-mail: per.svenningsson@ki.se

Current Position

Professor in Neurology, Dept. of Neurology, Karolinska University Hospital/Dept. of Clinical Neuroscience, Karolinska Institutet.

Education

1990-1996 Medical School, Karolinska Institute, Sweden. Medical Doctor, January 19 1996.
1992-1998 Graduate studies, Dept of Physiology and Pharmacology, Karolinska Institute. PhD October 15, 1998.
1999 Licensed medical doctor, May 21.
2002 Associate Professor (“Docent”), Karolinska Institutet, September 18.
2010 Specialist in Neurology, December 6.

Professional experience

1996-1999 Medical Internship (Surgery, Internal Medicine and Psychiatry wards)/Research, “Forskar-AT”, Karolinska University Hospital.
1999-2001 Postdoctoral fellow in Prof. Paul Greengard’s Laboratory of Molecular and Cellular Neuroscience, Rockefeller University, New York, USA.
2001-2002 Assistant professor in Prof. Paul Greengard’s Laboratory of Molecular and Cellular Neuroscience, Rockefeller University, New York, USA.
2002-2006 Research assistant (VR forskarasistenttjänst), Dept. of Physiology and Pharmacology, Karolinska Institutet, Sweden.
2005-2010 Medical Residency (ST-tjänst) in Neurology, Karolinska University Hospital.
2009-2015 Researcher (VR forskartjänst), Dept. of Clinical Neuroscience, Karolinska Institutet.
2012- Professor in Neurology, Dept. of Neurology, Karolinska University Hospital/Dept. of Clinical Neuroscience, Karolinska Institutet.

Honors and Awards

2006 Opening Plenary Lecture, XIV World Congress on Psychiatric Genetics
2007 NARSAD Young Investigator Award
2008 Werner Lowenthal’s Lecture, Richmond, USA
2008 Researcher position from the Royal Swedish Academy of Sciences
2011, 2012, 2013 Fisher Center Grant Award

Commissions of Trust

2005-2008 Grant reviewer for INSERM/ANR, France
2008- Swedish Movement Disorder Society, elected board member
2009- Swedish Parkinson Fund, scientific reviewing committee
2009 Finnish Medical Research Council, scientific reviewing committee
2010, 2013 Norwegian Medical Research Council, scientific reviewing committee
2010- Scientific coordinator between Karolinska Institutet and Rockefeller University

2010- Member of the Ulf von Euler Lecturer committee, Karolinska Institutet
2011, 2014 Member of the programme committee for the European College of Neuropsychopharmacology (ECNP) meetings in Paris 2011 and Berlin 2014
2012- Parkinson Research Foundation, scientific committee
2013 Swedish Foundation for Strategic Research (SSF), reviewing committee
2013- Member of the Executive Committee for ECNP
2013- Member of SAB for CBD solutions
2014- Member of the Steering Committee of the European Huntington Disease Network

Membership of Editorial Boards of Scientific Journals

2009- *J Mol Neuroscience*

2012- *PLoS ONE*

2012- Frontiers in Psychopharmacology

2012- ISRN Neurology

Invited lectures

Over the years, I have been invited to speak at a large number (>50) of congresses, symposia and workshops throughout the world.

Scientific supervision

Main supervision of 9 Ph.D. students (completed PhD), 2004-2014.

Currently main supervision of 5 Ph.D. students.

Supervision of 8 postdocs, 2004-2014.

Currently main supervision of 8 postdocs.

Publications

168 publications with 7001 citations; H-index 48.

8 book chapters

CV Lennart Pettersson

Adress: Nunnevägen 1, 134 34 Gustavsberg

Telefon: 08-57035120

E-post: lennartpettersson1@yahoo.se

Ålder: 72 år (2014)

Utbildning

- a) Fil.kand. vid Stockholms universitet 1966 (genetik, zoologi och mikrobiologi, 2 betyg av varje)
- b) Översikt kurs i miljövärd (10 poäng) vid Lunds universitet 1970
- c) Tre betyg i mikrobiologi vid Stockholms universitet 1974
- d) Grundkurs i klinisk läkemedelsprövning 1991
- e) Allmän patologi, 10 poäng, vid Karolinska institutet 1993
- f) Diverse datakurser

Anställningar

- a) Pharmacia 1967-1969 (medicinsk redaktör inom området infusionslösningar)
- b) Sockerbolaget 1969-1971 (mikrobiologiskt utvecklingsarbete)
- c) Arla 1971-1983 (mikrobiologiskt utvecklingsarbete)
- d) STU/NUTEK 1983-1996 (bioteknikhandläggare med ansvar för såväl kommersiella utvecklingsprojekt som för forskningsprogram inom områden som genteknik, protein engineering, kolhydratkemi, peptidteknologi, bioteknisk processteknik och bioteknisk separationsteknik)
- e) Regeringskansliet (Jordbruksdepartementet) 1996-2005 (handläggning av ärenden relaterade till genteknik- och genresursfrågor, deltog i internationella förhandlingar om jordbrukets växtgenetiska resurser inom ramen för FAO)

Övrigt

- a) Har representerat STU/NUTEK i t.ex. Nordisk Industrifond, MFR:s genomgrupp, programstyrelsen för Stiftelsen Bioteknisk Forskning, EU:s grupp inom protein engineering, tekniska kommittén för COST-projekt inom agrikultur och bioteknik och SIK:s industriella råd
- b) Svensk representant i Nordiska Genbankens styrelse 1996-2003
- c) Spelar bordtennis, går i fjällen, åker längdskidor, läser böcker och är som folk är mest